
<!DOCTYPE html>
<html lang="en">
<head>
    <script>
    // --- SECURITY CHECK ---
    // If the token is missing, they accessed this file directly (cheating)
    if (!sessionStorage.getItem('portalToken')) {
        // Replace 'index.html' with the actual name of your main login page
        window.location.href = 'index.html'; 
    }

    // Disable Right Click on Exam Page too
    document.addEventListener('contextmenu', event => event.preventDefault());
    
    // Disable Selection
    document.addEventListener('selectstart', event => event.preventDefault());
    </script>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>MCQ Exam</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/html2canvas/1.4.1/html2canvas.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jspdf/2.5.1/jspdf.umd.min.js"></script>
    <style>
        :root, [data-theme="light"] {
            --bg-primary: #f9fafb; /* gray-50 */
            --bg-secondary: #ffffff;
            --bg-tertiary: #f3f4f6; /* gray-100 */
            --bg-accent: #e5e7eb; /* gray-200 */
            --bg-accent-hover: #d1d5db; /* gray-300 */
            --bg-info: #eff6ff; /* blue-50 */
            --bg-info-border: #bfdbfe; /* blue-200 */
            --bg-success: #f0fdf4; /* green-50 */
            --bg-success-border: #bbf7d0; /* green-200 */
            --bg-danger: #fef2f2; /* red-50 */
            --bg-danger-border: #fecaca; /* red-200 */
            --bg-warning: #fffbeb; /* yellow-50 */
            --bg-warning-border: #fde68a; /* yellow-200 */
            --bg-code: #e5e7eb;
            --text-primary: #1f2937; /* gray-800 */
            --text-secondary: #4b5563; /* gray-600 */
            --text-tertiary: #6b7280; /* gray-500 */
            --text-accent: #3b82f6; /* blue-600 */
            --text-accent-hover: #2563eb; /* blue-700 */
            --text-inverted: #ffffff;
            --text-info: #1e40af; /* blue-800 */
            --text-success: #15803d; /* green-700 */
            --text-danger: #b91c1c; /* red-700 */
            --text-warning: #92400e; /* yellow-800 */
            --border-primary: #e5e7eb; /* gray-200 */
            --border-secondary: #d1d5db; /* gray-300 */
            --border-accent: #3b82f6;
            --shadow-color: rgba(0,0,0,0.1);
            --swipe-duration: 0.3s; /* Default Smooth */
            --font-explanation: 'Segoe UI', Roboto, 'Helvetica Neue', sans-serif;
        }

        [data-theme="dark"] {
            --bg-primary: #111827; /* gray-900 */
            --bg-secondary: #1f2937; /* gray-800 */
            --bg-tertiary: #374151; /* gray-700 */
            --bg-accent: #4b5563; /* gray-600 */
            --bg-accent-hover: #525c6a;
            --bg-info: #1e293b; 
            --bg-info-border: #334155;
            --bg-success: #064e3b; /* green-900 */
            --bg-success-border: #065f46;
            --bg-danger: #7f1d1d; /* red-900 */
            --bg-danger-border: #991b1b;
            --bg-warning: #451a03;
            --bg-warning-border: #78350f;
            --bg-code: #374151;
            --text-primary: #f3f4f6; /* near-white, AAA */
            --text-secondary: #d1d5db; /* gray-300, AAA */
            --text-tertiary: #9ca3af; /* gray-400 */
            --text-accent: #60a5fa; /* blue-400 */
            --text-accent-hover: #93c5fd; /* blue-300 */
            --text-inverted: #1f2937;
            --text-info: #bfdbfe;
            --text-success: #86efac; /* green-300 */
            --text-danger: #fca5a5; /* red-300 */
            --text-warning: #fcd34d;
            --border-primary: #374151; /* gray-700 */
            --border-secondary: #4b5563; /* gray-600 */
            --border-accent: #60a5fa;
            --shadow-color: rgba(0,0,0,0.4);
            --font-explanation: 'Segoe UI', Roboto, 'Helvetica Neue', sans-serif;
        }

        [data-theme="ambient"] {
            --bg-primary: #fdf6e3; /* cream */
            --bg-secondary: #f6efd8;
            --bg-tertiary: #eee8d5;
            --bg-accent: #dcd4c1;
            --bg-accent-hover: #c9c1ae;
            --bg-info: #e0f2f1; 
            --bg-info-border: #b2dfdb;
            --bg-success: #e8f5e9;
            --bg-success-border: #c8e6c9;
            --bg-danger: #ffebee;
            --bg-danger-border: #ffcdd2;
            --bg-warning: #fff3e0;
            --bg-warning-border: #ffe0b2;
            --bg-code: #eee8d5;
            --text-primary: #433e3f; /* dark brown */
            --text-secondary: #586e75;
            --text-tertiary: #657b83;
            --text-accent: #cb4b16; /* warm orange */
            --text-accent-hover: #d35400;
            --text-inverted: #fdf6e3;
            --text-info: #00695c;
            --text-success: #2e7d32;
            --text-danger: #c62828;
            --text-warning: #e65100;
            --border-primary: #dcd4c1;
            --border-secondary: #c9c1ae;
            --border-accent: #cb4b16;
            --shadow-color: rgba(67, 62, 63, 0.1);
            --font-explanation: 'Georgia', 'Cambria', 'Times New Roman', serif;
        }

        body { 
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, 'Helvetica Neue', Arial, sans-serif;
            background-color: var(--bg-tertiary);
            color: var(--text-primary);
            transition: background-color 0.3s, color 0.3s;
            /* Disable Selection and Touch Callouts */
            -webkit-user-select: none; /* Safari */
            -ms-user-select: none; /* IE 10 and IE 11 */
            user-select: none; /* Standard syntax */
            -webkit-touch-callout: none; /* iOS Safari */
        }
        
        /* Re-enable selection for inputs */
        input, textarea {
            -webkit-user-select: text;
            user-select: text;
        }

        /* View Transitions for Theme Switch */
        ::view-transition-old(root),
        ::view-transition-new(root) {
            animation: none;
            mix-blend-mode: normal;
        }
        ::view-transition-old(root) { z-index: 1; }
        ::view-transition-new(root) { z-index: 9999; }

        .screen { display: none; }
        .screen.active { display: flex; }
        .option-label { transition: background-color 0.2s ease-in-out, border-color 0.2s ease-in-out; }
        .prose strong { font-weight: 700; color: var(--text-primary); }
        .prose em { color: var(--text-primary); font-style: italic; }
        .prose br { content: ""; display: block; margin-bottom: 0.5rem; }
        .prose ul { list-style-type: disc; padding-left: 1.5rem; margin-top: 0.5rem; margin-bottom: 0.5rem; }
        .prose ol { list-style-type: decimal; padding-left: 1.5rem; margin-top: 0.5rem; margin-bottom: 0.5rem; }
        .prose p { margin-bottom: 1rem; }
        .calculator-btn { padding: 1rem 0; font-size: 1.25rem; border-radius: 0.5rem; transition: background-color 0.2s, transform 0.1s, filter 0.1s; text-align: center; }
        .key-press-feedback { transform: scale(0.95); filter: brightness(0.85); }
        .calculator-modal.dragging { opacity: 0.7; border: 2px dashed var(--border-accent); }
        
        /* Custom Radio Button for Exam Mode */
        .radio-circle::after {
            content: '';
            display: block;
            width: 1rem; /* 16px */
            height: 1rem; /* 16px */
            border-radius: 50%;
            background-color: var(--border-accent);
            position: absolute;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%) scale(0);
            transition: transform 0.2s ease-in-out;
        }
        .option-label.selected .radio-circle::after {
            transform: translate(-50%, -50%) scale(1);
        }
        
        /* Themed Components */
        .themed-bg-primary { background-color: var(--bg-primary); }
        .themed-bg-secondary { background-color: var(--bg-secondary); }
        .themed-bg-tertiary { background-color: var(--bg-tertiary); }
        .themed-bg-accent { background-color: var(--bg-accent); }
        .themed-bg-accent-hover:hover { background-color: var(--bg-accent-hover); }

        .themed-text-primary { color: var(--text-primary); }
        .themed-text-secondary { color: var(--text-secondary); }
        .themed-text-tertiary { color: var(--text-tertiary); }
        .themed-text-accent { color: var(--text-accent); }
        .themed-text-inverted { color: var(--text-inverted); }
        .themed-text-success { color: var(--text-success); }
        .themed-text-danger { color: var(--text-danger); }
        .themed-text-warning { color: var(--text-warning); }

        .themed-border-primary { border-color: var(--border-primary); }
        .themed-border-secondary { border-color: var(--border-secondary); }
        .themed-border-accent { border-color: var(--border-accent); }
        
        .themed-shadow { box-shadow: 0 4px 6px -1px var(--shadow-color), 0 2px 4px -2px var(--shadow-color); }
        
        /* Component specific overrides */
        #setup-screen .bg-white, #results-screen .bg-white, #review-screen .bg-white, #practice-screen .bg-white, #practice-results-screen .bg-white, #past-results-screen .bg-white, #progress-screen .bg-white, .modal-card, #calculator-modal {
            background-color: var(--bg-secondary);
            color: var(--text-primary);
        }
        header { background-color: var(--bg-secondary); }
        main, footer { background-color: var(--bg-tertiary); }
        footer { box-shadow: 0 -2px 5px var(--shadow-color); }
        input, textarea { background-color: var(--bg-secondary); border-color: var(--border-secondary); color: var(--text-primary); }
        input:focus, textarea:focus { --tw-ring-color: var(--text-accent); border-color: var(--text-accent); }
        #timer, #practice-timer { background-color: var(--bg-accent); }
        .option-label { background-color: var(--bg-tertiary); position: relative; overflow: hidden; }
        .option-label.selected { background-color: var(--bg-info); border-color: var(--border-accent); }
        .option-label:hover { background-color: var(--bg-accent); }
        #question-palette { background-color: var(--bg-secondary); }
        #hide-palette-btn, #show-palette-btn { background-color: var(--bg-secondary); color: var(--text-secondary); border-color: var(--border-primary); }
        
        /* Improved Explanation Typography and Styles */
        .explanation-card {
            background-color: var(--bg-secondary);
            border-top: 4px solid var(--text-accent);
            border-radius: 0.75rem;
            margin-top: 2rem;
            animation: fade-in-up 0.4s ease-out;
            box-shadow: 0 10px 15px -3px rgba(0, 0, 0, 0.1), 0 4px 6px -2px rgba(0, 0, 0, 0.05);
            position: relative; /* For toolbar anchor */
        }
        .explanation-header {
            padding: 1rem 1.5rem;
            font-weight: 700;
            color: var(--text-accent);
            display: flex;
            align-items: center;
            border-bottom: 1px solid var(--border-primary);
            font-size: 1.1rem;
        }
        .explanation-content {
            padding: 1.5rem 2rem;
            color: var(--text-primary);
            font-size: 1.05rem;
            line-height: 1.8;
            font-family: var(--font-explanation);
            user-select: text; /* Allow selection in explanation */
        }

        /* Feedback Header Badge */
        .feedback-badge {
            display: inline-flex;
            align-items: center;
            padding: 0.25rem 0.75rem;
            border-radius: 9999px;
            font-weight: 700;
            font-size: 0.875rem;
            margin-left: 1rem;
            opacity: 0;
            transform: translateY(-10px);
            transition: all 0.3s ease-out;
        }
        .feedback-badge.visible { opacity: 1; transform: translateY(0); }
        .feedback-badge.correct { background-color: var(--bg-success); color: var(--text-success); border: 1px solid var(--bg-success-border); }
        .feedback-badge.incorrect { background-color: var(--bg-danger); color: var(--text-danger); border: 1px solid var(--bg-danger-border); }

        @keyframes fade-in-up {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }

        /* Streak Badge */
        .streak-badge {
            display: flex;
            align-items: center;
            background: rgba(245, 158, 11, 0.1); /* amber-500 with opacity */
            color: #d97706; /* amber-600 */
            padding: 0.25rem 0.75rem;
            border-radius: 99px;
            font-weight: 700;
            font-size: 0.85rem;
            border: 1px solid rgba(245, 158, 11, 0.3);
            transition: transform 0.2s cubic-bezier(0.34, 1.56, 0.64, 1);
        }
        .streak-badge.active {
            transform: scale(1.1);
            background: rgba(245, 158, 11, 0.25);
            box-shadow: 0 0 10px rgba(245, 158, 11, 0.2);
        }
        
        /* Swipe Animations */
        @keyframes slide-out-left { to { transform: translateX(-100%); opacity: 0; } }
        @keyframes slide-in-from-right { from { transform: translateX(100%); opacity: 0; } to { transform: translateX(0); opacity: 1; } }
        @keyframes slide-out-right { to { transform: translateX(100%); opacity: 0; } }
        @keyframes slide-in-from-left { from { transform: translateX(-100%); opacity: 0; } to { transform: translateX(0); opacity: 1; } }

        .slide-out-left { animation: slide-out-left var(--swipe-duration) ease-out forwards; }
        .slide-in-from-right { animation: slide-in-from-right var(--swipe-duration) ease-out forwards; }
        .slide-out-right { animation: slide-out-right var(--swipe-duration) ease-out forwards; }
        .slide-in-from-left { animation: slide-in-from-left var(--swipe-duration) ease-out forwards; }
        
        /* Toast Notification */
        @keyframes fade-in-out {
            0% { transform: translateY(100%); opacity: 0; }
            10% { transform: translateY(0); opacity: 1; }
            90% { transform: translateY(0); opacity: 1; }
            100% { transform: translateY(100%); opacity: 0; }
        }
        #toast-notification {
            position: fixed;
            bottom: -100px;
            left: 50%;
            transform: translateX(-50%);
            padding: 1rem 1.5rem;
            background-color: #333;
            color: white;
            border-radius: 0.5rem;
            font-size: 0.875rem;
            z-index: 100;
            visibility: hidden;
            opacity: 0;
        }
        #toast-notification.show {
            visibility: visible;
            bottom: 2rem;
            animation: fade-in-out 3s ease-in-out forwards;
        }

        /* Save Button Animation */
        @keyframes pop {
            0% { transform: scale(1); }
            50% { transform: scale(1.25); }
            100% { transform: scale(1); }
        }
        .pop-animation {
            animation: pop 0.3s ease-out;
        }
        
        /* CHART CSS */
        .chart-wrapper {
            display: flex;
            align-items: flex-end;
            justify-content: flex-start;
            gap: 16px;
            height: 300px;
            width: 100%;
            overflow-x: auto;
            padding: 20px 10px 40px 10px;
            border-bottom: 2px solid var(--border-primary);
            border-left: 2px solid var(--border-primary);
            background: linear-gradient(to bottom, var(--bg-primary), var(--bg-secondary));
            border-radius: 12px;
            box-shadow: inset 0 0 20px rgba(0,0,0,0.02);
        }
        .chart-bar-container {
            display: flex;
            flex-direction: column;
            align-items: center;
            height: 100%;
            justify-content: flex-end;
            flex-shrink: 0;
            width: 50px;
            position: relative;
            transition: transform 0.2s;
        }
        .chart-bar-container:hover {
            transform: translateY(-5px);
            z-index: 10;
        }
        
        @keyframes grow-up {
            from { height: 0; opacity: 0; }
            to { opacity: 1; }
        }
        
        .chart-bar {
            width: 100%;
            border-radius: 6px 6px 0 0;
            position: relative;
            min-height: 24px;
            display: flex;
            align-items: flex-start;
            justify-content: center;
            padding-top: 5px;
            overflow: hidden;
            box-shadow: 0 4px 6px rgba(0,0,0,0.1);
            animation: grow-up 0.8s cubic-bezier(0.34, 1.56, 0.64, 1) forwards;
            opacity: 0; /* Start invisible for animation */
        }
        
        /* Interference/Gradient Effects */
        .bar-success {
            background: linear-gradient(180deg, #4ade80 0%, #16a34a 100%);
            border: 1px solid #15803d;
        }
        .bar-danger {
            background: linear-gradient(180deg, #f87171 0%, #dc2626 100%);
            border: 1px solid #b91c1c;
        }
        
        /* Text inside bar */
        .chart-bar-text {
            font-size: 12px;
            font-weight: bold;
            color: white;
            text-shadow: 0 1px 2px rgba(0,0,0,0.5);
            writing-mode: vertical-rl;
            transform: rotate(180deg);
            white-space: nowrap;
            margin-bottom: 5px;
        }
        
        .chart-bar-label {
            font-size: 11px;
            margin-top: 10px;
            color: var(--text-secondary);
            transform: rotate(-45deg);
            white-space: nowrap;
            text-align: right;
            width: 100%;
            transform-origin: top center;
            text-overflow: ellipsis;
            overflow: hidden;
        }
        .chart-bar-tooltip {
            position: absolute;
            bottom: 100%;
            left: 50%;
            transform: translateX(-50%) translateY(-8px);
            background: rgba(17, 24, 39, 0.95);
            color: #fff;
            padding: 8px 12px;
            border-radius: 6px;
            font-size: 12px;
            white-space: nowrap;
            box-shadow: 0 10px 15px -3px rgba(0, 0, 0, 0.3);
            opacity: 0;
            pointer-events: none;
            transition: opacity 0.2s, transform 0.2s;
            z-index: 20;
            border: 1px solid rgba(255,255,255,0.1);
            text-align: center;
        }
        .chart-bar-tooltip::after {
            content: '';
            position: absolute;
            top: 100%;
            left: 50%;
            margin-left: -6px;
            border-width: 6px;
            border-style: solid;
            border-color: rgba(17, 24, 39, 0.95) transparent transparent transparent;
        }
        .chart-bar-container:hover .chart-bar-tooltip {
            opacity: 1;
            transform: translateX(-50%) translateY(-12px);
        }
        
        /* STAT CARDS */
        .stat-card {
            background: var(--bg-primary);
            border: 1px solid var(--border-primary);
            border-radius: 12px;
            padding: 1rem;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: center;
            box-shadow: 0 2px 4px rgba(0,0,0,0.05);
            transition: transform 0.2s;
        }
        .stat-card:hover { transform: translateY(-2px); }
        .stat-value { font-size: 1.5rem; font-weight: 800; color: var(--text-primary); }
        .stat-label { font-size: 0.75rem; color: var(--text-tertiary); text-transform: uppercase; letter-spacing: 0.05em; }

        /* DYNAMIC ISLAND */
        #dynamic-island {
            position: fixed;
            z-index: 9999;
            background: rgba(30, 30, 30, 0.9);
            backdrop-filter: blur(16px);
            border-radius: 20px;
            padding: 6px;
            gap: 8px;
            display: flex;
            box-shadow: 0 10px 25px rgba(0, 0, 0, 0.3);
            transition: width 0.5s, height 0.5s, top 0.5s, left 0.5s, right 0.5s, bottom 0.5s, border-radius 0.5s, opacity 0.4s ease;
            cursor: grab;
            border: 1px solid rgba(255,255,255,0.15);
        }
        #dynamic-island:active { cursor: grabbing; }
        
        #dynamic-island.dragging { transition: none !important; }
        
        @keyframes hint-move {
            0% { transform: translateY(0); }
            25% { transform: translateY(5px); }
            50% { transform: translateY(-5px); }
            75% { transform: translateY(5px); }
            100% { transform: translateY(0); }
        }
        .hint-anim { animation: hint-move 0.6s ease-in-out; box-shadow: 0 0 25px rgba(255,255,255,0.5) !important; }
        
        #dynamic-island.idle { opacity: 0.3; }
        #dynamic-island.idle:hover { opacity: 1; }
        
        #dynamic-island.horizontal { flex-direction: row; height: auto; align-items: center; }
        #dynamic-island.vertical { flex-direction: column; width: auto; align-items: center; }

        .island-btn {
            background: rgba(255, 255, 255, 0.1);
            border: none;
            border-radius: 50%;
            width: 32px;
            height: 32px;
            display: flex;
            align-items: center;
            justify-content: center;
            color: white;
            transition: background 0.2s, transform 0.2s;
            cursor: pointer;
        }
        .island-btn:hover { background: rgba(255, 255, 255, 0.3); transform: scale(1.1); }
        .island-btn:active { transform: scale(0.95); }
        .island-btn svg { width: 18px; height: 18px; }
        
        .island-mini-btn {
            background: rgba(255, 255, 255, 0.05);
            border: none;
            border-radius: 50%;
            width: 20px;
            height: 20px;
            display: flex;
            align-items: center;
            justify-content: center;
            color: rgba(255,255,255,0.7);
            cursor: pointer;
            font-size: 16px;
            line-height: 1;
            padding: 0;
            padding-bottom: 2px;
        }
        .island-mini-btn:hover { background: rgba(255, 255, 255, 0.2); color: white; }

        .island-separator { background: rgba(255,255,255,0.2); border-radius: 99px; }
        #dynamic-island.horizontal .island-separator { width: 1px; height: 20px; }
        #dynamic-island.vertical .island-separator { width: 20px; height: 1px; }

        #dynamic-island.minimized {
            padding: 0;
            gap: 0;
            overflow: hidden;
            background: rgba(255, 255, 255, 0.25);
            border: 1px solid rgba(255, 255, 255, 0.4);
            backdrop-filter: blur(10px);
            cursor: pointer;
            justify-content: center;
            opacity: 1 !important; 
            box-shadow: 0 4px 10px rgba(0,0,0,0.2);
        }

        [data-theme="light"] #dynamic-island.minimized,
        [data-theme="ambient"] #dynamic-island.minimized {
            background: rgba(0, 0, 0, 0.6);
            border: 1px solid rgba(255, 255, 255, 0.2);
            color: white;
        }

        #dynamic-island.minimized > * { display: none !important; }

        #dynamic-island.minimized.horizontal { width: 40px; height: 6px; border-radius: 10px; }
        #dynamic-island.minimized.vertical { width: 6px; height: 40px; border-radius: 10px; }

    </style>
    <script>
        // Immediately apply theme from localStorage to prevent FOUC
        (function() {
            try {
                const examId = 'exam_1764420616199_o5x4c4y';
                const THEME_KEY = 'examTheme_' + examId;
                const savedTheme = localStorage.getItem(THEME_KEY);
                if (savedTheme) {
                    document.documentElement.dataset.theme = savedTheme;
                }
            } catch (e) {
                console.error('Could not apply saved theme.', e);
            }
        })();
    </script>
</head>
<body class="">
    
    <!-- DYNAMIC ISLAND: Left Side Center Default -->
    <div id="dynamic-island" class="vertical" style="top: 50%; left: 20px; transform: translateY(-50%);">
        <button id="island-minimize-btn" class="island-mini-btn" aria-label="Minimize Island" title="Minimize">&minus;</button>
        
        <div class="island-separator"></div>
        <button id="island-home-btn" class="island-btn" aria-label="Go Home">
             <svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor" stroke-width="2">
                <path stroke-linecap="round" stroke-linejoin="round" d="M3 12l2-2m0 0l7-7 7 7M5 10v10a1 1 0 001 1h3m10-11l2 2m-2-2v10a1 1 0 01-1 1h-3m-6 0a1 1 0 001-1v-4a1 1 0 011-1h2a1 1 0 011 1v4a1 1 0 001 1m-6 0h6" />
            </svg>
        </button>

        <div class="island-separator"></div>
        <button id="island-progress-btn" class="island-btn" aria-label="View Progress">
             <svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor" stroke-width="2">
                <path stroke-linecap="round" stroke-linejoin="round" d="M9 19v-6a2 2 0 00-2-2H5a2 2 0 00-2 2v6a2 2 0 002 2h2a2 2 0 002-2zm0 0V9a2 2 0 012-2h2a2 2 0 012 2v10m-6 0a2 2 0 002 2h2a2 2 0 002-2m0 0V5a2 2 0 012-2h2a2 2 0 012 2v14a2 2 0 01-2 2h-2a2 2 0 01-2-2z" />
            </svg>
        </button>
        <div class="island-separator"></div>
        <button id="island-theme-btn" class="island-btn" aria-label="Toggle Theme">
             <svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor" stroke-width="2">
                <path stroke-linecap="round" stroke-linejoin="round" d="M7 21a4 4 0 01-4-4V5a2 2 0 012-2h4a2 2 0 012 2v12a4 4 0 01-4 4zm0 0h12a2 2 0 002-2v-4a2 2 0 00-2-2h-2.343M11 7.343l1.657-1.657a2 2 0 012.828 0l2.829 2.829a2 2 0 010 2.828l-8.486 8.485M7 17h.01" />
            </svg>
        </button>
        <div class="island-separator"></div>
        <button id="island-settings-btn" class="island-btn" aria-label="Swipe Settings">
             <svg id="swipe-icon-smooth" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor" stroke-width="2">
                <path stroke-linecap="round" stroke-linejoin="round" d="M4 6h16M4 12h16M4 18h16" />
            </svg>
            <svg id="swipe-icon-hard" class="hidden" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor" stroke-width="2">
                <path stroke-linecap="round" stroke-linejoin="round" d="M13 10V3L4 14h7v7l9-11h-7z" />
            </svg>
        </button>
    </div>

    <div id="toast-notification"></div>
    <main id="app-container" class="h-screen w-screen relative">
        <!-- SCREEN 1: SECTION SETUP -->
        <div id="setup-screen" class="screen active flex-col justify-center items-center p-4">
            <div id="resume-banner" class="hidden w-full max-w-5xl bg-yellow-100 border-l-4 border-yellow-500 text-yellow-700 p-4 rounded-lg shadow-lg mb-6" role="alert">
                <div class="flex">
                    <div class="py-1"><svg class="fill-current h-6 w-6 text-yellow-500 mr-4" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20"><path d="M10 18a8 8 0 100-16 8 8 0 000 16zm-1-5.414V8a1 1 0 112 0v4.586a1 1 0 11-2 0zM10 6a1 1 0 100-2 1 1 0 000 2z"/></svg></div>
                    <div>
                        <p class="font-bold">Saved Exam Session Found!</p>
                        <p class="text-sm">You have a saved exam in progress. What would you like to do?</p>
                        <div class="mt-3">
                            <button id="resume-session-btn" class="bg-yellow-500 hover:bg-yellow-600 text-white font-bold py-2 px-4 rounded" aria-label="Resume previous session">Resume Session</button>
                            <button id="discard-draft-btn" class="ml-4 text-sm text-yellow-800 hover:underline" aria-label="Discard draft and start new">Discard and Start New</button>
                        </div>
                    </div>
                </div>
            </div>
            <div class="w-full max-w-5xl bg-white p-8 rounded-lg shadow-lg themed-bg-secondary themed-shadow">
                <p class="text-xs text-center mb-4 themed-text-tertiary">Read instructions before start</p>
                <h1 class="text-3xl font-bold mb-2 text-center themed-text-accent">PHARMACOLOGY</h1>
                <h2 class="text-xl font-semibold mb-6 text-center themed-text-secondary">Exam Setup</h2>
                
                <div class="grid grid-cols-1 md:grid-cols-3 gap-8">
                    <!-- Left Panel: Exam Configuration -->
                    <div class="md:col-span-2 space-y-6">
                        <div>
                            <p class="mb-4 themed-text-secondary">Total Questions Found: 100. Configure your exam sections below.</p>
                            
                            <div class="space-y-4 mb-6">
                                <div>
                                    <label for="subject-name" class="block text-sm font-medium themed-text-secondary">Subject Name</label>
                                    <input type="text" id="subject-name" value="PHARMACOLOGY" class="mt-1 block w-full p-2 border rounded-md shadow-sm focus:ring-blue-500 focus:border-blue-500">
                                </div>
                                <div>
                                    <label for="candidate-name" class="block text-sm font-medium themed-text-secondary">Candidate Name</label>
                                    <input type="text" id="candidate-name" class="mt-1 block w-full p-2 border rounded-md shadow-sm focus:ring-blue-500 focus:border-blue-500">
                                </div>
                                <div>
                                    <label for="short-note" class="block text-sm font-medium themed-text-secondary">Short Note (Optional)</label>
                                    <textarea id="short-note" rows="2" class="mt-1 block w-full p-2 border rounded-md shadow-sm focus:ring-blue-500 focus:border-blue-500" placeholder="Any notes for this test..."></textarea>
                                </div>
                            </div>

                            <div class="flex items-center mb-6">
                                <input type="checkbox" id="shuffle-mcqs-checkbox" class="h-4 w-4 text-blue-600 border-gray-300 rounded focus:ring-blue-500">
                                <label for="shuffle-mcqs-checkbox" class="ml-2 block text-sm font-medium themed-text-secondary">Shuffle Questions</label>
                            </div>

                            <hr class="my-6 themed-border-primary">
                            
                            <div class="flex justify-between items-center mb-4">
                                <h2 class="text-xl font-semibold themed-text-primary">Exam Sections</h2>
                                <button id="auto-set-sections-btn" class="px-3 py-1 rounded-full text-xs font-semibold border border-blue-500 text-blue-500 hover:bg-blue-50 transition-colors" title="Split into 50-question sections (1 min/q)">Auto Set</button>
                            </div>
                            <div id="sections-container" class="space-y-4 max-h-48 overflow-y-auto pr-2">
                                <!-- Sections will be injected here by JS -->
                            </div>

                            <div class="mt-4 flex justify-between items-center">
                                <button id="add-section-btn" class="py-2 px-4 rounded themed-bg-accent themed-bg-accent-hover" aria-label="Add a new section">Add Section</button>
                            </div>
                        </div>

                        <div class="mt-6 text-center">
                            <button id="start-exam-btn" class="py-3 px-8 rounded-lg font-bold text-lg w-full md:w-auto" style="background-color: var(--text-accent); color: var(--text-inverted);" aria-label="Start the exam">Start Exam</button>
                            <p id="setup-error" class="mt-4 themed-text-danger text-center h-5"></p>
                        </div>
                    </div>

                    <!-- Right Panel: Alternative Modes -->
                    <div class="md:col-span-1 p-6 rounded-lg border themed-bg-primary themed-border-primary">
                        <h2 class="text-xl font-semibold mb-6 text-center themed-text-primary">Alternative Modes</h2>
                        <div class="space-y-4">
                            <div class="p-4 rounded-lg border" style="background-color: var(--bg-warning); border-color: var(--bg-warning-border);">
                                <h3 class="font-semibold text-lg text-center mb-3 themed-text-warning">Practice Mode</h3>
                                <div class="space-y-4 text-sm">
                                     <div>
                                        <label for="practice-q-count-slider" class="block font-medium themed-text-secondary">Number of Questions: <span id="practice-q-count-label">100</span></label>
                                        <input type="range" id="practice-q-count-slider" min="1" max="100" value="100" class="mt-1 block w-full cursor-pointer">
                                    </div>
                                    <div>
                                        <label for="practice-time-overall" class="block font-medium themed-text-secondary">Overall Time Limit (minutes)</label>
                                        <input type="number" id="practice-time-overall" class="mt-1 block w-full p-2 border rounded-md shadow-sm" placeholder="Optional: e.g., 60">
                                    </div>
                                    <div>
                                        <label for="practice-time-per-mcq" class="block font-medium themed-text-secondary">Time per MCQ (seconds)</label>
                                        <input type="number" id="practice-time-per-mcq" class="mt-1 block w-full p-2 border rounded-md shadow-sm" placeholder="Optional: e.g., 30">
                                    </div>
                                </div>
                                <button id="start-practice-btn" class="mt-4 py-3 px-6 rounded-lg font-bold w-full" style="background-color: var(--text-warning); color: var(--bg-primary);" aria-label="Start Practice Mode">Start Practice</button>
                                <p class="text-xs mt-2 text-center themed-text-tertiary">Get instant feedback with streaks & gamification.</p>
                            </div>
                            <div class="text-center">
                                <button id="revise-btn" class="py-3 px-6 rounded-lg font-bold w-full" style="background-color: #8b5cf6; color: white;" aria-label="Start Revise Mode">Revise Test</button>
                                <p class="text-xs mt-2 themed-text-tertiary">Freely browse all questions, answers, and explanations.</p>
                            </div>
                             <div id="saved-questions-container" class="text-center hidden">
                                 <button id="view-saved-btn" class="py-3 px-6 rounded-lg font-bold w-full relative" style="background-color: #4f46e5; color: white;" aria-label="View Saved Questions">
                                     Saved Questions
                                     <span id="saved-questions-count" class="absolute top-0 right-0 -mt-2 -mr-2 bg-red-500 text-white text-xs font-bold rounded-full h-5 w-5 flex items-center justify-center">0</span>
                                 </button>
                                 <p class="text-xs mt-2 themed-text-tertiary">Review questions you've bookmarked.</p>
                            </div>
                            <div id="past-results-container" class="text-center hidden">
                                <button id="view-past-results-btn" class="py-3 px-6 rounded-lg font-bold w-full relative" style="background-color: #0d9488; color: white;" aria-label="View Past Results">
                                    View Past Results
                                    <span id="past-results-count" class="absolute top-0 right-0 -mt-2 -mr-2 bg-red-500 text-white text-xs font-bold rounded-full h-5 w-5 flex items-center justify-center">0</span>
                                 </button>
                                 <p class="text-xs mt-2 themed-text-tertiary">Review your past exam performances.</p>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <!-- SCREEN 2: EXAM -->
        <div id="exam-screen" class="screen h-full relative">
            <!-- Main Content -->
            <div class="flex-1 flex flex-col">
                <header class="p-3 shadow-md flex justify-between items-center themed-bg-secondary themed-shadow">
                    <div class="flex items-center space-x-4">
                        <div>
                            <h1 id="section-name" class="text-xl font-bold themed-text-accent"></h1>
                            <p id="question-counter" class="text-sm themed-text-tertiary"></p>
                        </div>
                    </div>
                    <div class="flex items-center space-x-4">
                        <span class="text-xs font-bold themed-text-tertiary">created by mano</span>
                        <button id="calculator-toggle-btn" class="p-2 rounded-full themed-bg-accent-hover" aria-label="Toggle Calculator">
                           <svg xmlns="http://www.w3.org/2000/svg" class="h-6 w-6 themed-text-secondary" fill="none" viewBox="0 0 24 24" stroke="currentColor">
                                <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 7h6m0 10v-3m-3 3h.01M9 17h.01M9 14h.01M12 14h.01M15 11h.01M12 11h.01M9 11h.01M7 21h10a2 2 0 002-2V5a2 2 0 00-2-2H7a2 2 0 00-2 2v14a2 2 0 002 2z" />
                           </svg>
                        </button>
                        <div id="timer" class="text-xl font-mono px-4 py-1 rounded themed-bg-accent themed-text-primary" aria-label="Timer"></div>
                    </div>
                </header>

                <main class="flex-1 p-6 overflow-y-auto themed-bg-tertiary">
                    <div class="p-6 rounded-lg themed-bg-secondary">
                        <p id="question-text" class="text-lg font-semibold mb-6 whitespace-pre-wrap"></p>
                        <div id="question-image-container" class="my-4 flex justify-center"></div>
                        <div id="options-container" class="space-y-4"></div>
                    </div>
                </main>
                
                <footer class="p-4 themed-bg-secondary" style="box-shadow: 0 -2px 5px var(--shadow-color);">
                    <div class="flex justify-between items-center">
                        <div>
                            <button id="mark-review-btn" class="py-2 px-4 rounded text-white bg-purple-600 hover:bg-purple-700" aria-label="Mark for Review and Next">Mark for Review & Next</button>
                            <button id="clear-response-btn" class="py-2 px-4 rounded ml-4 themed-bg-accent themed-bg-accent-hover" aria-label="Clear Selected Response">Clear Response</button>
                        </div>
                        <div class="flex items-center space-x-4">
                            <button id="prev-btn" class="py-2 px-6 rounded disabled:opacity-50 themed-bg-accent themed-bg-accent-hover" aria-label="Previous Question">Previous</button>
                            <button id="save-next-btn" class="py-2 px-6 rounded font-bold" style="background-color: #16a34a; color: white;" aria-label="Save Answer and Next Question">Save & Next</button>
                        </div>
                    </div>
                </footer>
            </div>

            <!-- Side Palette -->
            <aside id="question-palette" class="w-64 flex-shrink-0 relative transition-all duration-300 ease-in-out themed-bg-secondary">
                <div id="palette-content-wrapper" class="p-4 flex flex-col h-full w-full overflow-hidden transition-opacity duration-300">
                    <h2 class="text-lg font-bold mb-4 text-center">Question Palette</h2>
                    <div id="palette-container" class="grid grid-cols-5 gap-2 flex-1 overflow-y-auto"></div>
                     <div class="mt-4 text-xs space-y-2 themed-text-secondary">
                        <div class="flex items-center justify-between">
                            <div class="flex items-center"><div class="w-4 h-4 rounded bg-green-600 mr-2"></div> Answered</div>
                            <span id="answered-count" class="font-bold px-1.5 py-0.5 rounded-full text-[10px] themed-bg-accent themed-text-primary">0</span>
                        </div>
                        <div class="flex items-center justify-between">
                            <div class="flex items-center"><div class="w-4 h-4 rounded bg-red-600 mr-2"></div> Not Answered</div>
                            <span id="not-answered-count" class="font-bold px-1.5 py-0.5 rounded-full text-[10px] themed-bg-accent themed-text-primary">0</span>
                        </div>
                        <div class="flex items-center justify-between">
                            <div class="flex items-center"><div class="w-4 h-4 rounded bg-gray-500 mr-2"></div> Not Visited</div>
                            <span id="not-visited-count" class="font-bold px-1.5 py-0.5 rounded-full text-[10px] themed-bg-accent themed-text-primary">0</span>
                        </div>
                         <div class="flex items-center justify-between">
                            <div class="flex items-center"><div class="w-4 h-4 rounded bg-purple-600 mr-2 relative"><svg xmlns="http://www.w3.org/2000/svg" class="absolute top-1/2 left-1/2 -translate-x-1/2 -translate-y-1/2 h-2.5 w-2.5 text-white" viewBox="0 0 24 24" fill="currentColor"><path d="M14.4 6L14 4H5v17h2v-7h5.6l.4 2h7V6z" /></svg></div> Marked for Review</div>
                            <span id="marked-for-review-count" class="font-bold px-1.5 py-0.5 rounded-full text-[10px] themed-bg-accent themed-text-primary">0</span>
                        </div>
                    </div>
                </div>
                <button id="hide-palette-btn" class="absolute top-1/2 -left-3 z-10 p-1 rounded-full shadow-md border -translate-y-1/2" aria-label="Hide Question Palette">
                    <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" fill="none" viewBox="0 0 24 24" stroke="currentColor" stroke-width="2"><path stroke-linecap="round" stroke-linejoin="round" d="M9 5l7 7-7 7" /></svg>
                </button>
            </aside>

            <!-- Show Palette Button -->
            <button id="show-palette-btn" class="hidden absolute top-1/2 right-4 z-10 p-2 rounded-full shadow-lg border -translate-y-1/2" aria-label="Show Question Palette">
                <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" fill="none" viewBox="0 0 24 24" stroke="currentColor" stroke-width="2"><path stroke-linecap="round" stroke-linejoin="round" d="M15 19l-7-7 7-7" /></svg>
            </button>
        </div>

        <!-- SCREEN 3: RESULTS -->
        <div id="results-screen" class="screen flex-col items-center justify-center p-8">
            <div class="w-full max-w-4xl p-8 rounded-lg shadow-lg themed-bg-secondary themed-shadow">
                <h1 class="text-4xl font-bold mb-4 text-center themed-text-accent">Exam Results</h1>
                <div id="exam-details" class="text-sm themed-text-secondary mb-6 border-b pb-4 space-y-1 themed-border-primary"></div>
                <div id="overall-performance" class="p-6 rounded-lg mb-8 text-center themed-bg-primary"></div>
                <h2 class="text-2xl font-semibold mb-4 text-center">Section-wise Analysis</h2>
                <div id="section-analysis" class="space-y-4"></div>
                <div class="mt-8 flex justify-center gap-4">
                    <button id="review-answers-btn" class="py-3 px-8 text-white rounded font-bold" style="background-color: var(--text-accent);" aria-label="Review Answers">Review Answers</button>
                    <button id="download-report-btn" class="py-3 px-8 text-white rounded font-bold" style="background-color: var(--text-success); color: var(--text-inverted);" aria-label="Download Report">Download Report</button>
                    <button id="restart-btn" class="py-3 px-8 rounded font-bold themed-bg-accent themed-text-primary" aria-label="Start New Exam">New Exam</button>
                </div>
            </div>
        </div>
        
        <!-- SCREEN 4: REVIEW -->
        <div id="review-screen" class="screen h-full flex-col">
          <header class="p-3 shadow-md flex justify-between items-center w-full themed-bg-secondary">
              <h1 id="review-title" class="text-xl font-bold themed-text-accent">Review Mode</h1>
               <div class="flex items-center space-x-4">
                    <button id="save-mcq-btn" class="p-2 rounded-full themed-bg-accent-hover" aria-label="Save Question">
                        <!-- SVG will be injected here -->
                    </button>
                    <button id="exit-revise-btn" class="py-2 px-4 rounded themed-bg-accent themed-bg-accent-hover hidden" aria-label="Exit Revise Mode">Exit Revise</button>
                    <button id="back-to-results-btn" class="py-2 px-4 rounded themed-bg-accent themed-bg-accent-hover" aria-label="Back to Results">Back to Results</button>
                </div>
          </header>
          <div id="review-palette-container" class="w-full max-w-4xl mx-auto p-4 border-b overflow-x-auto themed-bg-primary themed-border-primary">
             <div id="review-palette-grid" class="flex flex-nowrap gap-3 justify-start">
                 <!-- Review palette buttons will be injected here -->
             </div>
          </div>
          <main class="flex-1 p-6 overflow-y-auto w-full max-w-4xl mx-auto">
              <div class="p-6 rounded-lg themed-bg-secondary">
                  <div class="flex justify-between items-center">
                    <p id="review-question-text" class="text-lg font-semibold mb-6 whitespace-pre-wrap flex-1"></p>
                    <div id="review-time-taken" class="text-sm flex items-center ml-4 flex-shrink-0 themed-text-secondary"></div>
                  </div>
                  <div id="review-question-image-container" class="my-4 flex justify-center"></div>
                  <div id="review-options-container" class="space-y-4"></div>
                  
                  <!-- EXPLANATION SECTION -->
                  <div class="explanation-card" id="review-explanation-card">
                       <div class="explanation-header">
                            <svg xmlns="http://www.w3.org/2000/svg" class="h-6 w-6 mr-2" fill="none" viewBox="0 0 24 24" stroke="currentColor"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M13 16h-1v-4h-1m1-4h.01M21 12a9 9 0 11-18 0 9 9 0 0118 0z" /></svg>
                            Explanation
                       </div>

                      <div id="explanation-image-container" class="my-4 flex justify-center"></div>
                      <div id="explanation-container" class="explanation-content prose max-w-none">
                          <!-- Explanation text will go here -->
                      </div>
                  </div>
              </div>
          </main>
          <footer class="p-4 shadow-inner flex justify-between items-center w-full themed-bg-secondary" style="box-shadow: 0 -2px 5px var(--shadow-color);">
              <button id="review-prev-btn" class="py-2 px-6 rounded disabled:opacity-50 themed-bg-accent themed-bg-accent-hover" aria-label="Previous Question">Previous</button>
              <span id="review-question-counter" class="font-bold"></span>
              <button id="review-next-btn" class="py-2 px-6 rounded disabled:opacity-50 themed-bg-accent themed-bg-accent-hover" aria-label="Next Question">Next</button>
          </footer>
        </div>
        
        <!-- SCREEN 5: PRACTICE MODE -->
        <div id="practice-screen" class="screen h-full flex-col relative">
            <header class="p-3 shadow-md flex justify-between items-center w-full themed-bg-secondary">
                <div class="flex items-center space-x-4">
                    <div>
                        <h1 class="text-xl font-bold themed-text-warning">Practice Mode</h1>
                        <p id="practice-subject-name" class="text-sm themed-text-tertiary"></p>
                    </div>
                </div>
                
                <!-- STREAK COUNTER & FEEDBACK -->
                <div id="practice-streak-container" class="flex-1 flex justify-center items-center">
                    <div id="streak-badge" class="streak-badge hidden">
                        <span class="mr-1">ðŸ”¥</span> Streak: <span id="streak-count" class="ml-1">0</span>
                    </div>
                    <!-- Header Feedback Badge -->
                    <div id="header-feedback-badge" class="feedback-badge">
                         <span id="header-feedback-text"></span>
                    </div>
                </div>

                <div class="flex items-center space-x-4">
                    <button id="save-mcq-practice-btn" class="p-2 rounded-full themed-bg-accent-hover" aria-label="Save Question">
                        <!-- SVG will be injected here -->
                    </button>
                    <button id="toggle-sparkles-btn" class="p-2 rounded-full themed-bg-accent-hover" aria-label="Toggle Sparkles">
                       <svg xmlns="http://www.w3.org/2000/svg" class="h-6 w-6 text-yellow-500" viewBox="0 0 24 24" fill="currentColor" stroke="currentColor" stroke-width="2">
                            <path stroke-linecap="round" stroke-linejoin="round" d="M5 3v4M3 5h4M6 17v4m-2-2h4m5-16l2.286 6.857L21 12l-5.714 2.143L13 21l-2.286-6.857L5 12l5.714-2.143L13 3z" />
                       </svg>
                    </button>
                    <button id="practice-calculator-toggle-btn" class="p-2 rounded-full themed-bg-accent-hover" aria-label="Toggle Calculator">
                       <svg xmlns="http://www.w3.org/2000/svg" class="h-6 w-6 themed-text-secondary" fill="none" viewBox="0 0 24 24" stroke="currentColor">
                            <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 7h6m0 10v-3m-3 3h.01M9 17h.01M9 14h.01M12 14h.01M15 11h.01M12 11h.01M9 11h.01M7 21h10a2 2 0 002-2V5a2 2 0 00-2-2H7a2 2 0 00-2 2v14a2 2 0 002 2z" />
                       </svg>
                    </button>
                    <div id="practice-timer" class="text-xl font-mono px-4 py-1 rounded hidden themed-bg-accent themed-text-primary" aria-label="Practice Timer"></div>
                    <button id="exit-practice-btn" class="py-2 px-4 rounded themed-bg-accent themed-bg-accent-hover" aria-label="Exit Practice Mode">Exit Practice</button>
                </div>
            </header>
            
            <div id="practice-palette-container" class="w-full max-w-4xl mx-auto p-4 border-b overflow-x-auto themed-bg-primary themed-border-primary">
                 <div id="practice-palette-grid" class="flex flex-nowrap gap-3 justify-start">
                     <!-- Practice palette buttons injected by JS -->
                 </div>
            </div>

            <div id="per-question-timer-container" class="w-full h-2 themed-bg-accent hidden">
                <div id="per-question-timer-bar" class="h-full bg-green-500" style="transition: width 150ms linear;"></div>
            </div>
            <main class="flex-1 p-6 overflow-y-auto w-full max-w-4xl mx-auto">
                <div class="p-6 rounded-lg themed-bg-secondary">
                    <p id="practice-question-text" class="text-lg font-semibold mb-6 whitespace-pre-wrap"></p>
                    <div id="practice-question-image-container" class="my-4 flex justify-center"></div>
                    <div id="practice-options-container" class="space-y-4"></div>
                    
                    <!-- EXPLANATION SECTION -->
                    <div id="practice-explanation-section" class="hidden explanation-card">
                        <div class="explanation-header">
                            <svg xmlns="http://www.w3.org/2000/svg" class="h-6 w-6 mr-2" fill="none" viewBox="0 0 24 24" stroke="currentColor"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M13 16h-1v-4h-1m1-4h.01M21 12a9 9 0 11-18 0 9 9 0 0118 0z" /></svg>
                            Explanation
                        </div>
                        
                        <div id="practice-explanation-image-container" class="my-4 flex justify-center"></div>
                        <div id="practice-explanation-container" class="explanation-content prose max-w-none">
                            <!-- Explanation text will go here -->
                        </div>
                    </div>
                </div>
            </main>
            <footer class="p-4 shadow-inner flex justify-between items-center w-full themed-bg-secondary" style="box-shadow: 0 -2px 5px var(--shadow-color);">
                <button id="practice-prev-btn" class="py-2 px-6 rounded disabled:opacity-50 themed-bg-accent themed-bg-accent-hover" aria-label="Previous Question">Previous</button>
                <span id="practice-question-counter" class="font-bold"></span>
                <button id="practice-next-btn" class="py-2 px-6 rounded disabled:opacity-50 themed-bg-accent themed-bg-accent-hover" aria-label="Next Question">Next</button>
            </footer>
        </div>

        <!-- SCREEN 6: PRACTICE RESULTS -->
        <div id="practice-results-screen" class="screen flex-col items-center justify-center p-8">
            <div class="w-full max-w-2xl p-8 rounded-lg shadow-lg text-center themed-bg-secondary themed-shadow">
                <h1 class="text-4xl font-bold mb-4 themed-text-warning">Practice Results</h1>
                <div id="practice-exam-details" class="text-sm themed-text-secondary mb-6 border-b pb-4 space-y-1 themed-border-primary"></div>
                
                <div class="p-6 rounded-lg mb-8 themed-bg-primary">
                    <h2 class="text-2xl font-semibold">Your Performance</h2>
                    <p id="practice-score" class="text-5xl font-bold my-4"></p>
                    <div class="flex justify-center space-x-8 text-lg">
                        <span id="practice-correct"></span>
                        <span id="practice-incorrect"></span>
                        <span id="practice-attempted"></span>
                    </div>
                     <div id="practice-avg-time" class="mt-4 themed-text-secondary"></div>
                </div>
                
                <div class="mt-8 flex justify-center gap-4">
                    <button id="review-practice-answers-btn" class="py-3 px-8 rounded font-bold" style="background-color: var(--text-accent); color: var(--text-inverted);" aria-label="Review Practice Answers">Review Answers</button>
                    <button id="restart-practice-btn" class="py-3 px-8 rounded font-bold" style="background-color: var(--text-warning); color: var(--bg-primary);" aria-label="Restart Practice">Restart Practice</button>
                    <button id="back-to-setup-btn" class="py-3 px-8 rounded font-bold themed-bg-accent themed-text-primary" aria-label="Back to Setup">Back to Setup</button>
                </div>
            </div>
        </div>

        <!-- SCREEN 7: PAST RESULTS HISTORY -->
        <div id="past-results-screen" class="screen flex-col items-center justify-center p-8">
            <div class="w-full max-w-3xl p-8 rounded-lg shadow-lg themed-bg-secondary themed-shadow">
                <h1 class="text-3xl font-bold mb-6 text-center themed-text-accent">Past Exam Results</h1>
                <div id="past-results-list" class="space-y-3 max-h-[60vh] overflow-y-auto pr-2">
                    <!-- Past results will be injected here -->
                </div>
                <div class="mt-8 flex justify-center">
                    <button id="back-to-setup-from-history-btn" class="py-3 px-8 rounded font-bold themed-bg-accent themed-text-primary" aria-label="Back to Setup">Back to Setup</button>
                </div>
            </div>
        </div>

        <!-- SCREEN 8: PROGRESS ANALYTICS (CHARTS) -->
        <div id="progress-screen" class="screen flex-col items-center justify-center p-8">
            <div class="w-full max-w-5xl p-8 rounded-lg shadow-lg themed-bg-secondary themed-shadow overflow-y-auto max-h-full">
                <h1 class="text-3xl font-bold mb-6 text-center themed-text-accent">Performance Analytics</h1>
                
                <!-- KPI Dashboard (Inserted) -->
                <div id="kpi-dashboard" class="grid grid-cols-2 md:grid-cols-4 gap-4 mb-8">
                    <!-- Cards injected by JS -->
                </div>

                <!-- Exam Progress -->
                <div class="mb-8">
                    <h2 class="text-xl font-bold mb-4 themed-text-primary flex items-center">
                        <svg class="w-5 h-5 mr-2 themed-text-accent" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 19v-6a2 2 0 00-2-2H5a2 2 0 00-2 2v6a2 2 0 002 2h2a2 2 0 002-2zm0 0V9a2 2 0 012-2h2a2 2 0 012 2v10m-6 0a2 2 0 002 2h2a2 2 0 002-2m0 0V5a2 2 0 012-2h2a2 2 0 012 2v14a2 2 0 01-2 2h-2a2 2 0 01-2-2z"></path></svg>
                        Exam History
                    </h2>
                    <div id="exam-chart-container" class="chart-wrapper">
                        <!-- Exam bars injected here -->
                    </div>
                    <p id="exam-chart-empty" class="text-sm themed-text-tertiary mt-2 text-center hidden">No exam attempts recorded yet.</p>
                </div>

                <!-- Practice Progress -->
                <div class="mb-8">
                    <div class="flex justify-between items-center mb-4">
                        <h2 class="text-xl font-bold themed-text-warning flex items-center">
                            <svg class="w-5 h-5 mr-2" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M13 10V3L4 14h7v7l9-11h-7z"></path></svg>
                            Practice History
                        </h2>
                        <button id="reset-practice-history-btn" class="text-xs py-1 px-3 rounded border border-red-300 text-red-500 hover:bg-red-50">Reset Practice History</button>
                    </div>
                    <div id="practice-chart-container" class="chart-wrapper">
                        <!-- Practice bars injected here -->
                    </div>
                    <p id="practice-chart-empty" class="text-sm themed-text-tertiary mt-2 text-center hidden">No practice sessions recorded yet.</p>
                </div>

                <div class="flex justify-center">
                    <button id="back-to-setup-from-progress-btn" class="py-3 px-8 rounded font-bold themed-bg-accent themed-text-primary" aria-label="Back to Setup">Back to Setup</button>
                </div>
            </div>
        </div>


        <!-- MODAL: CONFIRMATION -->
        <div id="confirmation-modal" class="fixed inset-0 bg-black bg-opacity-50 z-50 hidden items-center justify-center p-4">
            <div class="p-8 rounded-lg shadow-xl max-w-sm w-full text-center modal-card">
                <h2 class="text-xl font-bold mb-4">Confirm Action</h2>
                <p id="confirmation-message" class="mb-6 themed-text-secondary"></p>
                <div class="flex justify-center gap-4">
                    <button id="cancel-confirmation-btn" class="py-2 px-6 rounded font-semibold themed-bg-accent themed-bg-accent-hover" aria-label="Cancel Action">Cancel</button>
                    <button id="confirm-action-btn" class="py-2 px-6 rounded font-semibold text-white" style="background-color: var(--text-danger); color: var(--text-inverted);" aria-label="Confirm Action">Proceed</button>
                </div>
            </div>
        </div>

        <!-- MODAL: REPORT OPTIONS -->
        <div id="report-options-modal" class="fixed inset-0 bg-black bg-opacity-50 z-50 hidden items-center justify-center p-4">
            <div class="p-8 rounded-lg shadow-xl max-w-sm w-full text-center modal-card">
                <h2 class="text-xl font-bold mb-4">Download Report</h2>
                <p class="mb-6 themed-text-secondary">Would you like to include the explanations in your PDF report?</p>
                <div class="flex flex-col gap-4">
                    <button id="download-with-explanations-btn" class="py-2 px-6 rounded font-semibold" style="background-color: var(--text-success); color: var(--text-inverted);" aria-label="Download with explanations">With Explanations</button>
                    <button id="download-without-explanations-btn" class="py-2 px-6 rounded font-semibold" style="background-color: var(--text-accent); color: var(--text-inverted);" aria-label="Download without explanations">Without Explanations</button>
                    <button id="cancel-report-download-btn" class="py-2 px-6 rounded font-semibold mt-2 themed-bg-accent themed-bg-accent-hover" aria-label="Cancel Download">Cancel</button>
                </div>
            </div>
        </div>

        <!-- MODAL: PRACTICE RESUME -->
        <div id="practice-resume-modal" class="fixed inset-0 bg-black bg-opacity-50 z-50 hidden items-center justify-center p-4">
            <div class="p-8 rounded-lg shadow-xl max-w-sm w-full text-center modal-card">
                <h2 class="text-xl font-bold mb-4">Resume Practice</h2>
                <p class="mb-6 themed-text-secondary">You have a saved practice session. Would you like to continue where you left off?</p>
                <div class="flex justify-center gap-4">
                    <button id="practice-start-new-btn" class="py-2 px-6 rounded font-semibold themed-bg-accent themed-bg-accent-hover" aria-label="Start new practice">Start New</button>
                    <button id="practice-resume-btn" class="py-2 px-6 rounded font-semibold text-white bg-yellow-500 hover:bg-yellow-600" aria-label="Resume practice">Resume</button>
                </div>
            </div>
        </div>
        
        <!-- CALCULATOR MODAL -->
        <div id="calculator-modal" class="calculator-modal absolute w-64 rounded-lg shadow-2xl z-50 hidden">
            <div id="calculator-header" class="p-2 flex justify-between items-center rounded-t-lg cursor-move themed-bg-accent">
                <span class="font-bold themed-text-secondary">Calculator</span>
                <button id="calculator-close-btn" class="text-xl themed-text-secondary hover:themed-text-primary" aria-label="Close Calculator">&times;</button>
            </div>
            <div class="p-4">
                <div id="calculator-display" class="text-right text-3xl font-mono p-2 rounded mb-4 overflow-x-auto themed-bg-tertiary" aria-label="Calculator Display">0</div>
                <div id="calculator-buttons" class="grid grid-cols-4 gap-2">
                    <button class="calculator-btn col-span-2" style="background-color: var(--text-danger); color: var(--text-inverted);" aria-label="Clear Calculation">C</button>
                    <button class="calculator-btn operator themed-bg-accent themed-bg-accent-hover">/</button>
                    <button class="calculator-btn operator themed-bg-accent themed-bg-accent-hover">*</button>

                    <button class="calculator-btn digit themed-bg-tertiary">7</button>
                    <button class="calculator-btn digit themed-bg-tertiary">8</button>
                    <button class="calculator-btn digit themed-bg-tertiary">9</button>
                    <button class="calculator-btn operator themed-bg-accent themed-bg-accent-hover">-</button>

                    <button class="calculator-btn digit themed-bg-tertiary">4</button>
                    <button class="calculator-btn digit themed-bg-tertiary">5</button>
                    <button class="calculator-btn digit themed-bg-tertiary">6</button>
                    <button class="calculator-btn operator themed-bg-accent themed-bg-accent-hover">+</button>

                    <button class="calculator-btn digit themed-bg-tertiary">1</button>
                    <button class="calculator-btn digit themed-bg-tertiary">2</button>
                    <button class="calculator-btn digit themed-bg-tertiary">3</button>
                    <button class="calculator-btn equals row-span-2" style="background-color: var(--text-accent); color: var(--text-inverted);" aria-label="Calculate Result">=</button>
                    
                    <button class="calculator-btn col-span-2 digit themed-bg-tertiary">0</button>
                    <button class="calculator-btn decimal themed-bg-tertiary">.</button>
                </div>
            </div>
        </div>
    </main>

<script>
    // --- APP INITIALIZATION ---
    // Prevent right-click to protect content
    document.addEventListener('contextmenu', (e) => e.preventDefault());

    // Prevent inspection via keyboard shortcuts
    document.addEventListener('keydown', (e) => {
        // F12, Ctrl+Shift+I, Ctrl+Shift+J, Ctrl+U
        if (e.key === 'F12' || 
            (e.ctrlKey && e.shiftKey && (e.key === 'I' || e.key === 'J' || e.key === 'C')) || 
            (e.ctrlKey && e.key === 'U')) {
            e.preventDefault();
        }
    });

    window.addEventListener('DOMContentLoaded', () => {
      try {
        // --- DATA & STATE ---
        // FIX: Using renamed variable from outer scope.
        const examId = 'exam_1764420616199_o5x4c4y';
        const mcqs = [{"id":1,"question":"A patient with blood pressure 148/92 mmHg and chronic kidney disease with proteinuria is being evaluated for management. Which of the following is the most appropriate antihypertensive agent in this scenario?","options":{"a":"Telmisartan","b":"Spironolactone","c":"Amlodipine","d":"Metoprolol"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nPatients with Chronic Kidney Disease (CKD), especially those with proteinuria or diabetes, benefit most from ACE inhibitors (ACEis) or Angiotensin Receptor Blockers (ARBs) like Telmisartan. These drugs reduce intraglomerular pressure by dilating the efferent arteriole, thereby providing significant renoprotection and decreasing protein excretion.\n\n**2. Rationale for Incorrect Options:**\n- b) Spironolactone: An aldosterone antagonist; while useful in resistant hypertension, it carries a high risk of hyperkalemia in CKD patients and is not the first-line agent for renoprotection.\n- c) Amlodipine: A calcium channel blocker; it is effective for lowering blood pressure but does not offer the same degree of intrinsic renoprotection/antiproteinuric effect as ARBs.\n- d) Metoprolol: A beta-blocker; indicated primarily for heart failure or ischemic heart disease, not a first-line choice for renal protection in CKD.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **ACEis/ARBs** are the drugs of choice for HTN in Diabetics and CKD patients.\n- They delay the progression of nephropathy by reducing albuminuria.\n- **Contraindication:** Bilateral renal artery stenosis (can precipitate acute renal failure).\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"A-C-D\" Rule for HTN in CKD/Diabetes: **ACE inhibitors / ARBs** are preferred first."},{"id":2,"question":"A 27-year old female presents with irregular heartbeat, weight loss, excessive hunger, sweating, heat intolerance and restlessness. The patient also has difficulty falling asleep. After thorough examination the patient was started on the respective medication. Which of the following the patient might have been started on?","options":{"a":"Propranolol","b":"Lorazepam","c":"Methimazole","d":"Amiodarone"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe clinical presentation (weight loss, heat intolerance, palpitations, restlessness) is classic for hyperthyroidism (Thyrotoxicosis). Methimazole is a thioamide that acts by inhibiting thyroid peroxidase (TPO), thereby blocking the synthesis of thyroid hormones (T3/T4). It is the preferred antithyroid drug for most patients due to a longer half-life and lower side effect profile compared to Propylthiouracil (PTU).\n\n**2. Rationale for Incorrect Options:**\n- a) Propranolol: A beta-blocker used for symptomatic control (palpitations, tremors) but does not reduce thyroid hormone synthesis.\n- b) Lorazepam: A benzodiazepine; acts as a sedative/anxiolytic but treats none of the underlying endocrine pathology.\n- d) Amiodarone: An antiarrhythmic drug that contains iodine; it can actually induce thyroid dysfunction (hypo- or hyperthyroidism) and is not a treatment for spontaneous thyrotoxicosis.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Methimazole:** DOC for Graves' disease; teratogenic in 1st trimester (causes Aplasia Cutis).\n- **Propylthiouracil (PTU):** DOC in Pregnancy (1st Trimester) and Thyroid storm (blocks peripheral conversion of T4 to T3).\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"P\" for Pregnancy & Peripheral conversion: **PTU** is preferred in Pregnancy and blocks Peripheral conversion."},{"id":3,"question":"A 64-year-old patient begins aspirin therapy for exertional chest pain. After the first dose, however, he experiences shortness of breath and wheezing. Which of the following medications would serve as a suitable aspirin alternative in this patient?","options":{"a":"Heparin","b":"Warfarin","c":"Clopidogrel","d":"Streptokinase"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nIn patients with aspirin hypersensitivity (manifesting as respiratory symptoms like wheezing/SOB, often part of Samterâ€™s triad), Clopidogrel is the standard alternative antiplatelet agent. It works by irreversibly blocking the P2Y12 component of ADP receptors on the platelet surface, preventing aggregation.\n\n**2. Rationale for Incorrect Options:**\n- a) Heparin: An anticoagulant, not an antiplatelet agent; used for DVT/PE or acute coronary syndromes inpatient, not for chronic oral maintenance.\n- b) Warfarin: A Vitamin K antagonist (anticoagulant); used for AFib or valve replacement, not a substitute for antiplatelet therapy in CAD.\n- d) Streptokinase: A fibrinolytic (clot buster); used for acute MI or PE, not for chronic prevention of exertional angina.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Aspirin Exacerbated Respiratory Disease (AERD):** Asthma + Nasal Polyps + Aspirin Sensitivity (Samterâ€™s Triad).\n- **Clopidogrel:** A prodrug activated by CYP2C19; often combined with aspirin (DAPT) post-stent.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- No well-established, logical learning aid (mnemonic/trick) is required or available for this concept."},{"id":4,"question":"Mechanism of action of Sulfonylureas is:","options":{"a":"Inhibit ATP sensitive K+ channels","b":"â†‘ PPAR-Î³ activity","c":"Inhibit Î±-glucosidase activity","d":"SGLT-2 inhibitors"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nSulfonylureas (e.g., Glimepiride, Glibenclamide) bind to the SUR1 subunit of ATP-sensitive K+ channels on pancreatic beta cells. This inhibition closes the K+ channel, causing membrane depolarization, calcium influx, and the subsequent release of preformed insulin granules (insulin secretagogues).\n\n**2. Rationale for Incorrect Options:**\n- b) â†‘ PPAR-Î³ activity: Mechanism of Thiazolidinediones (Glitazones like Pioglitazone).\n- c) Inhibit Î±-glucosidase activity: Mechanism of Acarbose and Miglitol (prevents carb breakdown in gut).\n- d) SGLT-2 inhibitors: Mechanism of Gliflozins (e.g., Dapagliflozin), which block glucose reabsorption in the kidney.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Side Effects:** Hypoglycemia (most common) and Weight Gain.\n- **Contraindications:** Renal failure (risk of prolonged hypoglycemia), Pregnancy.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Sulfonylureas Squeeze\": Think of them Squeezing the pancreas to release insulin (Secretagogues)."},{"id":5,"question":"A patient with hypertension is currently on a combination of three antihypertensive medications. Despite this, the blood pressure remains poorly controlled. Laboratory investigations reveal hypokalemia. Which of the following is the most appropriate drug to be added to the treatment regimen?","options":{"a":"Eplerenone","b":"Furosemide","c":"Nitroglycerin","d":"Amlodipine"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe combination of resistant hypertension (uncontrolled on 3 drugs) and hypokalemia is highly suggestive of Primary Hyperaldosteronism (Conn's syndrome) or diuretic-induced potassium loss. Adding a Mineralocorticoid Receptor Antagonist (MRA) like Eplerenone or Spironolactone is effective as it blocks aldosterone, lowers BP, and conserves potassium.\n\n**2. Rationale for Incorrect Options:**\n- b) Furosemide: A loop diuretic; would worsen the hypokalemia significantly.\n- c) Nitroglycerin: A venodilator used for angina or hypertensive emergencies (IV), not for chronic maintenance of resistant HTN.\n- d) Amlodipine: Likely already part of the 3-drug regimen; adding it wouldn't address the specific electrolyte abnormality or aldosterone excess mechanism.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Resistant HTN:** BP not at target despite 3 drugs (including a diuretic).\n- **Eplerenone vs. Spironolactone:** Eplerenone is more selective (less gynecomastia risk) but expensive.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- No well-established, logical learning aid (mnemonic/trick) is required or available for this concept."},{"id":6,"question":"Which of the following is a 5th generation cephalosporin with anti MRSA activity?","options":{"a":"Ceftriaxone","b":"Aztreonam","c":"Cefazoline","d":"Ceftabiprole"},"correctAnswer":"d","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\n5th Generation Cephalosporins (e.g., Ceftaroline, Ceftabiprole) are unique because they have been engineered to bind to PBP-2a, the altered penicillin-binding protein responsible for methicillin resistance in Staphylococcus aureus (MRSA). They are the only cephalosporins with anti-MRSA activity.\n\n**2. Rationale for Incorrect Options:**\n- a) Ceftriaxone: 3rd gen; good Gram (-) coverage and CNS penetration, but no MRSA coverage.\n- b) Aztreonam: A Monobactam; active only against Gram (-) aerobes (including Pseudomonas), no Gram (+) activity.\n- c) Cefazolin: 1st gen; excellent for MSSA and surgical prophylaxis, but inactive against MRSA.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Ceftaroline/Ceftabiprole:** Only cephalosporins covering MRSA.\n- **Ceftazidime/Cefepime:** Cephalosporins with Pseudomonas coverage.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"CARoline and TABitha\": **Ceftaroline** and **Ceftabiprole** are the 5th gen sisters who fight the superbug (MRSA)."},{"id":7,"question":"Tocilizumab, that belongs to a class of drugs called SAARDâ€™s was used in cytokine storm works by inhibiting:","options":{"a":"IL-1","b":"IL-6","c":"TNF-alpha","d":"CD-20"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nTocilizumab is a monoclonal antibody that specifically binds to and inhibits the Interleukin-6 (IL-6) receptor. IL-6 is a key pro-inflammatory cytokine involved in the pathogenesis of Rheumatoid Arthritis and the \"Cytokine Storm\" seen in severe COVID-19 infections.\n\n**2. Rationale for Incorrect Options:**\n- a) IL-1: Inhibited by Anakinra (IL-1 receptor antagonist).\n- c) TNF-alpha: Inhibited by Infliximab, Adalimumab, Etanercept.\n- d) CD-20: Inhibited by Rituximab (B-cell depletion).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Tocilizumab Uses:** Rheumatoid Arthritis, Giant Cell Arteritis, CRS (Cytokine Release Syndrome).\n- **Side Effects:** Increased risk of infections (TB reactivation), hepatotoxicity, neutropenia.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Toci-liz-umab\": Think Toci targets Six (IL-6)."},{"id":8,"question":"A patient diagnosed with rheumatoid arthritis was on medications. After 2 years, he developed blurring of vision and was found to have corneal opacity. Which drug is most likely to cause this?","options":{"a":"Sulfasalazine","b":"Chloroquine","c":"Methotrexate","d":"Leflunomide"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nChloroquine and Hydroxychloroquine (antimalarials used in RA/SLE) can deposit in the cornea (causing vortex keratopathy/corneal opacity) and the retina (causing irreversible \"bull's eye\" maculopathy). Regular ophthalmologic screening is mandatory for patients on long-term therapy.\n\n**2. Rationale for Incorrect Options:**\n- a) Sulfasalazine: Causes reversible male infertility (oligospermia) and hemolysis in G6PD deficiency.\n- c) Methotrexate: Causes hepatotoxicity, pulmonary fibrosis, and bone marrow suppression.\n- d) Leflunomide: Causes diarrhea, hepatotoxicity, and is highly teratogenic.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Chloroquine Retinopathy:** Central visual field loss; \"Bull's eye\" appearance on fundoscopy.\n- **Monitoring:** Baseline eye exam + annual screening after 5 years (or sooner with risk factors).\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Chloroquine sees Colors\": Associated with color vision changes and blindness (retinopathy)."},{"id":9,"question":"Which of the following antiarrhythmic drug is contraindicated in a patient with interstitial lung disease?","options":{"a":"Amiodarone","b":"Sotalol","c":"Quinidine","d":"Lignocaine"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nAmiodarone is notorious for causing pulmonary toxicity, which can manifest as chronic interstitial pneumonitis, pulmonary fibrosis, or organizing pneumonia. In a patient with pre-existing Interstitial Lung Disease (ILD), Amiodarone is contraindicated as it can rapidly exacerbate the condition and lead to fatal respiratory failure.\n\n**2. Rationale for Incorrect Options:**\n- b) Sotalol: Beta-blocker with Class III activity; main risk is Torsades de Pointes (QT prolongation), not pulmonary fibrosis.\n- c) Quinidine: Class Ia; causes Cinchonism (tinnitus, headache) and thrombocytopenia.\n- d) Lignocaine (Lidocaine): Class Ib; CNS toxicity (seizures, confusion) is the primary concern.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Amiodarone Toxicity:** Pulmonary fibrosis, Thyroid (hypo/hyper), Liver toxicity, Blue-gray skin, Corneal deposits (P-T-L-B-C).\n- It has the longest half-life (~50+ days) of all antiarrhythmics.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Check PFTs, LFTs, TFTs\": The standard monitoring triad for Amiodarone."},{"id":10,"question":"A patient presents with severe anemia. History reveals chronic kidney disease. What is the most appropriate treatment to manage this patient?","options":{"a":"Ferrous sulphate","b":"Darbepoetin alfa","c":"Sargramostim","d":"Romiplostim"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nAnemia in CKD is primarily due to the kidney's failure to produce Erythropoietin (EPO). Management involves replacing this hormone. Darbepoetin alfa is a modified, long-acting form of recombinant erythropoietin (ESA - Erythropoiesis Stimulating Agent) that stimulates red blood cell production.\n\n**2. Rationale for Incorrect Options:**\n- a) Ferrous sulphate: Used for Iron Deficiency Anemia. While CKD patients may need iron, the primary defect is EPO deficiency.\n- c) Sargramostim: GM-CSF; used to stimulate white blood cell (granulocyte/macrophage) recovery after chemotherapy.\n- d) Romiplostim: Thrombopoietin receptor agonist; used for ITP (low platelets), not anemia.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Target Hb in CKD:** 10-11.5 g/dL. Normalizing Hb (>13) increases risk of stroke and thrombosis.\n- **Iron stores:** Must be replete (Ferritin >100, Saturation >20%) before starting ESAs.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- No well-established, logical learning aid (mnemonic/trick) is required or available for this concept."},{"id":11,"question":"A 64-year old man presented with to the hospital with complains of difficulty in breathing with brisk walking. Since Cardiac evaluation is normal, exercise induced asthma is suspected. During general check-up the IOP seems to be elevated. Which of the following medication must be avoided in this patient ?","options":{"a":"Apraclonidine","b":"Mannitol","c":"Acetazolamide","d":"Timolol"},"correctAnswer":"d","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nTimolol is a non-selective beta-blocker used topically for glaucoma to decrease aqueous humor production. Systemic absorption can occur, leading to beta-2 blockade in the lungs. In patients with asthma or COPD, this can precipitate severe bronchospasm.\n\n**2. Rationale for Incorrect Options:**\n- a) Apraclonidine: Alpha-2 agonist; side effects are local (lid retraction, blanching), not bronchospasm.\n- b) Mannitol: Osmotic diuretic used for acute angle-closure glaucoma; not contraindicated in asthma.\n- c) Acetazolamide: Carbonic anhydrase inhibitor; avoided in sulfa allergy, but safe in asthma.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Betaxolol:** A selective beta-1 blocker eye drop, theoretically safer in asthmatics but Timolol is strictly avoided.\n- **Latanoprost (PG analogues):** First-line for glaucoma; causes iris darkening and eyelash growth.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Timolol targets the Thorax\": Timolol (non-selective) hits the heart and the lungs (Thorax)."},{"id":12,"question":"Mycoplasma is resistant to:","options":{"a":"Vancomycin","b":"Doxycycline","c":"Moxifloxacin","d":"Azithromycin"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nMycoplasma species naturally lack a cell wall (peptidoglycan layer). Vancomycin acts by inhibiting cell wall synthesis (specifically binding to D-Ala-D-Ala). Therefore, Mycoplasma is intrinsically resistant to Vancomycin and all Beta-lactams (Penicillins, Cephalosporins).\n\n**2. Rationale for Incorrect Options:**\n- b) Doxycycline: A tetracycline (protein synthesis inhibitor); effective against Mycoplasma.\n- c) Moxifloxacin: A fluoroquinolone (DNA gyrase inhibitor); effective against Mycoplasma (Atypical coverage).\n- d) Azithromycin: A macrolide (protein synthesis inhibitor); drug of choice for Mycoplasma pneumonia.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Intrinisic Resistance:** Organisms lacking the target structure (e.g., Mycoplasma vs. Cell wall inhibitors).\n- **DOC for Mycoplasma:** Macrolides (Azithromycin) or Doxycycline.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Mycoplasma has No Wall\": So drugs that break walls (Penicillins, Vanco) can't break it."},{"id":13,"question":"Which of the following pairs have risk of hypoglycemia ?","options":{"a":"Glargine, Metformin","b":"Degludec, Acarbose","c":"Lispro, Glimepiride","d":"Detemir, Pioglitazone"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nHypoglycemia is the most common and dangerous side effect of drugs that increase insulin levels independent of glucose. Insulin Lispro (rapid-acting insulin) and Glimepiride (Sulfonylurea/Secretagogue) both actively drive glucose down regardless of current blood sugar levels, carrying the highest risk.\n\n**2. Rationale for Incorrect Options:**\n- a) Glargine, Metformin: Metformin is an insulin sensitizer (does not increase insulin secretion) and rarely causes hypoglycemia (\"euglycemic\").\n- b) Degludec, Acarbose: Acarbose delays absorption; alone it does not cause hypoglycemia.\n- d) Detemir, Pioglitazone: Pioglitazone (TZD) is a sensitizer; low risk of hypoglycemia monotherapy.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **High Risk Drugs:** Insulin, Sulfonylureas (Glimepiride, Glibenclamide), Meglitinides (Repaglinide).\n- **Low/No Risk Drugs:** Metformin, DPP-4 inhibitors (Gliptins), GLP-1 agonists, SGLT-2 inhibitors.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- No well-established, logical learning aid (mnemonic/trick) is required or available for this concept."},{"id":14,"question":"A 30-year-old male with history of head trauma presents with excessive thirst and polyuria. Laboratory tests reveal hypernatremia and low urine osmolality. What is the most appropriate pharmacological treatment?","options":{"a":"Hydrochlorothiazide","b":"Desmopressin","c":"Tolvaptan","d":"Insulin"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe patient has Central Diabetes Insipidus (History of head trauma -> pituitary damage -> lack of ADH). The clinical picture is Polyuria + Hypernatremia + Low Urine Osmolality. The treatment is to replace the missing hormone using Desmopressin, a synthetic analogue of ADH (Vasopressin) that is selective for V2 receptors (antidiuretic effect) with minimal V1 (vasoconstrictor) activity.\n\n**2. Rationale for Incorrect Options:**\n- a) Hydrochlorothiazide: Paradoxically used in Nephrogenic DI, not the first line for Central DI.\n- c) Tolvaptan: A V2 receptor antagonist; used for SIADH (too much ADH), would worsen DI.\n- d) Insulin: Used for Diabetes Mellitus, not Diabetes Insipidus.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Central DI:** ADH deficiency. Rx: Desmopressin.\n- **Nephrogenic DI:** ADH resistance (kidney doesn't respond). Rx: Thiazides, Amiloride (for Lithium induced), Indomethacin.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"D\" for Deficient and Desmopressin: Central DI is ADH Deficiency treated with Desmopressin."},{"id":15,"question":"A 54-year-old man is hospitalized after a planned abdominal surgery. One of his physicians administers a new drug whose mechanism of action you do not know. Shortly after administration of the drug the patient develops flushing, diaphoresis and nausea. His blood pressure is 100/70 mmHg and heart rate is 55/min. his pupils are constricted but reactive to light. This medication most likely works as?","options":{"a":"Muscarinic antagonist","b":"Muscarinic agonist","c":"Ach & stimulator","d":"Mu receptor agonist"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe symptoms describedâ€”Flushing, Diaphoresis (sweating), Nausea, Constricted pupils (Miosis), Bradycardia (HR 55), and Hypotensionâ€”are classic signs of parasympathetic overstimulation. This profile fits a Muscarinic Agonist (e.g., Bethanechol or Pilocarpine) or Cholinesterase inhibitor toxicity.\n\n**2. Rationale for Incorrect Options:**\n- a) Muscarinic antagonist: (e.g., Atropine) Causes \"Dry as a bone, Red as a beet, Mad as a hatter, Dilated pupils\" (Mydriasis, Tachycardia, Dry skin).\n- c) Ach & stimulator: Vague term, but likely refers to nicotinic/general stimulation which might include muscle fasciculations (not emphasized here).\n- d) Mu receptor agonist: (Opioids) Causes miosis and bradycardia but typically causes dry skin (not diaphoresis) and constipation (not nausea/diarrhea focus).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **DUMBBELSS Mnemonic for Cholinergic Excess:** Diarrhea, Urination, Miosis, Bradycardia/Bronchospasm, Emesis, Lacrimation, Salivation, Sweating.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- **DUMBBELSS** (as above)."},{"id":16,"question":"Which of the following Î±-blocker is used in the treatment of BPH and does not produce hypotension","options":{"a":"Doxazosin","b":"Phentolamine","c":"Tamsulosin","d":"Terazosin"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nTamsulosin is a selective Alpha-1A receptor blocker. The Alpha-1A subtype is primarily found in the smooth muscle of the prostate and bladder neck. Because it has low affinity for Alpha-1B receptors (found in blood vessels), it relaxes prostatic smooth muscle to improve BPH symptoms without causing significant systemic vasodilation or hypotension.\n\n**2. Rationale for Incorrect Options:**\n- a) Doxazosin & d) Terazosin: Non-selective Alpha-1 blockers. They block both 1A (prostate) and 1B (vessels), causing significant postural hypotension. Titration is required.\n- b) Phentolamine: Non-selective Alpha (1 & 2) blocker; used for Pheochromocytoma or cocaine hypertension, not BPH.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Floppy Iris Syndrome:** Tamsulosin relaxes iris dilator muscle; complication during cataract surgery.\n- **First Dose Phenomenon:** Seen with Prazosin/Terazosin (syncope); dose taken at bedtime.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Tamsulosin Targets The Prostate\": Selective for the urinary tract."},{"id":17,"question":"All of the following causes gynecomastia except:","options":{"a":"Digoxin","b":"Amiloride","c":"Cimetidine","d":"Spironolactone"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nGynecomastia is a known side effect of drugs that disrupt the estrogen/testosterone ratio. Amiloride is a potassium-sparing diuretic (ENaC blocker) that does not have anti-androgenic properties and does not cause gynecomastia.\n\n**2. Rationale for Incorrect Options:**\n- a) Digoxin: Has estrogen-like activity.\n- c) Cimetidine: Inhibits dihydrotestosterone (DHT) binding and metabolism of estradiol.\n- d) Spironolactone: Blocks androgen receptors and decreases testosterone production; classic cause of gynecomastia.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **\"DISCO\" causes Boobs:** Digoxin, Isoniazid, Spironolactone, Cimetidine, Oestrogens (and Ketoconazole).\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- **DISCO** mnemonic (as above)."},{"id":18,"question":"Phase IV clinical trial is :","options":{"a":"Most important for microdosing of drug","b":"Not helpful in measuring side effects","c":"Minimum year of this trial 10 years","d":"Post marketing trial"},"correctAnswer":"d","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nPhase IV clinical trials occur after the drug has been approved by regulatory bodies (FDA/DCGI) and marketed to the general public. The primary goal is Post-Marketing Surveillance (PMS) to detect rare, long-term, or idiosyncratic side effects that were not caught in the smaller, shorter Phase I-III trials.\n\n**2. Rationale for Incorrect Options:**\n- a) Microdosing: This is Phase 0 (Exploratory).\n- b) Not helpful in measuring side effects: Incorrect; detecting rare side effects is its main purpose.\n- c) Minimum year 10 years: There is no fixed duration; it is an ongoing surveillance process.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Phase I:** Safety (Healthy volunteers). \"Is it safe?\"\n- **Phase II:** Efficacy (Patients). \"Does it work?\"\n- **Phase III:** Comparison (Large scale RCTs). \"Is it better?\"\n- **Phase IV:** Surveillance (Public). \"Rare side effects?\"\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"SWIM\": Safe (I), Work (II), Improvement (III), Market (IV)."},{"id":19,"question":"An 8-year-old Asian immigrant is brought to the ER after a recent episode of brief loss of consciousness. His mother, who accompanies him to the hospital, says that he lost consciousness suddenly, felt on the floor and â€˜started shaking and jerkingâ€™. She also claims that her son has had episodes of â€˜staring in the spaceâ€™ that occur several times a day for the last year. The boy seems sleepy although he is oriented in time and place. Several hours later, he is alert and says that he wants to go home. Which of the following agents is the best long-term treatment for this patient?","options":{"a":"Ethosuximide","b":"Phenytoin","c":"Phenobarbital","d":"Valproate"},"correctAnswer":"d","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe child has symptoms of Absence seizures (\"staring in space\") and Generalized Tonic-Clonic Seizures (GTCS - loss of consciousness, shaking). Valproate is a broad-spectrum antiepileptic drug that is effective against both seizure types. It is the drug of choice when multiple seizure types coexist or the diagnosis is unclear.\n\n**2. Rationale for Incorrect Options:**\n- Ethosuximide: DOC for pure Absence seizures. It does not cover GTCS and offers no protection against the \"shaking/jerking\" episodes.\n- Phenytoin & Phenobarbital: Effective for GTCS but can worsen or precipitate Absence seizures.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Valproate:** DOC for Juvenile Myoclonic Epilepsy (JME), Absence + GTCS.\n- **Teratogenicity:** Neural tube defects (Spina bifida).\n- **Ethosuximide:** Blocks T-type Calcium channels (Thalamus).\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Valproate is Versatile\": Covers almost all seizure types (Broad spectrum)."},{"id":20,"question":"A patient with a history of peptic ulcer disease (PUD) presents with arthritis. Which of the following is the most appropriate anti-inflammatory drug to use in this patient?","options":{"a":"Aspirin","b":"Celecoxib","c":"Ibuprofen","d":"Diclofenac"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nTraditional NSAIDs inhibit both COX-1 (protects gastric lining) and COX-2 (inflammation). In patients with a history of Peptic Ulcer Disease (PUD), Selective COX-2 inhibitors like Celecoxib are preferred because they spare the protective gastric prostaglandins synthesized by COX-1, reducing the risk of GI bleeding and ulcers.\n\n**2. Rationale for Incorrect Options:**\n- a) Aspirin, c) Ibuprofen, d) Diclofenac: Non-selective COX inhibitors. They inhibit COX-1 significantly, increasing acid secretion and reducing mucus protection, leading to high risk of ulcer recurrence.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **COX-2 Selectivity:** Celecoxib > Etoricoxib > Meloxicam.\n- **Cardiovascular Risk:** COX-2 inhibitors increase risk of MI/Thrombosis (pro-thrombotic due to unbalance between TxA2 and PGI2).\n- **Sulfa Allergy:** Celecoxib is a sulfonamide; watch for allergies.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- No well-established, logical learning aid (mnemonic/trick) is required or available for this concept."},{"id":21,"question":"Which of the following will show Vasomotor reversal of Dale?","options":{"a":"Î± blocker followed by Dopamine","b":"Î± blocker followed by Nor Adrenaline","c":"Î± blocker followed by Serotonin","d":"Î± blocker followed by Adrenaline"},"correctAnswer":"d","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nNormally, Adrenaline causes a net rise in BP (Alpha-1 vasoconstriction > Beta-2 vasodilation).Dale's Vasomotor Reversal: If an Alpha-blocker (e.g., Phentolamine) is given first, the vasoconstrictive Alpha-1 effect of Adrenaline is blocked. The unopposed Beta-2 vasodilator action then dominates, causing a fall in Blood Pressure instead of a rise.\n\n**2. Rationale for Incorrect Options:**\n- a) Dopamine: Acts on D1, Beta-1, Alpha-1 depending on dose; not the classic agent for this phenomenon.\n- b) Noradrenaline: Predominantly Alpha agonist with minimal Beta-2 activity. Blocking Alpha results in no response or slight blockage, but not a \"reversal\" (fall) because there is no Beta-2 vasodilation to unmask.\n- c) Serotonin: Not involved in adrenergic reversal.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Biphasic Response of Adrenaline:** Initial rise (Alpha-1) followed by fall (Beta-2).\n- **Reversal:** Only seen with Adrenaline + Alpha Blocker.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- No well-established, logical learning aid (mnemonic/trick) is required or available for this concept."},{"id":22,"question":"A 42-year old male was brought to E.R in a confused state. Few minutes after patient was admitted he vomited thrice. Physical exam shows dry skin and mouth, flushed face and patient has deep breathing and breath smells fruity. Which of the following is the best management of this patient?","options":{"a":"Ringer lactate","b":"Regular insulin + I.V fluid","c":"Sulfonylureas","d":"Calcium gluconate"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe patient presents with classic DKA: Hyperglycemia, Dehydration (dry skin), Kussmaul breathing (deep breathing), and Fruity breath (Acetone). The cornerstone of management is IV Fluids (Normal Saline) to correct dehydration and IV Regular Insulin to arrest ketogenesis and lower blood glucose.\n\n**2. Rationale for Incorrect Options:**\n- a) Ringer lactate: Normal Saline (0.9% NaCl) is generally preferred initially for volume resuscitation.\n- c) Sulfonylureas: Contraindicated; slow onset and useless in insulin-deficient states like DKA (Type 1 DM pathology).\n- d) Calcium gluconate: Used for hyperkalemia with ECG changes; not a routine first-line for DKA unless cardiac instability from potassium is proven (DKA usually presents with total body K+ depletion despite serum hyperkalemia).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Potassium Management:** Serum K+ falls rapidly with insulin therapy. Add K+ to fluids once K+ \u003c 5.0-5.3 mEq/L to prevent fatal arrhythmias.\n- **Insulin Type:** Only Regular (Short-acting) insulin is given IV.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"F-I-P\" Protocol: Fluids, Insulin, Potassium."},{"id":23,"question":"Which of the following is a correct drug regimen for the treatment of Helicobacter pylori infection?","options":{"a":"Metronidazole + Omeprazole + Amoxicillin","b":"Metronidazole + Ciprofloxacin + Amoxicillin","c":"Omeprazole + Amoxicillin + Clarithromycin","d":"Omeprazole + Erythromycin + Metronidazole"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe standard first-line \"Triple Therapy\" for Helicobacter pylori infection consists of a Proton Pump Inhibitor (PPI) + Clarithromycin + Amoxicillin (or Metronidazole if PCN allergic). This regimen typically lasts for 14 days.\n\n**2. Rationale for Incorrect Options:**\n- a) Metronidazole + Omeprazole + Amoxicillin: Possible in penicillin allergy, but Clarithromycin-based regimens are the standard \"CAP\" or \"OAC\" definition.\n- b) Ciprofloxacin: Fluoroquinolones are not first-line; used in salvage therapy.\n- d) Erythromycin: Not effective for H. pylori (low acid stability/tissue penetration compared to Clarithromycin).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Quadruple Therapy:** Used in high resistance areas: PPI + Bismuth + Metronidazole + Tetracycline.\n- **Sequential Therapy:** PPI+Amox (5 days) then PPI+Clarith+Metro (5 days).\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"CAP\" your Ulcer: **C**larithromycin + **A**moxicillin + **P**PI."},{"id":24,"question":"A 45-year old patient was brought to the PHC with difficulty in breathing. The patient was found in severe shock near a field and is unable to speak. Physical exam reveals fang marks on the lower limb. Which of the following is the management to be given to this patient ?","options":{"a":"Neostigmine","b":"Neostigmine + Atropine","c":"Pyridostigmine","d":"Physostigmine"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nNeurotoxic snake venom (e.g., Cobra, Krait) causes neuromuscular blockade leading to paralysis (unable to speak) and respiratory failure (difficulty breathing). The toxin often acts like curare (post-synaptic blockade). Neostigmine (Anti-cholinesterase) increases Acetylcholine levels to overcome the blockade. Atropine is mandatory to block the muscarinic side effects (bradycardia, secretions) of Neostigmine.\n\n**2. Rationale for Incorrect Options:**\n- a) Neostigmine alone: Would cause severe muscarinic toxicity (DUMBBELSS).\n- c) Pyridostigmine: Slower onset; Neostigmine is preferred IV for acute crisis.\n- d) Physostigmine: Crosses Blood Brain Barrier (lipid soluble); usually reserved for central anticholinergic toxicity (e.g., Datura), not peripheral snake bite paralysis.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Neurotoxic Bite:** Cobra/Krait. Signs: Ptosis (first sign), paralysis. Rx: ASV + Neostigmine.\n- **Hemotoxic Bite:** Viper. Signs: Bleeding, swelling. Rx: ASV (No Neostigmine).\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- No well-established, logical learning aid (mnemonic/trick) is required or available for this concept."},{"id":25,"question":"A 40-year-old male is brought to the emergency department after being found unconscious at home. On examination, he is unresponsive with shallow breathing, respiratory depression, pinpoint pupils, and a weak pulse. His friend reports a history of opioid use. Which of the following is the most appropriate immediate pharmacologic intervention?","options":{"a":"Flumazenil","b":"Naloxone","c":"Atropine","d":"Naltrexone"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe patient presents with the classic Opioid Overdose Triad: Respiratory Depression, Pinpoint Pupils (Miosis), and Coma (Unresponsiveness). The immediate life-saving intervention is Naloxone, a pure opioid receptor antagonist that rapidly reverses respiratory depression.\n\n**2. Rationale for Incorrect Options:**\n- a) Flumazenil: Antidote for Benzodiazepine overdose.\n- c) Atropine: Antidote for Organophosphate poisoning / Bradycardia.\n- d) Naltrexone: Long-acting opioid antagonist used for maintenance of abstinence (preventing relapse), not for acute reversal (onset is too slow and oral route mostly).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Naloxone Half-life:** Short (30-60 mins). Monitor for \"Renarcotization\" (recurrence of overdose symptoms) as opioids often outlast the antidote.\n- **Withdrawal:** Rapid administration can precipitate acute severe withdrawal in dependent patients.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Naloxone is for NOW\": Acute rescue. Naltrexone is for NEXT: Maintenance/prevention."},{"id":26,"question":"Which of the following can be used in Renal failure without any dose adjustment ?","options":{"a":"Linagliptin","b":"Saxagliptin","c":"Sitagliptin","d":"Alogliptin"},"correctAnswer":"a","explanation":""},{"id":27,"question":"Bone resorption is not decreased by :","options":{"a":"Strontium ranelate","b":"Alendronate","c":"Teriparatide","d":"Raloxifene"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nTeriparatide (Synthetic Parathyroid Hormone analogue - PTH 1-34) INCREASES bone resorption as its primary mechanism. It acts via intermittent PTH signaling to stimulate both osteoblasts and osteoclasts, but net effect is increased bone formation. However, the antiresorptive (bone-protective) drugs like Alendronate, Raloxifene, and Strontium ranelate all decrease bone resorption.\n\n**2. Rationale for Incorrect Options:**\n- a) Strontium ranelate: Reduces bone resorption by decreasing osteoclast activity (acts like a \"calcium mimic\").\n- b) Alendronate: Bisphosphonate; inhibits osteoclasts, decreasing bone resorption.\n- d) Raloxifene: Selective Estrogen Receptor Modulator (SERM); increases bone density by reducing osteoclast activity.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Teriparatide:** Anabolic agent (builds bone). Used in severe osteoporosis; risk of Osteosarcoma in long-term use (contraindicated in Paget's disease).\n- **Bisphosphonates:** Antiresorptive agents; risk of Osteonecrosis of Jaw (ONJ).\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Teriparatide Tends to Build\": Teriparatide is Anabolic (builds); others are Antiresorptive (prevent breakdown)."},{"id":28,"question":"A 76-year old male presented with complains of difficulty in urination. PSA levels were elevated. Urologist started the patient on a medication that decreases size of prostate. Identify the medicine:","options":{"a":"Tamsulosin","b":"Prazosin","c":"Finasteride","d":"Bethenechol"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nFinasteride is a 5-Alpha Reductase Inhibitor that blocks the conversion of Testosterone to Dihydrotestosterone (DHT), the potent androgen responsible for prostate growth. By reducing DHT, Finasteride reduces prostate volume and is the only agent that actually shrinks an enlarged prostate. It addresses the underlying pathophysiology of BPH by reducing prostate size (unlike Alpha blockers which only relax smooth muscle).\n\n**2. Rationale for Incorrect Options:**\n- a) Tamsulosin: Alpha-1A blocker; relaxes prostatic smooth muscle but does NOT reduce prostate size.\n- b) Prazosin: Non-selective Alpha blocker; causes systemic vasodilation and hypotension.\n- d) Bethanechol: Cholinergic agonist; increases bladder contractility, not used for BPH management.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Finasteride:** Takes 6-12 months for maximal effect (prostate shrinkage).\n- **Side Effect:** Sexual Dysfunction (ED, reduced libido, decreased semen volume).\n- **Combination Therapy:** Finasteride + Alpha-blocker (e.g., Tamsulosin) for maximal benefit in moderate-severe BPH.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Finasteride FINISHES the Prostate\": Shrinks it; Alpha blockers only relax it."},{"id":29,"question":"A 38-year-old traveler presents to your office for a routine check-up. He will be leaving for a cruise next week, and asks for a drug that would prevent the severe nausea and vomiting he experiences on ships. After recommending the appropriate drug, you warn about which of the following side effects?","options":{"a":"Cough","b":"Dry mouth","c":"Frequent urination","d":"Diarrhea"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nFor motion sickness/travel-induced nausea, the drug of choice is typically Scopolamine (Hyoscine), a muscarinic antagonist (anticholinergic). After prescribing Scopolamine, patients should be warned about anticholinergic side effects, with Dry mouth (Xerostomia) being one of the most common.\n\n**2. Rationale for Incorrect Options:**\n- a) Cough: Not typical of anticholinergics; cough suppressants are antihistamines or opioids.\n- c) Frequent urination: While urinary retention is a risk, frequency is not typical.\n- d) Diarrhea: Anticholinergics cause constipation, not diarrhea.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Scopolamine (Hyoscine):** DOC for motion sickness; transdermal patches available.\n- **Other Antiemetics:** Metoclopramide, Ondansetron, Dimenhydrinate (antihistamine with anticholinergic properties).\n- **Anticholinergic Side Effects:** \"Dry as a bone, Red as a beet, Mad as a hatter, Blind as a bat.\"\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"ABCDM\" for Anticholinergic Effects: Amydriasis, Bradycardia/Block, Constipation, Dry mouth, Myth of tachycardia (actually some bradycardia)."},{"id":30,"question":"A woman presents with galactorrhea and amenorrhea. MRI reveals a pituitary macroadenoma compressing the optic chiasma. What is the drug of choice to manage this patient?","options":{"a":"Bromocriptine","b":"Octreotide","c":"Pramipexole","d":"Fluvestrant"},"correctAnswer":"a","explanation":""},{"id":31,"question":"Sumatriptan acts as an agonist of which receptor ?","options":{"a":"5HT-2A/2C","b":"5HT-1B/1D","c":"5HT-4","d":"5HT-1A"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nSumatriptan is a selective 5-HT1B/1D receptor agonist (a Triptan/5-HT1 agonist). These receptors are present on cerebral blood vessels and trigeminal nerve terminals. Sumatriptan's mechanism involves vasoconstriction of cranial blood vessels and inhibition of trigeminal neuropeptide release, effectively terminating migraine headaches within 30 minutes to 1 hour.\n\n**2. Rationale for Incorrect Options:**\n- a) 5HT-2A/2C: Agonism at these receptors is associated with hallucinogenic effects (LSD works here).\n- c) 5HT-4: Involved in GI motility; agonism causes diarrhea.\n- d) 5HT-1A: Agonism produces anxiolytic effects (e.g., Buspirone).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Triptans:** Sumatriptan, Zolmitriptan, Naratriptan, Rizatriptan, Frovatriptan.\n- **Contraindications:** Coronary artery disease (vasospasm risk), Uncontrolled HTN, Hemiplegic migraine.\n- **Serotonin Syndrome Risk:** When combined with SSRIs (rare but serious).\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- No well-established, logical learning aid (mnemonic/trick) is required or available for this concept."},{"id":32,"question":"Which of the following is the drug choice for preoperative antibiotic prophylaxis in a patient undergoing cardiac surgery ?","options":{"a":"Azithromycin","b":"Penicillin g","c":"Cefazolin","d":"Erythromycin"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nCefazolin (1st generation Cephalosporin) is the standard preoperative antibiotic prophylaxis for Cardiac Surgery and most clean surgical procedures. It provides excellent coverage against Skin flora (Gram-positive cocci like Staphylococcus aureus and Streptococcus) with rapid onset, good tissue penetration, and a favorable safety profile. Dosing should occur within 60 minutes before incision.\n\n**2. Rationale for Incorrect Options:**\n- a) Azithromycin: A macrolide; used for respiratory infections and atypical organisms, not typical surgical prophylaxis.\n- b) Penicillin G: Parenteral Penicillin; less ideal for surgical prophylaxis due to shorter half-life and risk of resistance.\n- d) Erythromycin: Another macrolide; not first-line for surgical prophylaxis (GI side effects).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Timing:** Within 60 min before incision (120 min for Vancomycin/Fluoroquinolones).\n- **Redosing:** Required if operative time exceeds 2 half-lives (e.g., every 2 hours for Cefazolin).\n- **MRSA Colonization:** Use Vancomycin or Linezolid instead.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"CefiZolin for CardiAc surgery\": Cefazolin is the 1st-line Cephalosporin."},{"id":33,"question":"A 75-year old man presents to the hospital with urinary incontinence, he was recently diagnosed for a disease for which he is taking Donepazil. Which of the following is the best medication for managing ? The symptoms :","options":{"a":"Tolderodine","b":"Flavoxate","c":"Trospium","d":"Darifenacin"},"correctAnswer":"c","explanation":""},{"id":34,"question":"All of the following produces mydriasis plus cycloplegia except:","options":{"a":"Homatropine","b":"Cyclopentolate","c":"Tropicamide","d":"Phenylephrine"},"correctAnswer":"d","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nMydriasis (pupil dilation) + Cycloplegia (paralysis of accommodation) occurs with Anticholinergic (Muscarinic antagonist) drugs. Homatropine, Cyclopentolate, and Tropicamide all block muscarinic receptors on the iris sphincter and ciliary muscle, causing both mydriasis and cycloplegia. Phenylephrine is an Alpha-1 adrenergic agonist that causes mydriasis ONLY (via stimulation of the dilator muscle) but does NOT block accommodation, so NO cycloplegia.\n\n**2. Rationale for Incorrect Options:**\n- a) Homatropine: Anticholinergic; produces both mydriasis and cycloplegia.\n- b) Cyclopentolate: Anticholinergic; produces both mydriasis and cycloplegia (also CNS side effects in children).\n- c) Tropicamide: Anticholinergic; produces both mydriasis and cycloplegia (shorter duration than others).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Mydriatic Agents:** Anticholinergics (cycloplegia) vs. Alpha agonists (no cycloplegia).\n- **Tropicamide:** Used in refraction because of shorter duration; still causes cycloplegia.\n- **Phenylephrine:** Used for mydriasis alone when cycloplegia is NOT desired.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Phenyl-ephrine is Only for Pupils\": Phenylephrine causes only Pupil dilation (Mydriasis), not Cycloplegia."},{"id":35,"question":"A patient presents with hypertension, tachycardia and early signs of renal dysfunction. ARBâ€™s are administered that inhibits the RAAS pathway. Which of the following best explains the mechanism by which the drug reduces BP?","options":{"a":"They decrease blood pressure by decreasing peripheral vascular resistance","b":"They decrease blood pressure by decreasing cardiac preload","c":"They decrease blood pressure by increasing peripheral vascular resistance","d":"They decrease blood pressure by increasing cardiac preload."},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nARBs (Angiotensin II Receptor Blockers) like Losartan, Valsartan, Telmisartan block AT1 receptors on vascular smooth muscle, preventing angiotensin II-mediated vasoconstriction. This results in decreased Peripheral Vascular Resistance (PVR), which is the primary mechanism of BP reduction. Additionally, they indirectly reduce Cardiac Preload via aldosterone suppression and natriuresis.\n\n**2. Rationale for Incorrect Options:**\n- b) Decreasing cardiac preload: Secondary mechanism (via aldosterone antagonism and Na+ retention prevention); NOT the primary mechanism.\n- c) Increasing peripheral vascular resistance: Opposite of true effect; would increase BP.\n- d) Increasing cardiac preload: Would increase BP, not decrease it.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **ARB Advantages:** Selective for AT1 (not AT2); less bradykinin accumulation than ACEis (less cough).\n- **RAAS Blockade:** ACEis inhibit Angiotensin II formation. ARBs block its action. Combined use risks hyperkalemia.\n- **Renoprotection:** Both ACEis and ARBs reduce glomerular pressure and albuminuria.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"ARBs Block AT1 and open Blood vessels\": Results in vasodilation and lower PVR."},{"id":36,"question":"Which of the following test is used for laboratory monitoring of enoxaparin?","options":{"a":"APTT","b":"Bleeding time","c":"PT/INR","d":"None of the above"},"correctAnswer":"d","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nEnoxaparin is a Low-Molecular-Weight Heparin (LMWH) that has predictable pharmacokinetics and doesn't require routine coagulation monitoring. Unlike Unfractionated Heparin (UFH), LMWH doesn't require APTT monitoring because its anticoagulant effect is consistent and doesn't prolongone APTT proportionally. Anti-Xa activity can be measured if needed (therapeutic range 0.5-1.0 IU/mL), but it is NOT routine.\n\n**2. Rationale for Incorrect Options:**\n- a) APTT: Used to monitor UFH (unfractionated heparin), not LMWH.\n- b) Bleeding time: Does not reflect anticoagulation effectiveness; poor predictor of bleeding.\n- c) PT/INR: Used to monitor Warfarin, not Heparin-based anticoagulants.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **LMWH:** Fixed dosing (weight-based); no monitoring required in uncomplicated cases.\n- **Monitoring Needed:** Renal failure (Cr \u003c30 mL/min), Obesity, Pregnancy (controversial).\n- **Anti-Xa Activity:** Gold standard for LMWH level monitoring when needed.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"LMWH is Low-Maintenance\": No routine APTT checks needed."},{"id":37,"question":"Mechanism of colchicine in acute gout is :","options":{"a":"Inhibition of leukotriene synthesis","b":"Inhibition of uric acid formation","c":"Prevention of granulocyte migration","d":"Inhibition of purine metabolism"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nColchicine works by inhibiting tubulin polymerization, disrupting microtubule formation and the movement of Neutrophils/Granulocytes into the joint space. It prevents neutrophil chemotaxis and extravasation into the inflamed joint, thus reducing the inflammatory cascade that perpetuates acute gout attacks. It does NOT reduce uric acid production or reabsorption.\n\n**2. Rationale for Incorrect Options:**\n- a) Leukotriene synthesis: Not the mechanism; NSAIDs and other agents target this.\n- b) Uric acid formation: That's Allopurinol's mechanism (Xanthine oxidase inhibitor).\n- d) Purine metabolism: Allopurinol and Febuxostat inhibit this pathway.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Colchicine Uses:** Acute gout attack (gold standard), prophylaxis in chronic gout, Mediterranean Fever.\n- **Side Effects:** GI Toxicity (severe diarrhea, nausea) is dose-limiting. GI symptoms herald toxicity.\n- **Long-term Use:** Not for chronic management (urate-lowering needed).\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Colchicine COLLECTS microtubules\": Disrupts cell migration of immune cells."},{"id":38,"question":"A male patient develops tendon rupture after taking a certain antibiotic. What is the most likely mechanism of action of this drug?","options":{"a":"Inhibition of bacterial DNA gyrase (topoisomerase)","b":"Inhibition of bacterial protein synthesis at 50S ribosomal subunit","c":"Inhibition of folic acid synthesis","d":"Inhibition of bacterial cell wall synthesis"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nFluoroquinolones (e.g., Ciprofloxacin, Levofloxacin, Moxifloxacin) inhibit Bacterial DNA Gyrase (Topoisomerase II), preventing bacterial DNA unwinding and replication. However, fluoroquinolones also inhibit Human Mitochondrial Topoisomerases, leading to cellular damage, particularly in Tendons. This causes Tendinopathy and Tendon Rupture (especially Achilles tendon).\n\n**2. Rationale for Incorrect Options:**\n- b) 50S ribosomal inhibition: Mechanism of Macrolides and Tetracyclines, not Fluoroquinolones.\n- c) Folic acid synthesis: Mechanism of Sulfonamides and Trimethoprim.\n- d) Cell wall synthesis: Mechanism of Beta-lactams and Vancomycin.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Risk Factors for Tendon Rupture:** Age >60 years, Concurrent corticosteroid use, Previous tendon disease, Renal failure.\n- **Onset:** Typically 2-6 weeks after starting fluoroquinolone.\n- **Management:** Discontinue drug, immobilization, consider surgical repair if complete rupture.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Fluoro Tendons Tear\": Fluoroquinolones cause tendon damage via topoisomerase inhibition."},{"id":39,"question":"A female presents with black discoloration near nose History reveals use of high dose steroid therapy in recent past. What is the most appropriate treatment in this case?","options":{"a":"Amphotericin B","b":"Itraconazole","c":"Griseofulvin","d":"Fluconazole"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe clinical presentation of \"black discoloration\" in a high-dose steroid user is classic for Mucormycosis, a life-threatening fungal infection. The black eschar (necrotic tissue) results from vascular invasion and tissue necrosis. Amphotericin B (Liposomal or conventional) is the gold standard and first-line treatment. Immediate ENT and surgical debridement are also crucial alongside antifungal therapy.\n\n**2. Rationale for Incorrect Options:**\n- b) Itraconazole: An azole antifungal; NOT effective against Mucor (Azoles are contraindicated as monotherapy).\n- c) Griseofulvin: For dermatophyte infections; ineffective against Mucor.\n- d) Fluconazole: An azole; NOT effective against Mucor. Mucor is inherently resistant to Fluconazole and other azoles.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Mucormycosis Risk:** Diabetes (DKA), Immunosuppression (Steroids, Chemo, Transplant), HIV.\n- **Presentation:** Rapid, fulminant course; black eschar, facial swelling, proptosis, vision loss.\n- **Amphotericin B:** Lipid formulation preferred (lower nephrotoxicity); often combined with Surgical debridement.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Ampho for Anything Fungal\": Amphotericin B is broad-spectrum (works for Mucor, Candida, Aspergillus)."},{"id":40,"question":"Which of the following is not used for the treatment of Sickle cell anaemia?","options":{"a":"Denosumab","b":"Voxelotor","c":"Hydroxyurea","d":"Crizanlizumab"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nDenosumab is a RANK Ligand inhibitor used primarily for Osteoporosis (prevents bone resorption). It has NO role in Sickle Cell Anemia management. Sickle cell treatments target hemolysis prevention (Hydroxyurea - increases HbF), vaso-occlusion prevention (Crizanlizumab - P-selectin antagonist), or oxygen delivery (Voxelotor - increases Hb-O2 affinity).\n\n**2. Rationale for Incorrect Options:**\n- b) Voxelotor: FDA-approved for SCA; increases oxygen affinity of Hemoglobin, reducing sickling.\n- c) Hydroxyurea: Gold standard for SCA; increases Fetal Hemoglobin (HbF), which doesn't sickle.\n- d) Crizanlizumab: Selectin antagonist; reduces vaso-occlusive episodes by preventing cell adhesion.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Hydroxyurea:** Decreases vaso-occlusive crises, ACS, and mortality; increases HbF.\n- **Voxelotor & Crizanlizumab:** Newer agents; used in combination with Hydroxyurea for severe disease.\n- **Bone Health in SCA:** Patients often have low bone mass (paradoxical). Bisphosphonates may help, but Denosumab not typically used.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Denosumab is for Bones, NOT Sickle Cells\": Mnemonic distinguishing its use."},{"id":41,"question":"Which of the following is true about competitive antagonism?","options":{"a":"Vmax increases and Km remains same","b":"Km increases and Vmax remains same","c":"Vmax and Km remains same","d":"Vmax decreases and Km remains same"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nIn Competitive Antagonism, an antagonist competes with the agonist for the same binding site on an enzyme or receptor. When the antagonist is present, a higher concentration of agonist is required to reach half-maximal effect (Km increases/shifts rightward on Michaelis-Menten curve). However, the Maximum velocity (Vmax) remains unchanged because if you add excess agonist, it will eventually displace the antagonist and achieve the same maximal effect.\n\n**2. Rationale for Incorrect Options:**\n- a) Vmax increases, Km remains: Typical of enzyme induction, not competitive antagonism.\n- c) Both remain same: True for Non-competitive antagonism (doesn't use Km/Vmax terms typically).\n- d) Vmax decreases, Km remains: Pattern of Non-competitive antagonism (Vmax â†“) or enzyme inhibition.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Competitive vs. Non-competitive:** Competitive antagonism is Reversible (with excess agonist); Non-competitive is often Irreversible.\n- **Clinical Relevance:** Warfarin-Aspirin (competitive for COX); can overcome with more substrate.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Competitive = Can outcompete (Km â†‘), Final yield same (Vmax â†’)\": More of the drug needed but same max possible."},{"id":42,"question":"A 75-year-old female is brought to your office by her son because of worsening forgetfulness over the past few years and several recent episodes of getting lost while performing errands around the house. She exhibits no signs or symptoms of depression. On physical examination, the patient has blood pressure of 139-88 mmHg. She is alret and cooperative but disconnected to time an can only recall 1 to 3 items on a short term memory test. An extensive work-up, including appropriate laboratory tests and a brain MRI scan, reveals diffuse cortical atrophy with no other abnormalities. This patient would likely benefit from treatment with which of the following?","options":{"a":"Reslizumab","b":"Denosumab","c":"Pertuzumab","d":"Adacanumab"},"correctAnswer":"d","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nAducanumab is a monoclonal antibody that targets Amyloid-Beta (AÎ²) aggregates in the brain. It was recently approved by the FDA (though with some controversy regarding efficacy data) for Mild Cognitive Impairment (MCI) and Mild Dementia stages of Alzheimer's disease. It works by immunizing against AÎ² plaques, the pathological hallmark of AD.\n\n**2. Rationale for Incorrect Options:**\n- a) Reslizumab: A monoclonal antibody against IL-4 receptor; used for severe eosinophilic asthma.\n- b) Denosumab: RANK Ligand inhibitor; used for osteoporosis.\n- c) Pertuzumab: Anti-HER2 antibody; used for breast cancer.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Aducanumab (Aduhelm):** First-in-class anti-amyloid monoclonal antibody approved for AD.\n- **Side Effects:** AMIA (Amyloid-Related Imaging Abnormalities) - microhemorrhages or microinfarcts on MRI.\n- **Monitoring:** Regular MRI to detect AMIA; baseline cognitive and imaging assessment.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Adu-canumab Attacks Amyloid\": Monoclonal antibody targeting AÎ² plaques."},{"id":43,"question":"A young male patient presents with jaundice. Serological status (HBsAg +, Anti-HBc-IgM + and HBeAg +). What is the most likely treatment for this patient?","options":{"a":"Dolutegravir","b":"Lamivudine","c":"Zidovudine","d":"Sofusbuvir"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe patient is HBsAg positive, Anti-HBc-IgM positive, HBeAg positive = Acute Hepatitis B infection. All three positive indicate current active viral replication. Lamivudine is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) that inhibits Hepatitis B Polymerase and is a first-line agent for HBV treatment. Most acute HB infections resolve spontaneously; antivirals are given in severe/fulminant cases or immunocompromised patients.\n\n**2. Rationale for Incorrect Options:**\n- a) Dolutegravir: Integrase inhibitor; used for HIV, not HBV.\n- c) Zidovudine: NRTI; used primarily for HIV (though can suppress HBV as it has activity).\n- d) Sofosbuvir: NS5B polymerase inhibitor; used for Hepatitis C, not HBV.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Anti-HBc-IgM:** Marker of Acute infection (IgG indicates past/chronic infection).\n- **HBV Antivirals:** Lamivudine, Tenofovir, Entecavir (NRTIs/NtRTIs); Interferon-Alpha.\n- **Contraindication:** Lamivudine monotherapy risks drug resistance; often combined with Tenofovir or given as part of ART.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Lami for Lysis (Viral)\": Lamivudine Lyses HBV replication."},{"id":44,"question":"Which of the following anti-glaucoma medication must be avoided in patient having cystoid macular edema?","options":{"a":"Acetazolamide","b":"Latanoprost","c":"Timolol","d":"Brimonidine"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nLatanoprost (Prostaglandin F2Î± analogue) is contraindicated in Cystoid Macular Edema (CME) because Prostaglandin F analogues increase uveitis and inflammatory cell infiltration into the posterior segment, exacerbating existing macular edema. Latanoprost should be avoided in patients with a history of CME, uveitis, or risk factors for edema.\n\n**2. Rationale for Incorrect Options:**\n- a) Acetazolamide: Carbonic anhydrase inhibitor; actually beneficial in CME (reduces aqueous production and macular edema).\n- c) Timolol: Beta-blocker; neutral in CME; generally safe.\n- d) Brimonidine: Alpha-2 agonist; no specific contraindication in CME.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Prostaglandin Analogues & Uveitis:** Latanoprost, Travoprost, Bimatoprost all have slight uveitic risk.\n- **First-line Glaucoma Drugs:** Prostaglandin analogues; if CME contraindication, use Timolol or Brimonidine.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Prostaglandin Produces Puffiness\": Latanoprost and other PG analogues can cause CME (swelling in macula)."},{"id":45,"question":"A patient in ATT develops tingling on lower limb. Which of the following drugs should be used?","options":{"a":"Pyridoxine","b":"Thiamine","c":"Folic acid","d":"Vitamin B-12"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nIsoniazid (INH), a key component of Anti-Tuberculous Therapy (ATT), causes Pyridoxine (Vitamin B6) deficiency by inhibiting its metabolism. This leads to Peripheral Neuropathy (tingling in lower limbs) and other neurological manifestations. Pyridoxine supplementation (25-50 mg daily) is given prophylactically or therapeutically during ATT to prevent/treat this common side effect.\n\n**2. Rationale for Incorrect Options:**\n- b) Thiamine (Vitamin B1): Prevents Wernicke-Korsakoff syndrome (thiamine deficiency); not specifically related to INH side effects.\n- c) Folic acid: Useful in Methotrexate toxicity; not standard in ATT.\n- d) Vitamin B-12: Deficiency causes different neuropathy patterns; not directly related to INH.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **INH Peripheral Neuropathy:** Dose-dependent; occurs in ~2% of patients on standard therapy.\n- **Prophylaxis:** All ATT patients should receive Pyridoxine, especially those at high risk (Diabetes, Alcohol, Malnutrition).\n- **Other INH Side Effects:** Hepatotoxicity, Drug-induced Lupus, Seizures.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"INH + Iso = Inadequate B6\": Isoniazid depletes B6; Isoniazid â†’ Insulin-like neuropathy prevented by Pyridoxine."},{"id":46,"question":"A 55 year old male undergoing chemotherapy presents with progressive shortness of breath. \n\nDiagnosis of pulmonary fibrosis is made. Which of the following drug is most likely responsible for the patientâ€™s condition?","options":{"a":"Cisplatin","b":"Bleomycin","c":"Doxorubicin","d":"5-FU"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nBleomycin is a Glycopeptide antibiotic with potent chemotherapeutic activity used for testicular cancer, lymphomas, and squamous cell cancers. Its most notorious toxicity is Pulmonary Fibrosis (Bleomycin-induced Pulmonary Toxicity - BPT), occurring in up to 40% of patients on high cumulative doses (>400 units). The mechanism involves direct lung injury, inflammatory cascade, and collagen deposition.\n\n**2. Rationale for Incorrect Options:**\n- a) Cisplatin: Platinum agent; nephrotoxicity and neurotoxicity are primary concerns, not pulmonary fibrosis.\n- c) Doxorubicin: Anthracycline; Cardiotoxicity (cardiomyopathy) is the major organ toxicity.\n- d) 5-FU: Pyrimidine antagonist; Cardiotoxicity and mucositis are primary concerns.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Bleomycin Pulmonary Toxicity:** Risk increases with cumulative dose >400-500 units and age >70 years.\n- **Monitoring:** Baseline PFTs, baseline CXR; monitor for symptoms (dyspnea, cough).\n- **Prevention:** Avoid high concentrations of oxygen (paradoxically worsens toxicity).\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Bleo-mycin Breaches the Lungs\": Bleomycin causes Pulmonary Toxicity."},{"id":47,"question":"An infant presents with seziures, Dx of infantile spasm is made. Which drug is preferred for management?","options":{"a":"Vigabatrin","b":"ACTH","c":"Ethosuximide","d":"Valproate"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nInfantile Spasm (West Syndrome) is a severe form of childhood epilepsy presenting with Infantile Spasms (sudden flexor/extensor muscle jerks), Developmental regression, and Hypsarrhythmic EEG pattern. ACTH (Adrenocorticotropic Hormone) is the gold standard first-line treatment, with response rates of 50-80%. Corticosteroids (like Prednisone) are second-line alternatives.\n\n**2. Rationale for Incorrect Options:**\n- a) Vigabatrin: Increasingly used as alternative/add-on, especially in Tuberous Sclerosis-associated infantile spasm; not first-line overall.\n- c) Ethosuximide: For Absence seizures; no effect on infantile spasms.\n- d) Valproate: Useful for generalized seizures but less effective than ACTH for infantile spasms.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **ACTH & Corticosteroids:** Superior to anticonvulsants for infantile spasm.\n- **Prognosis:** Early treatment (\u003c3 months of symptom onset) improves developmental outcome.\n- **Vigabatrin Exception:** Preferred if Tuberous Sclerosis Complex (TSC) is suspected as underlying cause.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"ACTH for Acute Infantile Spasm\": ACTH is Action-Better first-line than Antiepileptics in West Syndrome."},{"id":48,"question":"NSAID induced ulcer are best treated by?","options":{"a":"Antacids","b":"H2 blockers","c":"Misoprostol","d":"PPI (proton pump inhibitors)"},"correctAnswer":"d","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nNSAID-induced ulcers are caused by disruption of the protective layer (COX-1 inhibition reduces prostaglandin production). The most effective treatment is PPI (Proton Pump Inhibitors) like Omeprazole or Lansoprazole, which powerfully suppress acid secretion and allow ulcer healing. H2-blockers are less effective for NSAID ulcers.\n\n**2. Rationale for Incorrect Options:**\n- a) Antacids: Temporary symptom relief; don't address underlying acid suppression needed for healing.\n- b) H2-blockers: Moderate acid suppression; PPIs are superior for NSAID ulcers.\n- c) Misoprostol: A prostaglandin analogue used for prevention of NSAID ulcers; not ideal for treatment once ulcer develops.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Prevention of NSAID Ulcers:** Misoprostol (expensive) or PPI co-therapy.\n- **H. pylori Eradication:** If H. pylori positive, treat accordingly.\n- **Long-term NSAID Users:** Consider COX-2 selective inhibitor (e.g., Celecoxib) + PPI.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"PPI Patches NSAID damage\": PPI heals the Ulcer best."},{"id":49,"question":"A 60-year-old man was diagnosed with type 2 diabetes mellitus 6 years ago. His current treatment regimen includes a long-acting subcutaneous insulin injection once a day. Review of his home glucose measurements shows that his postprandial glucose levels are too high. Which of the following types of insulin would be most appropriate to administer before each meal?","options":{"a":"Insulin aspart","b":"Insulin glargine","c":"Inslulin detemir","d":"Inslulin degludec"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe patient is on long-acting basal insulin (once daily, likely Glargine or Detemir) but has elevated postprandial glucose. The solution is to add a Rapid-Acting Insulin (onset 10-15 minutes, peak 30-90 minutes) before each meal to cover the meal-induced glucose spike. Insulin Aspart (Novorapid) is one such rapid-acting insulin analog.\n\n**2. Rationale for Incorrect Options:**\n- b) Insulin glargine: Long-acting basal insulin (already on this); not helpful for postprandial control.\n- c) Insulin detemir: Long-acting basal insulin; similar issue as Glargine.\n- d) Insulin degludec: Ultra-long-acting basal; not appropriate for bolus coverage at meals.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Rapid-Acting Insulins:** Aspart, Lispro, Glulisine (faster than Regular insulin).\n- **Basal-Bolus Regimen:** Long-acting basal + Rapid-acting bolus with meals is standard for T2DM intensification.\n- **Hypoglycemia Risk:** Higher with rapid-acting insulins; patient education critical.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Rapid for Meals\": Rapid-acting insulins are given before meals to cover postprandial glucose."},{"id":50,"question":"Which of the following is given to treat thrombocytopenia secondary to anti-cancer therapy and is known to stimulate progenitor megakaryocytes?","options":{"a":"Filgrastim","b":"Oprelvekin","c":"Erythropoietin","d":"Iron dextran"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nOprelvekin (Neumega) is a recombinant Thrombopoietin Receptor Agonist (also called Megakaryocyte Growth and Development Factor - MGDF) that stimulates progenitor megakaryocytes to produce platelets. It is used to treat Thrombocytopenia secondary to chemotherapy, preventing severe thrombocytopenia and the need for platelet transfusions.\n\n**2. Rationale for Incorrect Options:**\n- a) Filgrastim: G-CSF (Granulocyte-Colony Stimulating Factor); stimulates neutrophil production, not platelets.\n- c) Erythropoietin: Stimulates red blood cell production; used for chemotherapy-induced anemia.\n- d) Iron dextran: Iron supplementation for iron deficiency; not a growth factor.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Oprelvekin:** Given SC; often causes Fluid Retention and Cardiac Arrhythmias (atrial fibrillation).\n- **Other Platelet Stimulants:** Romiplostim (IV TPO-R agonist); used for immune thrombocytopenia (ITP).\n- **Use:** Primarily in solid tumors and lymphomas; less used now due to side effects and transfusion alternatives.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Oprel-vekin Orchestrates Platelets\": Oprelvekin stimulates progenitor megakaryocytes to make Platelets."},{"id":51,"question":"Which of the following drug is C/I in bilateral renal artery stenosis?","options":{"a":"Enalapril","b":"Methyldopa","c":"Hydralazine","d":"Dopamine"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nIn Bilateral Renal Artery Stenosis (RAS), the kidney's perfusion pressure depends on Angiotensin II-mediated efferent arteriolar vasoconstriction. ACE Inhibitors like Enalapril block angiotensin II formation, causing efferent arteriolar dilation. This dramatically reduces glomerular filtration pressure, precipitating Acute Renal Failure with a sudden rise in creatinine. This is a classic contraindication to ACEis in bilateral RAS.\n\n**2. Rationale for Incorrect Options:**\n- b) Methyldopa: Alpha-2 agonist; acts centrally and doesn't depend on RAS. Safe in RAS.\n- c) Hydralazine: Direct vasodilator; doesn't interfere with RAS physiology.\n- d) Dopamine: At low-dose, causes renal vasodilation independent of RAS.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Unilateral RAS:** ACEi/ARB is safe and can help preserve the contralateral kidney function.\n- **Bilateral RAS/Single Kidney:** ACEi/ARB is contraindicated (risk of hyperkalemia + renal failure).\n- **\"Abrupt Creatinine Rise\":** Key clinical clue for ACEi-induced renal failure in RAS.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Bilateral RAS Blocks ACEi\": Bilateral artery narrowing + ACEi = Acute renal crisis."},{"id":52,"question":"Peripheral vasospasm is observed with which of the following anti-Parkinsonian drugs ?","options":{"a":"Ropinirole","b":"Levodopa","c":"Bromocriptine","d":"Entacapone"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nBromocriptine (D2 dopamine agonist) causes Peripheral Vasospasm and Raynaud's Phenomenon through dopamine's vasoconstrictor effects (especially at higher doses). Patients may experience cold extremities, numbness, and in severe cases, digital ulceration or gangrene.\n\n**2. Rationale for Incorrect Options:**\n- a) Ropinirole: D2/D3 agonist; less vasospasm risk compared to Bromocriptine.\n- b) Levodopa: Converted to dopamine; causes systemic effects but less peripheral vasospasm than Bromocriptine.\n- d) Entacapone: COMT inhibitor (extends Levodopa effect); no intrinsic vasospasm risk.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Bromocriptine Vasospasm:** Dose-dependent; occurs more at higher doses used for prolactinoma.\n- **Management:** Discontinue or reduce dose; Peripheral vasodilators (Nifedipine) may help.\n- **Other Dopamine Agonists:** Newer agents (Pramipexole, Ropinirole) have lower vasospasm risk.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Bromo Vasoconstricts\": Bromocriptine causes Peripheral Vasospasm and Raynaud's."},{"id":53,"question":"A 22-year old patient presented with constipation, urinary retention, blurred vision, Tachycardia and dry mouth. Which of the following is the patient most likely effected by?","options":{"a":"Organophosphate","b":"Opiod","c":"Datura","d":"Physostigmine"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe clinical presentation is Anticholinergic Toxicity Syndrome: Constipation, Urinary retention, Blurred vision (mydriasis/cycloplegia), Tachycardia, and Dry mouth. Datura species (Brugmansia, Datura stramonium) contain tropane alkaloids (Scopolamine, Hyoscyamine, Atropine) that are potent Muscarinic antagonists. Classic mnemonic: \"Dry as a bone, Red as a beet, Mad as a hatter, Blind as a bat, Hot as a hare.\"\n\n**2. Rationale for Incorrect Options:**\n- a) Organophosphate: Causes DUMBBELSS (cholinergic excess) - opposite of this picture.\n- b) Opioid: Causes Miosis (NOT mydriasis), Respiratory depression, and Constipation/Urinary retention.\n- d) Physostigmine: Cholinesterase inhibitor; causes cholinergic toxicity (opposite).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Datura Toxidrome:** Anticholinergic overdose (Mydriasis, Tachycardia, Hyperthermia, Agitation).\n- **Management:** Supportive care + Physostigmine (if needed; reverses anticholinergic effects).\n- **Street Names:** \"Angel's Trumpet,\" \"Jimson Weed.\"\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"ABDHO\": Antichol, Blurry, Dry, Hot, Over-excited (Datura toxidrome)."},{"id":54,"question":"A new drug is developed that activated the peroxisome proliferator-activated receptor gamma a nuclear receptor and transcription factor. Activation of this receptor would most likely help in which of the following?","options":{"a":"HTN","b":"Graveâ€™s disease","c":"DM","d":"Hyperlipidemia"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nPPAR-Î³ (Peroxisome Proliferator-Activated Receptor Gamma) is a nuclear receptor that, when activated, improves Insulin Sensitivity in adipose tissue and skeletal muscle. This makes it ideal for Type 2 Diabetes Mellitus. Thiazolidinediones (Glitazones) like Pioglitazone and Rosiglitazone are PPAR-Î³ agonists and effectively lower blood glucose.\n\n**2. Rationale for Incorrect Options:**\n- a) HTN: No primary effect of PPAR-Î³ activation.\n- b) Grave's disease: Autoimmune thyroiditis; PPAR-Î³ activation not indicated.\n- d) Hyperlipidemia: While TZDs may affect lipids (variable effects), they're not DOC for hyperlipidemia.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Glitazones:** Improve insulin sensitivity; used in Type 2 DM.\n- **Side Effects:** Weight gain, Fluid retention, Heart failure exacerbation, Fractures (increased bone loss).\n- **Use Limitation:** Withdrawn from many markets (Rosiglitazone) due to cardiovascular concerns.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"PPAR-Î³ Pulls Glucose in\": Increases Insulin Sensitivity in Diabetes."},{"id":55,"question":"NSAID induced ulcer are best treated by?","options":{"a":"Antacids","b":"H2 blockers","c":"Misoprostol","d":"PPI (proton pump inhibitors)"},"correctAnswer":"d","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThis is a repeat question (identical to Q48). NSAID-induced ulcers result from COX-1 inhibition and loss of protective prostaglandins. PPI (Proton Pump Inhibitors) like Omeprazole provide the most potent acid suppression, allowing ulcer healing. PPIs are superior to H2-blockers for NSAID-related ulcers.\n\n**2. Rationale for Incorrect Options:**\n- a) Antacids: Temporary symptom relief only; insufficient for healing.\n- b) H2-blockers: Moderate suppression; less effective than PPIs.\n- c) Misoprostol: Prophylactic agent (prostaglandin analogue); not first-line for treatment.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Prevention:** PPI or Misoprostol co-therapy with chronic NSAIDs.\n- **Duration:** Typically 4-8 weeks of PPI therapy for healing.\n- **Follow-up:** Address NSAID continuation; consider Celecoxib + PPI if NSAID essential.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"PPI Powerfully shuts Protons\": Strongest acid suppression for ulcer healing."},{"id":56,"question":"Which of the following is given to treat thrombocytopenia secondary to anti-cancer therapy and is known to stimulate progenitor megakaryocytes?","options":{"a":"Filgrastim","b":"Oprelvekin","c":"Erythropoietin","d":"Iron dextran"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThis is a repeat question (identical to Q50). Oprelvekin (Neumega) is a Thrombopoietin Receptor Agonist that stimulates Progenitor Megakaryocytes to produce platelets. It is used specifically for Chemotherapy-Induced Thrombocytopenia to prevent severe bleeding complications.\n\n**2. Rationale for Incorrect Options:**\n- a) Filgrastim: G-CSF; stimulates neutrophils (white cells), not platelets.\n- c) Erythropoietin: Stimulates RBCs; used for chemo-induced anemia.\n- d) Iron dextran: Iron supplementation; not a growth factor.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Oprelvekin:** Given SC; side effects include atrial fibrillation and fluid retention.\n- **Timing:** Started after chemotherapy once counts are dropping.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Oprel makes Platelets\": Oprelvekin stimulates Megakaryocytes to boost platelet count."},{"id":57,"question":"Which of the following drug is C/I in bilateral renal artery stenosis?","options":{"a":"Enalapril","b":"Methyldopa","c":"Hydralazine","d":"Dopamine"},"correctAnswer":"a","explanation":"[Identical explanation as Q51 - See above]"},{"id":58,"question":"Peripheral vasospasm is observed with which of the following anti-Parkinsonian drugs ?","options":{"a":"Ropinirole","b":"Levodopa","c":"Bromocriptine","d":"Entacapone"},"correctAnswer":"c","explanation":"[Identical explanation as Q52 - See above]"},{"id":59,"question":"A 22-year old patient presented with constipation, urinary retention, blurred vision, Tachycardia and dry mouth. Which of the following is the patient most likely effected by?","options":{"a":"Organophosphate","b":"Opiod","c":"Datura","d":"Physostigmine"},"correctAnswer":"c","explanation":"[Identical explanation as Q53 - See above]"},{"id":60,"question":"A 60-year old male with history of HTN and Diabetes complains that he feels he canâ€™t get enough air while climbing stairs. Other complains include cough, weakness even after rest. Which of the following inhibits cardiac remodelling?","options":{"a":"Furosemide","b":"Milrinone","c":"Carvedilol","d":"Dobutamine"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe patient has Heart Failure (Dyspnea on exertion, Orthopnea, Fatigue, Cardiomegaly on CXR after MI). Carvedilol is a Non-selective Beta-blocker + Alpha-1 blocker that not only reduces BP and Heart Rate but also has Cardioprotective properties that actively Inhibit Cardiac Remodeling (ventricular hypertrophy and fibrosis). It improves survival in HF via anti-apoptotic and anti-remodeling mechanisms.\n\n**2. Rationale for Incorrect Options:**\n- a) Furosemide: Loop diuretic; reduces fluid overload but does NOT inhibit remodeling.\n- b) Milrinone: Inotrope; increases contractility but is inotropic (vasodilatory); no remodeling benefit.\n- d) Dobutamine: Beta-1 agonist; increases contractility but increases demand and doesn't prevent remodeling.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Beta-blockers in HF:** Bisoprolol, Carvedilol, Metoprolol (all shown to reduce mortality).\n- **Carvedilol:** Only non-selective beta-blocker in HF with evidence; combines beta + alpha blockade.\n- **ACEi/ARB + Beta-blocker:** Gold standard for HF management; addresses remodeling.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"CARvedilol CARdio-protects\": CARVedilol CARdioprotection (remodeling inhibition)."},{"id":61,"question":"Not an adverse effect of ACE inhibitors:","options":{"a":"Cough","b":"Hypokalemia","c":"Angioedema","d":"Hyperkalemia"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nACE Inhibitors cause Hyperkalemia (HIGH potassium), NOT Hypokalemia. They inhibit aldosterone secretion, reducing urinary potassium excretion. Common ACEi side effects include: Cough (bradykinin accumulation), Angioedema (bradykinin), and Hyperkalemia. Hypokalemia is NOT an ACEi side effect; it's more commonly seen with Diuretics/Loops.\n\n**2. Rationale for Incorrect Options:**\n- a) Cough: Classic ACEi side effect (~10-20% of patients).\n- c) Angioedema: Bradykinin-mediated; life-threatening but rare.\n- d) Hyperkalemia: The expected electrolyte abnormality with ACEi.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **ACEi + K+-sparing Diuretics/NSAIDs:** Severe Hyperkalemia risk.\n- **Baseline K+/Creatinine Monitoring:** Essential before starting and periodically during ACEi therapy.\n- **Discontinuation Triggers:** K+ >5.5-6.0 mEq/L or Creatinine rise >30% from baseline.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"ACEi = High K+\": Remember Hyperkalemia, not Hypokalemia."},{"id":62,"question":"A new antiarrhythmic medication, Drug A, is tested in several animal experiments. The action potentials of ventricular muscle cells are recorded before and after administration of the drug: \n\n{image 1} a) Diltiazem","options":{"a":"Diltiazem","b":"Digoxin","c":"Propranolol","d":"Procainamide"},"correctAnswer":"d","explanation":""},{"id":63,"question":"A 57-year old female patient presented with hyperuricemia, hyperphosphatemia, hyperkalemia and hypocalcemia a week after starting chemotherapy for endometrial cancer. The patientâ€™s creatinine levels are also elevated. Which of the following would be the best in the management of this condition?","options":{"a":"Alendronate","b":"Rasburicase","c":"Febuxostat","d":"Colchicine"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe patient presents with classic Tumor Lysis Syndrome (TLS): Hyperuricemia (from nucleic acid breakdown), Hyperkalemia (intracellular potassium release), Hyperphosphatemia (intracellular phosphate release), and Hypocalcemia (phosphate precipitates calcium). Rasburicase is a Uricase enzyme that directly converts Uric Acid â†’ Allantoin (water-soluble, easily excreted), rapidly lowering uric acid levels and preventing renal crystal formation/acute kidney injury.\n\n**2. Rationale for Incorrect Options:**\n- a) Alendronate: Bisphosphonate; treats hypercalcemia, not useful in TLS hypocalcemia.\n- c) Febuxostat: Xanthine oxidase inhibitor; prevents uric acid formation (slower than Rasburicase).\n- d) Colchicine: Gout management; doesn't address TLS directly.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Rasburicase:** Rapid onset (hours); FDA-approved specifically for TLS.\n- **G6PD Deficiency:** Contraindication (Rasburicase risk of hemolysis in G6PD).\n- **Comprehensive TLS Management:** Hydration, Rasburicase (or Allopurinol), Potassium binders, Calcium if symptomatic hypocalcemia.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"RasbUR-icase Reduces URic acid\": RASBuricase converts uric acid rapidly."},{"id":64,"question":"A 42-year old patient presented with fever, chills and acute shortness of breath. The patient also informed presence of diarrhea along with other symptoms. History revealed the symptoms started few days after cleaning air conditioner. What is the DOC for this condition?","options":{"a":"Ceftobiprole","b":"Daptomycin","c":"Azithromycin","d":"Norfloxacin"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe clinical scenario is Legionella pneumophila infection (Legionnaires' disease): Fever, Respiratory symptoms (SOB), GI symptoms (diarrhea), and History of air conditioner exposure (classic environmental source). Azithromycin (Macrolide) is the drug of choice for Legionella infection. Fluoroquinolones are alternatives.\n\n**2. Rationale for Incorrect Options:**\n- a) Ceftobiprole: 5th-gen cephalosporin; has anti-Legionella activity but not preferred.\n- b) Daptomycin: Lipopeptide; used for Gram-positive bacteria, not atypical organisms.\n- d) Norfloxacin: Fluoroquinolone; weaker against Legionella compared to newer agents like Levofloxacin.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Legionella Culture:** Requires BMPA (Buffered Charcoal Yeast Extract); slow growth.\n- **Atypical Pneumonia:** Mycoplasma, Chlamydia, Legionella â€” all covered by Macrolides.\n- **Alternative:** Fluoroquinolones (Levofloxacin) are highly effective for Legionella.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Azith for Atypical\": Azithromycin is DOC for Atypical respiratory pathogens (Legionella, Mycoplasma, Chlamydia)."},{"id":65,"question":"The drug not use in acute asthma is :","options":{"a":"Salbutamaol","b":"Terbutaline","c":"Salmeterol","d":"Formeterol"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nSalmeterol is a Long-Acting Beta-2 Agonist (LABA) with an onset of 10-15 minutes and duration of ~12 hours. It is used for chronic maintenance of asthma, NOT for acute exacerbations where rapid onset is critical. Salbutamol (Albuterol) and Terbutaline are Short-Acting Beta-2 Agonists (SABA) with rapid onset (minutes) and are appropriate for acute asthma attacks.\n\n**2. Rationale for Incorrect Options:**\n- a) Salbutamol (Albuterol): SABA; FIRST-LINE for acute asthma.\n- b) Terbutaline: SABA; used for acute asthma or subcutaneously for severe exacerbations.\n- d) Formoterol: LABA; like Salmeterol, primarily for maintenance therapy.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **SABAs:** Acute relief (Salbutamol, Terbutaline, Levalbuterol).\n- **LABAs:** Maintenance therapy; NEVER monotherapy (increased mortality risk in asthma).\n- **Combination Inhalers:** LABA + ICS (e.g., Salmeterol/Fluticasone) for better control.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Long-Acting = Long-term maintenance\": SALbutamol for Sudden acute attacks."},{"id":66,"question":"A 24-year-old male presents to the emergency department with sudden onset of palpitatons. He had an episode similar to this one year ago that resolved spontaneously. Rapid IV injection of a drug into this patient results in instantaneous resolution of the arrhythmia but is accompanied with transitory flushing, burning in the chest and shortness of breath. Which of the following drugs was used to treat this patientâ€™s condition?","options":{"a":"Verapamil","b":"Adenosine","c":"Amiodarone","d":"Lidocaine"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe patient has Paroxysmal Supraventricular Tachycardia (PSVT) (sudden palpitations, recurrent episodes that resolve spontaneously). Adenosine is the first-line IV drug for acute termination of PSVT due to its ultra-rapid onset (seconds) and ability to block conduction through the AV node. Its characteristic side effectsâ€”Flushing, Chest burning, SOBâ€”are transient (half-life \u003c10 seconds) and predictable, not dangerous.\n\n**2. Rationale for Incorrect Options:**\n- a) Verapamil: Calcium channel blocker; slower onset; can be used but adenosine preferred.\n- c) Amiodarone: Reserved for life-threatening arrhythmias or refractory cases.\n- d) Lidocaine: Antiarrhythmic; not effective for SVT termination.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Adenosine:** Given as rapid IV push; effectiveness 80-90% for PSVT.\n- **Transient Effects:** Flushing, Dyspnea, Chest discomfort resolve within seconds.\n- **Contraindications:** Severe asthma/COPD (bronchospasm), Severe AV block.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Adeno-SINE = SINe Wave Terminator\": Adenosine terminates PSVT by blocking AV conduction."},{"id":67,"question":"Streptokinase was infused in a patient for management of DVT, following which the patient developed hematemesis. Which of the following agents can be used as an antidote ?","options":{"a":"Vitamin K","b":"Noradrenaline","c":"Epsilon aminocaproic acid / Tranexemic acid","d":"Rutin"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nStreptokinase is a fibrinolytic (thrombolytic) agent that activates plasminogen to dissolve clots. Overdose or excessive fibrinolysis leads to bleeding (hematemesis in this case). Epsilon Aminocaproic Acid (EACA) and Tranexamic Acid are Fibrinolysis Inhibitors (prevent plasminogen activation) that serve as Antidotes for fibrinolytic overdose.\n\n**2. Rationale for Incorrect Options:**\n- a) Vitamin K: Reverses Warfarin; not specific for fibrinolytic agents.\n- b) Noradrenaline: Vasopressor; doesn't specifically reverse fibrinolysis.\n- d) Rutin: A bioflavonoid; not an established antidote for fibrinolytic overdose.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Fibrinolytic Complications:** Bleeding (GI, ICH, Retroperitoneal).\n- **EACA/Tranexamic Acid:** Lysine analogues; inhibit plasminogen/plasmin activation.\n- **Dosing:** EACA loading dose 4-5 gm IV followed by 1-1.25 gm/hr infusion.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"EACA/TXA stop Clot Breakdown\": Reverses Excessive fibrinolysis (Epsilon Aminocaproic Acid)."},{"id":68,"question":"Which of the following drugs has both 5HT4 agonist and D2 antagonist property?","options":{"a":"Ondansetron","b":"Metoclopramide","c":"Benzhexol","d":"Ibutilide"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nMetoclopramide has a unique Dual Mechanism: (1) D2 Dopamine Antagonist (antiemetic effect) and (2) 5HT4 Agonist (prokinetic effect - enhances gastric motility). This combination makes it effective for both nausea/vomiting AND gastric dysmotility. It is the most commonly used antiemetic in clinical practice.\n\n**2. Rationale for Incorrect Options:**\n- a) Ondansetron: 5HT3 antagonist (NOT 5HT4 agonist); purely antiemetic (no prokinetic).\n- c) Benzhexol: Anticholinergic (used for Parkinson's); not an antiemetic.\n- d) Ibutilide: Antiarrhythmic; unrelated to antiemesis.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Metoclopramide Side Effects:** EPS (Extrapyramidal Symptoms - Dystonia, Akathisia) â€” D2 antagonism.\n- **Tardive Dyskinesia Risk:** With long-term use; FDA warning for >3 months.\n- **Contrast with Ondansetron:** 5HT3 antagonist; no EPS risk but also no prokinetic benefit.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Metoclo = Motor + Nausea control\": D2 blocker (nausea) + 5HT4 agonist (motility)."},{"id":69,"question":"Which of the following drug has least chances of causing the side effect shown below? \n\n {image 2}","options":{"a":"Ciclesonide","b":"Fluticasone","c":"Budesonide","d":"Mometasone"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nCiclesonide is a Pro-drug inhaled corticosteroid (ICS) that is locally activated in the lungs to its active metabolite (desisobutyryl ciclesonide). Unlike other ICS, Ciclesonide has minimal systemic bioavailability and less oropharyngeal deposition, resulting in the lowest risk of Oral Candidiasis among available ICS agents. It also has the lowest HPA axis suppression.\n\n**2. Rationale for Incorrect Options:**\n- b) Fluticasone: ICS; moderate oral candidiasis risk.\n- c) Budesonide: ICS; higher oropharyngeal deposition than Ciclesonide.\n- d) Mometasone: ICS; similar candidiasis risk to Budesonide.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Preventing Oral Candidiasis:** Rinse mouth after ICS use; use spacer device.\n- **Ciclesonide Advantage:** Pro-drug activation; best local targeting; minimal systemic effects.\n- **All ICS:** Can cause Dysphonia, Throat irritation; less common with Ciclesonide.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Cicle-sonide = Cleanest\": Ciclesonide has the Cleanest safety profile (least candidiasis)."},{"id":70,"question":"Drug used in Chemotherapy induced vomiting is:","options":{"a":"Doxylamine","b":"Scopalmine","c":"Palonosetron","d":"Domperidone"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nPalonosetron is a 5HT3 Receptor Antagonist (Setron) with the longest half-life (~40 hours) among 5HT3 antagonists. It is the most effective agent for Chemotherapy-Induced Nausea and Vomiting (CINV), particularly for highly emetogenic chemotherapy. It is given as a single IV or PO dose and provides prolonged protection.\n\n**2. Rationale for Incorrect Options:**\n- a) Doxylamine: First-generation antihistamine; sedating, not preferred for CINV.\n- b) Scopolamine: Anticholinergic; used for motion sickness, not CINV.\n- d) Domperidone: D2 antagonist; less effective for CINV; more GI motility focus.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **5HT3 Antagonists:** Ondansetron (8 hrs), Granisetron (24 hrs), Palonosetron (40 hrs).\n- **CINV Management:** 5HT3 antagonist + NK1 antagonist (Aprepitant) + Dexamethasone for optimal control.\n- **Breakthrough CINV:** Treated with Metoclopramide or additional Dexamethasone doses.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Palonos = Prolonged Protection\": Palonosetron has the Longest half-life among 5HT3 antagonists."},{"id":71,"question":"Anti-emetic associated with EPS:","options":{"a":"Metoclopramide","b":"Domperidone","c":"Doxylamine","d":"Ondansetron"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nMetoclopramide is a D2 Dopamine Antagonist that can cause Extrapyramidal Symptoms (EPS): Dystonia, Akathisia, Parkinsonism, and Tardive Dyskinesia (especially with long-term use). EPS occurs in ~10-20% of patients, particularly in elderly and those with predisposing factors. This is the major limitation of Metoclopramide use.\n\n**2. Rationale for Incorrect Options:**\n- b) Domperidone: D2 antagonist; similar EPS risk as Metoclopramide but less penetration across BBB (lower EPS incidence).\n- c) Doxylamine: Antihistamine; sedation is main side effect, not EPS.\n- d) Ondansetron: 5HT3 antagonist; NO EPS risk (advantage over Metoclopramide).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Metoclopramide Controversy:** FDA black box warning for Tardive Dyskinesia risk >3 months use.\n- **EPS Management:** Beta-blockers (Propranolol) or Anticholinergics (Benztropine, Trihexyphenidyl).\n- **Safer Alternatives:** Ondansetron (no EPS), 5HT4 agonists like Domperidone.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Metoclo = Motor Problems\": D2 antagonism â†’ EPS (Extrapyramidal Symptoms)."},{"id":72,"question":"Which anti-neoplastic drug is cell cycle specific and acts on S-phase?","options":{"a":"Vincristine","b":"Cyclophosphamide","c":"Vinblastine","d":"Cytarabine"},"correctAnswer":"d","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nCytarabine (Ara-C) is a Pyrimidine Antagonist (Antimetabolite) that is S-phase specific because it acts during DNA synthesis. It inhibits DNA polymerase and ribonucleotide reductase, blocking DNA synthesis and S-phase progression. Cytarabine is used for Acute Myeloid Leukemia (AML) and lymphomas.\n\n**2. Rationale for Incorrect Options:**\n- a) Vincristine: Vinca alkaloid; M-phase specific (inhibits microtubule formation).\n- b) Cyclophosphamide: Alkylating agent; Non-cycle specific (active in all phases).\n- c) Vinblastine: Vinca alkaloid; M-phase specific.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **S-Phase Drugs:** Cytarabine, 5-Fluorouracil (5-FU), Methotrexate.\n- **M-Phase Drugs:** Vincristine, Vinblastine, Paclitaxel.\n- **Non-Specific:** Alkylating agents, Platinum drugs, Bleomycin.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Cytara-bine = Cellular Synthesis blocker\": Cytarabine blocks S-phase DNA synthesis."},{"id":73,"question":"Hand and Foot syndrome is caused by which anticancer drug?","options":{"a":"Cyclophosphamide","b":"Capecitabine","c":"Chloramphenicol","d":"Mitomycin C"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nCapecitabine (5-FU pro-drug) is notorious for causing Hand-Foot Syndrome (Palmoplantar Erythrodysesthesia - PPE): Redness, Swelling, Pain, and blistering of palms and soles. It occurs in 50% of patients on Capecitabine. The mechanism involves toxic metabolite accumulation in areas of high eccrine sweat gland activity. Management includes dose reduction and supportive care (cooling, topical treatments).\n\n**2. Rationale for Incorrect Options:**\n- a) Cyclophosphamide: Alkylating agent; causes hemorrhagic cystitis, not Hand-Foot syndrome.\n- c) Chloramphenicol: Antibiotic; causes bone marrow suppression, not Hand-Foot syndrome.\n- d) Mitomycin C: Alkylating agent; causes pulmonary fibrosis and HUS, not Hand-Foot syndrome.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Capecitabine PPE:** Occurs with peak incidence 4-6 weeks into therapy.\n- **Risk Factors:** Dose intensity, baseline renal dysfunction, female gender.\n- **Management:** Dose hold/reduction, Vitamin B6, Topical emollients, Cooling measures.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Capecita-bine Blisters Hands/Feet\": Capecitabine is notorious for Hand-Foot Syndrome (PPE)."},{"id":74,"question":"Botulinum toxin acts by:","options":{"a":"Inhibiting the entry of Ca ++ in presynaptic nerve terminal","b":"Inhibiting the release of acetylcholine from presynaptic nerve terminal","c":"Stimulating acetylcholine receptors","d":"Inhibit acetylcholinesterase"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nBotulinum Toxin (from Clostridium botulinum) is a Zinc-dependent Serine Protease that specifically cleaves SNARE proteins (Soluble NSF Attachment Receptor proteins) in the presynaptic terminal. This prevents Acetylcholine vesicles from docking and fusing with the presynaptic membrane, effectively blocking ACh release. The result is Flaccid Paralysis at the neuromuscular junction.\n\n**2. Rationale for Incorrect Options:**\n- a) Ca++ Entry Inhibition: Contributes minimally; SNARE cleavage is the primary mechanism.\n- c) Stimulating ACh Receptors: Opposite of true effect; Botox causes paralysis by reducing ACh.\n- d) Acetylcholinesterase Inhibition: That's Physostigmine's mechanism (opposite effect).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Clinical Use:** Cosmetic (Wrinkles), Therapeutic (Dystonia, Migraines, Hyperhidrosis).\n- **Onset:** 3-7 days; peaks at 2-3 weeks; lasts ~3 months.\n- **Contrast with Tetanus Toxin:** Both cleave SNARE proteins but at different sites.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Botox Blocks ACh Release\": Cleaves SNARE proteins â†’ No ACh vesicle fusion â†’ Paralysis."},{"id":75,"question":"A female developed pain and insect crawling like sensation on legs at night which is relieved by shaking her legs. Which of the following is drug of choice for this condition?","options":{"a":"Tramadol","b":"Gabapentin","c":"Vitamin B12","d":"Iron tablets"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nRestless Legs Syndrome (RLS) presents as uncomfortable sensations in the legs (pain, crawling, burning), worse at night, relieved by movement/shaking. Gabapentin is a Calcium Channel Modulator/Anticonvulsant that is highly effective for RLS. It reduces the hyperexcitability of sensory neurons. Dopamine agonists (Pramipexole, Ropinirole) are alternatives but carry augmentation risk.\n\n**2. Rationale for Incorrect Options:**\n- a) Tramadol: Opioid; used for severe RLS but not first-line (addiction risk, tolerance).\n- c) Vitamin B12: Used for B12-deficiency neuropathy; not effective for idiopathic RLS.\n- d) Iron tablets: Useful only if RLS is due to Iron deficiency (specific subgroup).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **RLS Pathophysiology:** Likely dopaminergic and iron metabolism dysfunction.\n- **Gabapentin Dosing:** Typically 300-3600 mg/day in divided doses; pregabalin is alternative.\n- **Augmentation:** Long-term dopamine agonist use paradoxically worsens RLS; less with Gabapentin.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"GabapenTIN for TINgling RLS\": Gabapentin treats the TINgling and INcomfort of RLS."},{"id":76,"question":"Patient with bacterial meningitis was started on antimicrobial therapy. After 5 days of therapy he developed pain in the right upper part of abdomen. Ultrasound reveals gallstones. Which of the following antimicrobial may be responsible for this?","options":{"a":"Ceftriaxone","b":"Penicillin","c":"Vancomycin","d":"Ampicillin"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nCeftriaxone, a 3rd generation Cephalosporin commonly used for meningitis, is well-known for causing Biliary Sludge and Gallstones (Cholelithiasis). The mechanism involves ceftriaxone precipitation in the biliary system, forming reversible pseudostone-like precipitates. This typically occurs 5-7 days into therapy and is mostly asymptomatic, resolving after drug discontinuation. However, symptomatic biliary colic can occur (as in this case).\n\n**2. Rationale for Incorrect Options:**\n- b) Penicillin: No association with gallstone formation.\n- c) Vancomycin: No association with gallstone formation; rarely causes nephrotoxicity.\n- d) Ampicillin: No association with gallstone formation.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Incidence:** ~7-25% of patients on high-dose Ceftriaxone develop biliary sludge.\n- **Mechanism:** Drug precipitation in bile; reversible upon discontinuation.\n- **Management:** Usually supportive; discontinue if symptomatic; rarely requires intervention.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"CeftriAXone creates AxE in Gallbladder\": Known for Cholelithiasis/Biliary sludge."},{"id":77,"question":"A 60-year-old man comes to the physician because of worsening fatigue and dyspnea on exertion that has started to limit his daily activities. Recently, he has also been having difficulty sleeping and requires four pillows in order to sleep at night. His past medical history is significant for a myocardial infarction 2 years ago. Physical examination reveals bilateral lung crackles and lower extremity edema. Chest x-ray shows cardiomegaly. The patient is admitted to the hospital, where his blood pressure is stable at 150-160/90-100. Long-term control of his hypertension would be best achieve with which of the following agents?","options":{"a":"Hydrochlorothiazide","b":"Terazosin","c":"Lisinopril","d":"Amlodipine"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe patient has Systolic Heart Failure (Cardiomegaly, Orthopnea, Fatigue, Bilateral crackles) post-MI. Lisinopril (ACE Inhibitor) is the gold standard for long-term management because it: (1) Reduces Cardiac Remodeling, (2) Decreases Preload/Afterload, (3) Improves Survival (proven in landmark trials like SAVE, AIRE), (4) Provides Renoprotection. ACEis have strong mortality benefit in post-MI HF.\n\n**2. Rationale for Incorrect Options:**\n- a) Hydrochlorothiazide: Thiazide diuretic; used for HTN but no mortality benefit in HF; risk of electrolyte abnormalities.\n- b) Terazosin: Alpha blocker; causes reflex tachycardia and increased mortality in HF (stopped in ALLHAT subgroup).\n- d) Amlodipine: CCB; effective for HTN but no HF/remodeling benefit; neutral mortality.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **HF Medications:** ACEi/ARB + Beta-blocker + Aldosterone antagonist (Gold standard triad).\n- **Lisinopril in HF:** Reduces mortality by ~20%; standard first-line therapy.\n- **Contraindication:** Bilateral RAS, Pregnancy, History of angioedema.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"ACEi Amends the heart\": ACE inhibitors improve Heart failure Outcomes (Mortality, Remodeling)."},{"id":78,"question":"A 45-year old man presented with recurrent episodes of headache, palpitations and sweating. His blood pressure at presentation was 180/100 mm Hg. Further testing revealed elevated urinary metanephrines, CT abdomen showed a right adrenal mass. What is the drug of choice for the management of this patient?","options":{"a":"Labetalol","b":"Nitroprusside","c":"Phenoxybenzamine","d":"Phentolamine"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe patient has Pheochromocytoma: Classic triad of Headache, Palpitations, Sweating + Elevated BP (180/100) + Elevated Urinary Metanephrines + Adrenal Mass on CT. Management requires Alpha-Blockade FIRST using Phenoxybenzamine (Non-selective, irreversible Alpha blocker), followed by Beta-blockade (AFTER Alpha blockade to avoid hypertensive crisis from unopposed Alpha stimulation). Never give Beta-blocker first (risk of hypertensive crisis).\n\n**2. Rationale for Incorrect Options:**\n- a) Labetalol: Alpha + Beta blocker; while convenient, not optimal because Alpha blockade must be established first.\n- b) Nitroprusside: Vasodilator; used for acute hypertensive crisis, not chronic pre-op management.\n- d) Phentolamine: Short-acting Alpha blocker; used for acute hypertensive episodes, not chronic preparation.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Preparation for Surgery:** Phenoxybenzamine â†’ then Beta-blocker (Propranolol) â†’ Surgery after 10-14 days.\n- **Why Phenoxy First:** Non-selective Alpha blockade needed to prevent catecholamine surge â†’ hypertensive crisis if Beta-blocked first.\n- **Operative Management:** IV Phentolamine on standby during surgery for acute hypertensive surges.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"PHENto-xy First, then BETA\": PHENoxybenzamine must precede BETA-blocker in Pheochromocytoma."},{"id":79,"question":"A patient who has mechanical valves in the heart develops atrial fibrillation, which of the following is the best drug for management of thromboses ?","options":{"a":"DOAC","b":"UFH","c":"WARFARIN","d":"ALTEPLASE"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nMechanical Heart Valves have the HIGHEST thromboembolism risk and require Lifelong Anticoagulation. DOACs (Direct Oral Anticoagulants) are CONTRAINDICATED in mechanical valves (inadequate thrombus prevention, increased valve thrombosis risk). Warfarin is the only approved anticoagulant for mechanical valves, even in AFib. INR target is typically 2-3 (or higher for mitral valves).\n\n**2. Rationale for Incorrect Options:**\n- a) DOAC: Specifically contraindicated in mechanical valves (inadequate protection, FDA warning).\n- b) UFH: Unfractionated Heparin; used acutely or bridge therapy, not long-term.\n- d) ALTEPLASE: Fibrinolytic; for acute thromboembolism, not chronic anticoagulation.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Mechanical Valves:** Warfarin mandatory (INR 2-3 or higher depending on valve position/type).\n- **Bioprosthetic Valves:** May use Warfarin (3 months) then aspirin alone.\n- **AFib + Mechanical Valve:** Warfarin is standard; DOACs still contraindicated.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Mechanical = Warfarin mandatory\": DOACs are dangerous in mechanical valves."},{"id":80,"question":"A patient was started on empirical management with Cefpodoxime, Clindamycin for a serious infection. Now the patient developed diarrhea and abdominal pain. All of the following can be used in the management for this patient except?","options":{"a":"Vancomycin","b":"Metronidazole","c":"Fidoxamicin","d":"Ciprofloxacin"},"correctAnswer":"d","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe patient has Clostridium difficile-Associated Diarrhea (CDAD), likely triggered by Cephalosporin/Clindamycin use. Treatment options include Vancomycin (oral), Metronidazole, Fidoxamicin. Ciprofloxacin (Fluoroquinolone) is NOT used for C. difficile because: (1) Fluoroquinolones can actually trigger CDI (antimicrobial-associated diarrhea), (2) Limited activity against Clostridium difficile, (3) Would perpetuate or worsen the condition.\n\n**2. Rationale for Incorrect Options:**\n- a) Vancomycin: First-line for severe/fulminant CDI (oral route).\n- b) Metronidazole: Used for mild-moderate CDI (cheaper, adequate).\n- c) Fidoxamicin: Newest agent; highest efficacy, lowest recurrence risk (very expensive).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **C. difficile Risk:** Antibiotic exposure (especially Beta-lactams, Clindamycin), PPI use, Age >65.\n- **Treatment Algorithm:** Mild (Metronidazole) â†’ Moderate (Vancomycin) â†’ Severe/Fulminant (Vancomycin Â± Metronidazole Â± Bezlotoxumab).\n- **Discontinue Offending Agent:** Critical step in CDI management.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Cipro Causes CDI\": Cipro Causes or Worsens C. difficile infection."},{"id":81,"question":"Which of the following is paired correctly?","options":{"a":"Hemicholinium prevents the release of Ach from storage vesicle","b":"Botulinum increases the Ach release","c":"Pralidoxime reactivates acetylcholinesterase","d":"Vesamicol inhibits the uptake of choline"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nPralidoxime (2-PAM) is an Oxime compound that reactivates Acetylcholinesterase (AChE) inhibited by Organophosphates. It works by removing the phosphoryl group from the AChE active site, restoring enzyme function. This is particularly effective in the early phase of organophosphate poisoning (before \"aging\" of the complex occurs).\n\n**2. Rationale for Incorrect Options:**\n- a) Hemicholinium: Inhibits uptake of Choline (not release from vesicles).\n- b) Botulinum: Prevents ACh release (cleaves SNARE proteins).\n- d) Vesamicol: Inhibits Acetylcholine Storage in vesicles (not Choline uptake, though related).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Organophosphate Poisoning Management:** Atropine (muscarinic blocker) + Pralidoxime (AChE reactivator).\n- **Pralidoxime Timing:** Most effective within first 24 hours (aging limits effectiveness).\n- **Hemicholinium vs. Vesamicol:** Both reduce ACh synthesis but by different mechanisms.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Pralidoxime PRActically Resurrects Enzyme\": PRALIdoxime REACTS with phosphorylated AChE."},{"id":82,"question":"What is the mechanism of action of the drug that happens to be DOC for chemotherapy induced vomitting ?","options":{"a":"Muscarinic blocker","b":"Anti-histaminic","c":"5HT3-blocker","d":"D2 blocker"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe DOC (Drug of Choice) for Chemotherapy-Induced Nausea and Vomiting (CINV) is a 5HT3 Receptor Antagonist like Ondansetron, Granisetron, or Palonosetron. These agents block Serotonin (5-Hydroxytryptamine) Type 3 receptors on chemoreceptor trigger zone neurons and vagal afferents, preventing CINV. They are highly effective, especially for highly emetogenic chemotherapy.\n\n**2. Rationale for Incorrect Options:**\n- a) Muscarinic blocker: Used for motion sickness/post-op nausea (Scopolamine), less effective for CINV.\n- b) Anti-histaminic: Mild antiemetic effect; used in combination, not monotherapy for CINV.\n- d) D2 blocker: (Metoclopramide, Domperidone) less effective than 5HT3 antagonists; carries EPS risk.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **5HT3 Antagonists:** Ondansetron (8 hrs), Granisetron (24 hrs), Palonosetron (40 hrs).\n- **Optimal CINV Regimen:** 5HT3 antagonist + NK1 antagonist (Aprepitant) + Dexamethasone.\n- **Newer Agents:** Palonosetron and NK1 antagonists for better control of delayed CINV.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"5HT3-BAN the Nausea\": 5HT3 antagonists BAN (block) chemotherapy-induced vomiting."},{"id":83,"question":"A patient underwent a hysterectomy and was given morphine in the post â€“ operative period and in the ward for pain. She now presents with biliary colic pain. What is the drug used that might have caused it ?","options":{"a":"Aceclofenac","b":"Naloxone","c":"Morphine","d":"Atropine"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nMorphine is a well-known cause of Biliary Colic (abdominal pain from bile duct spasm). The mechanism: Morphine increases sphincter of Oddi pressure, causing increased intraductal bile pressure and pain, particularly in susceptible patients or those with pre-existing gallbladder disease. This is a classic post-operative complication, especially in patients receiving Morphine for post-surgical pain management.\n\n**2. Rationale for Incorrect Options:**\n- a) Aceclofenac: NSAID; no biliary effect.\n- b) Naloxone: Opioid antagonist; would reverse Morphine's effects, not cause them.\n- d) Atropine: Anticholinergic; would theoretically relax sphincter of Oddi (opposite effect).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Opioid Effects on Biliary System:** All opioids increase sphincter of Oddi pressure; Morphine > Codeine > Meperidine.\n- **Meperidine:** Preferred opioid for biliary pain (minimal sphincter effect).\n- **Management:** Discontinue Morphine, use NSAIDs or alternative analgesics (Meperidine).\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Morphine Makes Bile Duct Tighten\": Morphine causes Sphincter of Oddi contraction â†’ Biliary pain."},{"id":84,"question":"A 50-year old man presents with complains of urinary retention. He has hypertension but not compliant with treatment. B.P 160 /100, DRE reveals an enlarged prostate with rubbery consistency. Which of the following drugs would be the most appropriate initial therapy ?","options":{"a":"Phenoxybenzamine","b":"Tamsulosin","c":"Terazosin","d":"Finasteride"},"correctAnswer":"c","explanation":""},{"id":85,"question":"Use of tiotropium is contra-indicated in:","options":{"a":"Bronchial asthma","b":"Hypertension","c":"Urinary retention","d":"Peptic ulcer disease"},"correctAnswer":"c","explanation":""},{"id":86,"question":"All of the following statements about nesiritide are true except ?","options":{"a":"It is a BNP analogue","b":"It can be used in acute decompensated CHF","c":"It can be administered orally","d":"It causes loss of Na+ in the urine"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nNesiritide is a recombinant B-type Natriuretic Peptide (BNP) used for Acute Decompensated Heart Failure (AcHF). It is a BNP analogue that causes natriuresis (sodium loss) and is administered ONLY intravenously. It CANNOT be given orally because BNP is a peptide hormone that would be digested in the GI tract, making absorption impossible.\n\n**2. Rationale for Incorrect Options:**\n- a) BNP analogue: TRUE; Nesiritide mimics endogenous BNP.\n- b) Used in AcHF: TRUE; IV Nesiritide reduces dyspnea in AcHF.\n- d) Causes Na+ loss: TRUE; Natriuresis and diuresis are its mechanisms.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Nesiritide Dosing:** IV infusion only; loading dose followed by continuous infusion.\n- **Monitoring:** Renal function, Electrolytes, BP (hypotension risk).\n- **Advantage over Dobutamine:** No tachycardia or increased myocardial oxygen demand; improves hemodynamics more favorably.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Nesiritide is NOT for the Mouth\": Nesiritide is Never oral; Intravenous only (I = IV)."},{"id":87,"question":"Imipenem, a newer antibiotic with a broad antibacterial spectrum, is co administered with Cilastatin. Which of the following is the best reason for the same ?","options":{"a":"Combination of antibiotics is synergistic against pseudomonas species","b":"Cilastatin aids gastrointestinal absorption of active moiety, Imipenem","c":"Cilastatin inhibits beta-lactamase enzyme destroying Imipenem","d":"Cilastatin inhibits an enzyme in kidney destroying Imipenem"},"correctAnswer":"d","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nImipenem is a Beta-lactam antibiotic with broad-spectrum activity, but it undergoes significant renal metabolism by Dehydropeptidase-I (DHP-I), a kidney tubular enzyme that inactivates Imipenem. Cilastatin is a Dehydropeptidase-I inhibitor that prevents renal inactivation of Imipenem, thereby maintaining therapeutic urinary levels and preventing nephrotoxicity from toxic metabolites.\n\n**2. Rationale for Incorrect Options:**\n- a) Synergy vs. Pseudomonas: Not the reason; Imipenem already covers Pseudomonas monotherapy.\n- b) Aids GI absorption: Imipenem is given IV, not orally; absorption irrelevant.\n- c) Inhibits Beta-lactamase: Cilastatin doesn't inhibit bacterial beta-lactamase; it inhibits host DHP-I.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Imipenem/Cilastatin Combination:** Always given together; cilastatin reduces DHP-I inactivation by 99%.\n- **Dosing:** Cilastatin always 1:1 ratio with Imipenem.\n- **Comparison:** Meropenem (more stable, less DHP-I substrate) can be given monotherapy; Ertapenem similar to Imipenem (needs cilastatin consideration).\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Cilastatin = Clinically helps Imipenem\": Cilastatin Inhibits Imipenem's renal inactivation."},{"id":88,"question":"A patient receiving allopurinol requires a dose reduction of:","options":{"a":"6-Mercaptopurine","b":"Cyclophosphamide","c":"5-FU","d":"Cimetidine"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nAllopurinol (Xanthine oxidase inhibitor) increases levels of 6-Mercaptopurine (6-MP), a purine antagonist used in leukemia/lymphoma therapy. The mechanism: Allopurinol inhibits the metabolism of 6-MP by xanthine oxidase, leading to Increased 6-MP accumulation and toxicity. Therefore, 6-MP dose must be reduced by 60-75% when co-administered with Allopurinol.\n\n**2. Rationale for Incorrect Options:**\n- b) Cyclophosphamide: Metabolized by hepatic cytochrome P450; no significant interaction with Allopurinol.\n- c) 5-FU: Metabolized by different pathways; no major Allopurinol interaction.\n- d) Cimetidine: H2-blocker; metabolized by cytochrome P450; not affected by Allopurinol.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Allopurinol Interactions:** 6-MP (major), Theophylline, Warfarin (minor).\n- **6-MP Toxicity Amplification:** Increased bone marrow suppression, hepatotoxicity.\n- **Clinical Management:** Reduce 6-MP to 1/3 - 1/4 standard dose; monitor CBC, LFTs closely.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"6-MP Must be Minimized with Allopurinol\": Allopurinol Accumulates 6-MP levels."},{"id":89,"question":"A 28-year old woman presents to the clinic with complain of hair growth all over her body. She is a known case of epilepsy and has been compliant over the years. Which of the following drug could be attributed to her present complaints ?","options":{"a":"Carbamazepine","b":"Ethosuximide","c":"Phenytoin","d":"Valproate"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nPhenytoin (Diphenylhydantoin), a Class Ia Antiarrhythmic/Anticonvulsant, causes Hirsutism (Abnormal Hair Growth) in up to 30% of patients, especially women. The mechanism is androgenic stimulation (phenytoin's effect on sex hormone metabolism), leading to increased facial/body hair growth. Other notable chronic phenytoin side effects include Gingival Hyperplasia and Facial Coarsening.\n\n**2. Rationale for Incorrect Options:**\n- a) Carbamazepine: Anticonvulsant; similar but less hirsutism risk compared to Phenytoin.\n- b) Ethosuximide: Absence seizure drug; no hirsutism association.\n- d) Valproate: Can cause hair loss (alopecia), NOT hirsutism.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Phenytoin Toxicity Triad:** GINGIVAL hyperplasia, Hirsutism, FACIAL coarsening.\n- **Gingival Hyperplasia:** Preventable by good oral hygiene.\n- **Switching Drugs:** Consider Levetiracetam or Lamotrigine as alternatives if hirsutism cosmetically unacceptable.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Phenytoin's GHairy Problem\": Gingival hyperplasia, Hirsutism, Growin' facial features."},{"id":90,"question":"A patient underwent a Gastrointestinal surgery in which the jejunum was resected. Which of the following drugs would possibly be required in the treatment of this patient ?","options":{"a":"Semaglutide","b":"Liraglutide","c":"Teduglutide","d":"Exanatide"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nJejunal Resection results in Short Bowel Syndrome (SBS), characterized by malabsorption, diarrhea, and dependence on parenteral nutrition. Teduglutide is a Glucagon-Like Peptide-2 (GLP-2) Receptor Agonist that increases bowel mucosal growth and blood flow, improving intestinal absorption and reducing dependence on parenteral nutrition/PN. It is the only FDA-approved pharmacological treatment specifically for SBS.\n\n**2. Rationale for Incorrect Options:**\n- a) Semaglutide & b) Liraglutide: GLP-1 agonists for Type 2 Diabetes/Weight loss; not for SBS.\n- d) Exenatide: GLP-1 agonist; similar to above, not for SBS.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Teduglutide (Gattex):** SC injection 3x weekly; improves intestinal absorption.\n- **SBS Management:** Dietary modification, Antidiarrheal agents (Loperamide), Nutrition support, Teduglutide for moderate-severe cases.\n- **Other GLP-2 Agonist:** Glepaglutide (under development).\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Teduglutide Tends to Grow Bowel\": TEDuglutide Grows Intestinal epithelium in SBS."},{"id":91,"question":"A 2-month pregnant female presented with plasmodium vivax malaria. Which of the following is the appropriate treatment for this patient ?","options":{"a":"Chloroquine + primaquine","b":"ACT","c":"Chloroquine","d":"Doxycycline"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nChloroquine is SAFE in Pregnancy (Category A) for Plasmodium vivax malaria. However, Primaquine is CONTRAINDICATED in Pregnancy because it causes Hemolysis in G6PD-deficient fetuses and carries Teratogenic risk. Therefore, pregnant patients with P. vivax should receive Chloroquine only (skip the eradication/exoerythrocytic phase treatment with Primaquine until post-delivery/post-lactation).\n\n**2. Rationale for Incorrect Options:**\n- a) Chloroquine + Primaquine: Primaquine is contraindicated in pregnancy.\n- b) ACT (Artemisinin-based Combination Therapy): Emerging data shows safety; can be used in 2nd/3rd trimester, but Chloroquine is traditional first choice.\n- d) Doxycycline: Tetracycline; CONTRAINDICATED in Pregnancy (Fetal bone/teeth staining, inhibits bone growth).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Chloroquine in Pregnancy:** Safe; Category A; still effective against P. vivax.\n- **Primaquine:** Wait until postpartum or post-breastfeeding (enters breast milk, hemolytic risk in G6PD infants).\n- **P. falciparum in Pregnancy:** More complicated; requires Quinine or ACT in 2nd/3rd trimester.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Chloroquine for Pregnancy + P. vivax\": Chloroquine is Clean/Safe for Carrying mothers."},{"id":92,"question":"A 50-year old woman was admitted to critical care due to a drug overdose of a substance causing central nervous system depression, respiratory failure, and hemodynamic instability. An iv infusion of sodium bicarbonate is administered as a part of treatment plan, which of the following drug would be the causative agent for this condition?","options":{"a":"Phenobarbitone","b":"Amphetamine","c":"Morphine","d":"Opioids"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nThe patient has Barbiturate Overdose (CNS depression, Respiratory failure, Hemodynamic instability). Sodium Bicarbonate is administered as part of management because Phenobarbitone and other long-acting barbiturates are weak acids that undergo renal tubular reabsorption. By alkalinizing urine (Bicarbonate increases urinary pH), the barbiturate becomes ionized and is trapped in the urine, increasing excretion and reducing serum levels (ion-trapping mechanism).\n\n**2. Rationale for Incorrect Options:**\n- b) Amphetamine: Stimulant; causes opposite of CNS depression. Bicarbonate would cause ion-trapping of amphetamine RETENTION (opposite of desired effect; Ammonium chloride preferred).\n- c) Morphine & d) Opioids: Don't require Bicarbonate; treated with Naloxone + Supportive care.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Barbiturate Toxicity Management:** Airway protection, Mechanical ventilation, IV Fluids, Sodium Bicarbonate (for urine alkalinization).\n- **Ion-Trapping Principle:** Weak acids â†’ alkaline urine increases excretion; weak bases â†’ acidic urine increases excretion.\n- **Long-acting Barbiturates:** Phenobarbital benefits from Bicarbonate; Short-acting (Thiopental) less so.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Barb Bicarbonate Boosts Excretion\": Sodium Bicarbonate ion-traps and increases urinary Barbiturate elimination."},{"id":93,"question":"Finasteride acts by blocking:","options":{"a":"Alpha receptors","b":"5- alpha reductase enzyme","c":"Androgen receptore","d":"Beta receptors"},"correctAnswer":"b","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nFinasteride is a 5-Alpha Reductase Inhibitor (Type II isoenzyme-specific or non-selective depending on formulation). It blocks the conversion of Testosterone to Dihydrotestosterone (DHT), the potent androgen responsible for BPH and Male Pattern Baldness. By reducing DHT levels by ~70%, Finasteride causes Prostate Shrinkage and prevents/slows hair loss in androgenetic alopecia.\n\n**2. Rationale for Incorrect Options:**\n- a) Alpha receptors: Mechanism of Alpha blockers (Tamsulosin, Terazosin).\n- c) Androgen receptors: Mechanism of Bicalutamide/Antiandrogens (used for prostate cancer).\n- d) Beta receptors: Not relevant to Finasteride mechanism.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Finasteride Dosing:** 5 mg for BPH, 1 mg for Male Pattern Baldness.\n- **Onset:** 6-12 months for BPH; Baldness response may take 3-6 months.\n- **Side Effects:** ED, Reduced Libido, Decreased Semen Volume (all due to DHT reduction).\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Fina = 5-Alpha Finisher\": Finasteride Finishes DHT by blocking 5-Alpha reductase."},{"id":94,"question":"Lithium induced diabetes insipidus is treated by :","options":{"a":"Diclofenac","b":"Vasopressin","c":"Amiloride","d":"Indapamide"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nLithium causes Nephrogenic Diabetes Insipidus (NDI) by inhibiting Aquaporin-2 water channels in the collecting duct, making the kidney unresponsive to ADH. Amiloride, a Potassium-Sparing Diuretic (ENaC blocker), is the DOC for Lithium-Induced NDI because: (1) It blocks Lithium entry into collecting duct principal cells (via ENaC inhibition), (2) Reduces urinary loss of water and sodium, (3) Preserves potassium.\n\n**2. Rationale for Incorrect Options:**\n- a) Diclofenac: NSAID; can reduce urine output in NDI but not specific for Lithium DI.\n- b) Vasopressin: Ineffective in Nephrogenic DI (kidney doesn't respond to ADH).\n- d) Indapamide: Thiazide diuretic; paradoxically helpful in Nephrogenic DI but Amiloride superior for Lithium-induced.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Lithium NDI Incidence:** 20-40% of long-term users; often irreversible even after discontinuation.\n- **Amiloride Dosing:** 5-10 mg daily; can reduce polyuria dramatically.\n- **Monitoring:** Serum Lithium levels (therapeutic 0.6-1.2 mEq/L), Renal function, Electrolytes.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Amiloride Antagonizes Lithium's Damage\": Amiloride Acts at the Nephron to reduce Lithium-DI symptoms."},{"id":95,"question":"Most effective method of treatment of digitalis toxicity is:","options":{"a":"Hemodialysis","b":"Cardioversion","c":"Digoxin antibody","d":"Atropine"},"correctAnswer":"c","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nDigoxin Antibody (Digoxin-Specific Fab Fragment - DigiFab, Digibind) is the Most Effective and Specific Treatment for Digoxin Toxicity. The antibody fragments bind and sequester free digoxin, rendering it inactive and markedly increasing renal excretion of the digoxin-antibody complex. It is indicated for Life-threatening digoxin toxicity (severe arrhythmias, hyperkalemia).\n\n**2. Rationale for Incorrect Options:**\n- a) Hemodialysis: Minimally effective; Digoxin is highly protein-bound and has large volume of distribution.\n- b) Cardioversion: Can precipitate serious arrhythmias in digoxin toxicity (risk of VF); generally avoided.\n- d) Atropine: Provides symptomatic relief (bradycardia) but doesn't remove digoxin toxin.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Digoxin Toxicity Signs:** Arrhythmias (PVCs, AV blocks, Bidirectional VT), GI symptoms, Neuropsychiatric (confusion).\n- **Hyperkalemia:** Key electrolyte abnormality in Digoxin toxicity; poor prognostic sign.\n- **Digoxin Antibody Dosing:** Based on serum digoxin level and body weight; dose calculation essential.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Digoxin Antibody = Definitive\": Digoxin Antibody (Fab) is the Definitive treatment for severe toxicity."},{"id":96,"question":"Maintenance dose is calculated by using value of:","options":{"a":"Clearance","b":"Volume of distribution","c":"Oral bioavailability","d":"Daily dosage"},"correctAnswer":"a","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nMaintenance Dose (Dm) is calculated using Clearance (CL) via the formula: Dm = (CL Ã— Css Ã— Ï„) / F, where Css = Target steady-state concentration, Ï„ = Dosing interval, F = Bioavailability. Clearance is the key parameter determining how much drug must be given to maintain therapeutic levels, accounting for drug elimination rate.\n\n**2. Rationale for Incorrect Options:**\n- b) Volume of Distribution: Used to calculate Loading Dose (DL), not maintenance dose.\n- c) Oral Bioavailability: Affects the Fraction of dose absorbed; already incorporated into clearance for oral drugs.\n- d) Daily Dosage: This is the OUTPUT (calculated result), not the parameter used for calculation.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Loading Dose (DL) = Vd Ã— Css / F**\n- **Maintenance Dose (Dm) = CL Ã— Css Ã— Ï„ / F**\n- **Pharmacokinetics:** Understanding these formulas is critical for dosing in renal/hepatic impairment.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Clear Load Maintain\": Clearance determines Maintenance dose. Vd determines Loading dose."},{"id":97,"question":"Correct match of anti-arrhythymic drug is :","options":{"a":"Quinidine - Class Ib","b":"Amiodarone - Class IV","c":"Lignocaine â€“ Class Ia","d":"Esmolol â€“ Class II"},"correctAnswer":"d","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nEsmolol is a Class II Antiarrhythmic (Beta-blocker). It is a Short-acting, IV-only Beta-1 selective blocker used for acute rate control in SVT and intraoperative tachycardia. Class II drugs work by Slowing AV nodal conduction and prolonging AV nodal refractoriness.\n\n**2. Rationale for Incorrect Options:**\n- a) Quinidine - Class Ia: Correct; Quinidine is a Class Ia (not Ib). (This option is WRONG match).\n- b) Amiodarone - Class IV: Incorrect; Amiodarone is a Class III (also has properties of I, II, IV). (Wrong match).\n- c) Lignocaine - Class Ia: Incorrect; Lignocaine is a Class Ib (not Ia). (Wrong match).\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Antiarrhythmic Classes:** I (Na+ blocker), II (Beta), III (K+ blocker), IV (Ca++ blocker).\n- **Esmolol:** Ultra-short acting (~9 min half-life); ideal for perioperative use.\n- **Amiodarone:** Class III (not IV) with multi-class properties.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Esmo = Beta = II\": Esmolol is a Beta-blocker (Class II)."},{"id":98,"question":"Drug of choice for mass chemoprophylaxis of meningococcal meningitis is:","options":{"a":"Rifampicin","b":"Ciprofloxacin","c":"Chloramphenicol","d":"Doxycycline"},"correctAnswer":"b","explanation":""},{"id":99,"question":"Drug which does not inhibit nucleic acid synthesis:","options":{"a":"Rifampicin","b":"Fluoroquinolone","c":"Nitrofurantoin","d":"Linezolid"},"correctAnswer":"d","explanation":"**1. High-Yield Topic Explanation (The Core Concept):**\nLinezolid is an Oxazolidinone antibiotic that works by Inhibiting Bacterial Protein Synthesis (binds 50S ribosomal subunit). It does NOT inhibit nucleic acid (DNA/RNA) synthesis, making it the exception among the options. It's useful for Gram-positive infections including VRE and MRSA.\n\n**2. Rationale for Incorrect Options:**\n- a) Rifampicin: Inhibits RNA Polymerase; blocks RNA synthesis.\n- b) Fluoroquinolone: Inhibits DNA Gyrase; blocks DNA synthesis.\n- c) Nitrofurantoin: Inhibits DNA Reductase and interferes with nucleic acid synthesis.\n\n**3. Exam Essentials (High-Yield Facts):**\n- **Linezolid Mechanism:** 50S ribosomal inhibition (protein synthesis).\n- **Linezolid Side Effects:** Bone marrow suppression, Lactic acidosis, Serotonin syndrome (with SSRIs).\n- **Nucleic Acid Synthesis Inhibitors:** Fluoroquinolones, Rifampicin, Metronidazole, Nitrofurantoin.\n\n**4. Logical Learning Aids (Mnemonics & Tricks):**\n- \"Linezolid Levels-up Protein\": Linezolid targets Protein synthesis, NOT nucleic acids."},{"id":100,"question":"Which of the following is contraindicated in a myasthenic patients?","options":{"a":"Aminoglycosides","b":"Penicillin","c":"Sulphonamides","d":"All"},"correctAnswer":"a","explanation":""}];
        const images = ["data:image/jpeg;base64,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","data:image/jpeg;base64,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"];
        const initialMcqsState = JSON.parse(JSON.stringify(mcqs)); // For exam reset
        let currentMcqs = []; // Can be a subset for practice mode
        let sections = [];
        let answerStates = [];
        let practiceStates = [];
        let currentSectionIndex = 0;
        let currentQuestionIndexInSection = 0;
        let currentPracticeIndex = 0;
        let timerInterval;
        let practiceTimerInterval;
        let perQuestionTimerInterval;
        let timePerMcq = 0;
        let timeOverall = 0;
        let questionStartTime = 0;
        let subjectName, candidateName, shortNote;
        let onConfirmCallback = null;
        let reviewReturnScreen = 'results'; // 'results' or 'practiceResults'
        let isShuffled = false;
        let isReviewingSaved = false;
        // FIX: Changed to string concatenation to avoid nested template literal parsing issues.
        const EXAM_DRAFT_KEY = 'examDraft_' + examId;
        const PRACTICE_DRAFT_KEY = 'practiceDraft_' + examId;
        const SAVED_MCQS_KEY = 'savedMcqs_' + examId;
        const EXAM_RESULTS_HISTORY_KEY = 'examResultsHistory_' + examId;
        const PRACTICE_RESULTS_HISTORY_KEY = 'practiceResultsHistory_' + examId;
        const THEME_KEY = 'examTheme_' + examId;
        let savedMcqIds = [];
        let isSmoothSwipe = true;
        let isSparklesEnabled = true;
        
        // --- GAMIFICATION STATE ---
        let currentStreak = 0;

        const QuestionStatus = {
            NotVisited: 'NOT_VISITED',
            NotAnswered: 'NOT_ANSWERED',
            Answered: 'ANSWERED',
            MarkedForReview: 'MARKED_FOR_REVIEW',
        };
        
        const statusColors = {
            [QuestionStatus.Answered]: 'bg-green-600 hover:bg-green-500',
            [QuestionStatus.NotAnswered]: 'bg-red-600 hover:bg-red-500',
            [QuestionStatus.NotVisited]: 'bg-gray-500 hover:bg-gray-600',
            [QuestionStatus.MarkedForReview]: 'bg-purple-600 hover:bg-purple-500',
        };

        const svgBookmarkOutline = '<svg xmlns="http://www.w3.org/2000/svg" class="h-6 w-6" style="color: var(--text-secondary);" fill="none" viewBox="0 0 24 24" stroke="currentColor" stroke-width="2"><path stroke-linecap="round" stroke-linejoin="round" d="M5 5a2 2 0 012-2h10a2 2 0 012 2v16l-7-3.5L5 21V5z"></path></svg>';
        const svgBookmarkSolid = '<svg xmlns="http://www.w3.org/2000/svg" class="h-6 w-6" style="color: var(--text-accent);" viewBox="0 0 20 20" fill="currentColor"><path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path></svg>';

        // --- DOM ELEMENTS ---
        const screens = {
            setup: document.getElementById('setup-screen'),
            exam: document.getElementById('exam-screen'),
            results: document.getElementById('results-screen'),
            review: document.getElementById('review-screen'),
            practice: document.getElementById('practice-screen'),
            practiceResults: document.getElementById('practice-results-screen'),
            pastResults: document.getElementById('past-results-screen'),
            progress: document.getElementById('progress-screen'),
        };
        const confirmationModal = document.getElementById('confirmation-modal');
        const confirmationMessageEl = document.getElementById('confirmation-message');
        const confirmActionBtn = document.getElementById('confirm-action-btn');
        const cancelConfirmationBtn = document.getElementById('cancel-confirmation-btn');
        const reportOptionsModal = document.getElementById('report-options-modal');
        const calculatorModal = document.getElementById('calculator-modal');
        const questionPalette = document.getElementById('question-palette');
        const paletteContentWrapper = document.getElementById('palette-content-wrapper');
        const hidePaletteBtn = document.getElementById('hide-palette-btn');
        const showPaletteBtn = document.getElementById('show-palette-btn');
        const practiceResumeModal = document.getElementById('practice-resume-modal');
        const savedQuestionsContainer = document.getElementById('saved-questions-container');
        const viewSavedBtn = document.getElementById('view-saved-btn');
        const savedQuestionsCountEl = document.getElementById('saved-questions-count');
        const saveMcqBtn = document.getElementById('save-mcq-btn');
        const saveMcqPracticeBtn = document.getElementById('save-mcq-practice-btn');
        const toggleSparklesBtn = document.getElementById('toggle-sparkles-btn');
        const reviewTitleEl = document.getElementById('review-title');
        const toastEl = document.getElementById('toast-notification');
        
        // --- CONFETTI LOGIC (Gravity Burst) ---
        function triggerConfetti(rect) {
            if (!isSparklesEnabled) return;
            const centerX = rect.left + rect.width / 2;
            const centerY = rect.top + rect.height / 2;
            const colors = ['#EF476F', '#FFD166', '#06D6A0', '#118AB2', '#073B4C', '#9D4EDD'];
            
            for (let i = 0; i < 50; i++) {
                const particle = document.createElement('div');
                particle.style.position = 'fixed';
                particle.style.left = centerX + 'px';
                particle.style.top = centerY + 'px';
                particle.style.width = (Math.random() * 10 + 5) + 'px';
                particle.style.height = particle.style.width;
                particle.style.backgroundColor = colors[Math.floor(Math.random() * colors.length)];
                particle.style.zIndex = '9999';
                particle.style.pointerEvents = 'none';
                
                // Random Shapes: Square, Circle, Triangle, Star
                const shapeType = Math.floor(Math.random() * 4);
                if (shapeType === 1) { // Circle
                    particle.style.borderRadius = '50%';
                } else if (shapeType === 2) { // Triangle
                     particle.style.width = '0'; 
                     particle.style.height = '0'; 
                     particle.style.backgroundColor = 'transparent';
                     particle.style.borderLeft = '6px solid transparent';
                     particle.style.borderRight = '6px solid transparent';
                     particle.style.borderBottom = '12px solid ' + colors[Math.floor(Math.random() * colors.length)];
                } else if (shapeType === 3) { // Star (using clip-path)
                     particle.style.clipPath = 'polygon(50% 0%, 61% 35%, 98% 35%, 68% 57%, 79% 91%, 50% 70%, 21% 91%, 32% 57%, 2% 35%, 39% 35%)';
                }
                // shapeType 0 is Square (default)

                document.body.appendChild(particle);

                // Physics variables
                // Burst effect: high velocity, random angle
                const angle = Math.random() * Math.PI * 2;
                const velocity = Math.random() * 15 + 5; 
                let vx = Math.cos(angle) * velocity;
                let vy = Math.sin(angle) * velocity;
                const gravity = 0.8;
                const drag = 0.96;
                let posX = centerX;
                let posY = centerY;
                let rotation = Math.random() * 360;
                let rotationSpeed = (Math.random() - 0.5) * 20;
                let opacity = 1;

                function animate() {
                    posX += vx;
                    posY += vy;
                    vy += gravity; // Apply gravity
                    vx *= drag;    // Air resistance
                    vy *= drag;
                    rotation += rotationSpeed;
                    opacity -= 0.01;

                    particle.style.left = posX + 'px';
                    particle.style.top = posY + 'px';
                    if (shapeType !== 2) { 
                        particle.style.transform = 'rotate(' + rotation + 'deg)';
                    } else {
                        particle.style.transform = 'rotate(' + rotation + 'deg)';
                    }
                    particle.style.opacity = opacity;

                    if (opacity > 0 && posY < window.innerHeight) {
                        requestAnimationFrame(animate);
                    } else {
                        particle.remove();
                    }
                }
                
                requestAnimationFrame(animate);
            }
        }

        // --- DYNAMIC ISLAND LOGIC ---
        const island = document.getElementById('dynamic-island');
        const islandMinimizeBtn = document.getElementById('island-minimize-btn');
        const islandThemeBtn = document.getElementById('island-theme-btn');
        const islandSettingsBtn = document.getElementById('island-settings-btn');
        const islandProgressBtn = document.getElementById('island-progress-btn');
        const islandHomeBtn = document.getElementById('island-home-btn');
        const swipeIconSmooth = document.getElementById('swipe-icon-smooth');
        const swipeIconHard = document.getElementById('swipe-icon-hard');
        
        let islandIdleTimeout;
        let isMinimized = false;
        
        function resetIslandIdle() {
            if (isMinimized) return; // Don't fade out if minimized (handled by style)
            island.classList.remove('idle');
            if (islandIdleTimeout) clearTimeout(islandIdleTimeout);
            islandIdleTimeout = setTimeout(() => {
                island.classList.add('idle');
            }, 3000);
        }

        // Initialize drag for Dynamic Island
        function initDynamicIsland() {
            // Trigger startup vibration
            island.classList.add('hint-anim');
            setTimeout(() => { island.classList.remove('hint-anim'); }, 1000);

            let isDragging = false;
            let dragOffsetX, dragOffsetY;
            const threshold = 5; // Movement threshold

            const onStart = (clientX, clientY) => {
                if (isMinimized) return;
                
                // Calculate offset from the top-left of the island to the cursor
                const rect = island.getBoundingClientRect();
                dragOffsetX = clientX - rect.left;
                dragOffsetY = clientY - rect.top;
                
                isDragging = false;
                resetIslandIdle();
                
                document.addEventListener('mousemove', onMove);
                document.addEventListener('mouseup', onEnd);
                document.addEventListener('touchmove', onTouchMove, { passive: false });
                document.addEventListener('touchend', onEnd);
            };
            
            const onMove = (e) => handleMove(e.clientX, e.clientY);
            const onTouchMove = (e) => {
                if (isMinimized) return;
                e.preventDefault();
                handleMove(e.touches[0].clientX, e.touches[0].clientY);
            };

            const handleMove = (clientX, clientY) => {
                if (!isDragging) {
                    // Check if moved enough to count as drag
                    isDragging = true;
                    island.classList.add('dragging'); // Disables transition for 1:1 tracking
                    
                    // Clear transform logic used for centering, switch to absolute pos
                    island.style.transform = 'none';
                    island.style.right = 'auto'; 
                    island.style.bottom = 'auto';
                }

                // Move exactly with cursor
                island.style.left = (clientX - dragOffsetX) + 'px';
                island.style.top = (clientY - dragOffsetY) + 'px';
                resetIslandIdle();
            };

            const onEnd = () => {
                document.removeEventListener('mousemove', onMove);
                document.removeEventListener('mouseup', onEnd);
                document.removeEventListener('touchmove', onTouchMove);
                document.removeEventListener('touchend', onEnd);
                
                if (isDragging) {
                    island.classList.remove('dragging'); // Re-enable transition for snap
                    snapIsland();
                }
            };
            
            island.addEventListener('mousedown', (e) => {
                if (isMinimized) return;
                if (e.target.closest('button')) return;
                onStart(e.clientX, e.clientY);
            });
            
            island.addEventListener('touchstart', (e) => {
                if (isMinimized) return;
                if (e.target.closest('button')) return;
                onStart(e.touches[0].clientX, e.touches[0].clientY);
            }, { passive: false });
            
            island.querySelectorAll('button').forEach(btn => {
                btn.addEventListener('click', resetIslandIdle);
            });
            
            island.addEventListener('click', (e) => {
                if (isMinimized && !e.target.closest('button')) {
                    toggleMinimize();
                }
            });
            
            resetIslandIdle();
        }
        
        function snapIsland() {
            const rect = island.getBoundingClientRect();
            const winW = window.innerWidth;
            const winH = window.innerHeight;
            
            const distTop = rect.top;
            const distBottom = winH - rect.bottom;
            const distLeft = rect.left;
            const distRight = winW - rect.right;
            
            const minDist = Math.min(distTop, distBottom, distLeft, distRight);
            const padding = 20;

            island.classList.remove('horizontal', 'vertical');

            // Snap logic
            if (minDist === distTop) {
                island.style.top = padding + 'px';
                island.style.bottom = 'auto';
                island.classList.add('horizontal');
            } else if (minDist === distBottom) {
                island.style.top = 'auto';
                island.style.bottom = padding + 'px';
                island.classList.add('horizontal');
            } else if (minDist === distLeft) {
                island.style.left = padding + 'px';
                island.style.right = 'auto';
                island.classList.add('vertical');
            } else { // Right
                island.style.left = 'auto';
                island.style.right = padding + 'px';
                island.classList.add('vertical');
            }
            
            // Constrain within window
            const newRect = island.getBoundingClientRect();
            if (island.classList.contains('horizontal')) {
               if(newRect.left < 0) island.style.left = padding + 'px';
               if(newRect.right > winW) island.style.left = (winW - newRect.width - padding) + 'px';
            } else {
               if(newRect.top < 0) island.style.top = padding + 'px';
               if(newRect.bottom > winH) island.style.top = (winH - newRect.height - padding) + 'px';
            }
        }
        
        function toggleMinimize() {
            isMinimized = !isMinimized;
            
            if (isMinimized) {
                island.classList.add('minimized');
                // Force snap to closest wall with 0 padding for the "dash" look
                const rect = island.getBoundingClientRect();
                const winW = window.innerWidth;
                const winH = window.innerHeight;
                
                // Determine orientation based on current class
                if (island.classList.contains('horizontal')) {
                    if (rect.top < winH / 2) { // Top wall
                        island.style.top = '0px';
                        island.style.bottom = 'auto';
                    } else { // Bottom wall
                        island.style.top = 'auto';
                        island.style.bottom = '0px';
                    }
                } else { // Vertical
                     if (rect.left < winW / 2) { // Left wall
                        island.style.left = '0px';
                        island.style.right = 'auto';
                    } else { // Right wall
                        island.style.left = 'auto';
                        island.style.right = '0px';
                    }
                }
            } else {
                island.classList.remove('minimized');
                snapIsland(); // Restore to padded position
                resetIslandIdle();
            }
        }
        
        initDynamicIsland();

        islandMinimizeBtn.addEventListener('click', toggleMinimize);
        
        const themes = ['light', 'dark', 'ambient'];
        islandThemeBtn.addEventListener('click', (e) => {
            const currentTheme = document.documentElement.dataset.theme || 'light';
            const currentIndex = themes.indexOf(currentTheme);
            const nextIndex = (currentIndex + 1) % themes.length;
            const newTheme = themes[nextIndex];
            
            // Fix: Ensure coordinates are valid for touch/click
            const x = (e.clientX !== undefined && e.clientX !== 0) ? e.clientX : window.innerWidth / 2;
            const y = (e.clientY !== undefined && e.clientY !== 0) ? e.clientY : window.innerHeight / 2;
            
            const endRadius = Math.hypot(
                Math.max(x, innerWidth - x),
                Math.max(y, innerHeight - y)
            );

            // View Transition API for "Sunrise" effect
            if (document.startViewTransition) {
                 const transition = document.startViewTransition(() => {
                    applyTheme(newTheme);
                });

                transition.ready.then(() => {
                    // Animate the clip-path of the new view
                    document.documentElement.animate(
                        {
                            clipPath: [
                                `circle(0px at ${x}px ${y}px)`,
                                `circle(${endRadius}px at ${x}px ${y}px)`
                            ],
                        },
                        {
                            duration: 500,
                            easing: 'ease-in',
                            pseudoElement: '::view-transition-new(root)',
                        }
                    );
                });
            } else {
                // Fallback Animation for devices without View Transition API
                 const themeColors = {
                    'light': '#f3f4f6',
                    'dark': '#374151',
                    'ambient': '#eee8d5'
                };
                
                const overlay = document.createElement('div');
                overlay.style.position = 'fixed';
                overlay.style.top = y + 'px';
                overlay.style.left = x + 'px';
                overlay.style.width = '0px';
                overlay.style.height = '0px';
                overlay.style.borderRadius = '50%';
                overlay.style.backgroundColor = themeColors[newTheme];
                overlay.style.zIndex = '10000';
                overlay.style.transform = 'translate(-50%, -50%)';
                overlay.style.pointerEvents = 'none';
                document.body.appendChild(overlay);
                
                const anim = overlay.animate(
                    [{ width: '0px', height: '0px' }, { width: (endRadius * 2) + 'px', height: (endRadius * 2) + 'px' }],
                    { duration: 500, easing: 'ease-in', fill: 'forwards' }
                );
                
                anim.onfinish = () => {
                    applyTheme(newTheme);
                    overlay.remove();
                };
            }
        });
        
        islandSettingsBtn.addEventListener('click', () => {
            isSmoothSwipe = !isSmoothSwipe;
            if (isSmoothSwipe) {
                document.documentElement.style.setProperty('--swipe-duration', '0.3s');
                swipeIconSmooth.classList.remove('hidden');
                swipeIconHard.classList.add('hidden');
                showToast("Swipe Animation: Smooth");
            } else {
                document.documentElement.style.setProperty('--swipe-duration', '0s');
                swipeIconSmooth.classList.add('hidden');
                swipeIconHard.classList.remove('hidden');
                showToast("Swipe Animation: Instant");
            }
        });
        
        islandProgressBtn.addEventListener('click', () => {
            switchScreen('progress');
            renderProgressCharts();
        });

        islandHomeBtn.addEventListener('click', () => {
            const currentScreenId = document.querySelector('.screen.active')?.id;
            const goHome = () => {
                 if (document.startViewTransition) {
                     document.startViewTransition(() => switchScreen('setup'));
                 } else {
                     switchScreen('setup');
                 }
            };
            
            if (currentScreenId === 'exam-screen') {
                showConfirmation("Exit exam and go home? Progress is saved locally.", () => {
                    saveExamDraft();
                    goHome();
                });
            } else if (currentScreenId === 'practice-screen') {
                 showConfirmation("Exit practice session?", () => {
                    savePracticeDraft();
                    goHome();
                 });
            } else {
                goHome();
            }
        });

        // --- THEME LOGIC ---
        function applyTheme(theme) {
            document.documentElement.dataset.theme = theme;
            try {
                localStorage.setItem(THEME_KEY, theme);
            } catch (e) { console.error('Failed to save theme'); }
        }

        // --- UTILS ---
        let toastTimeout;
        function showToast(message) {
            if (toastTimeout) clearTimeout(toastTimeout);
            toastEl.textContent = message;
            toastEl.classList.add('show');
            toastTimeout = setTimeout(() => {
                toastEl.classList.remove('show');
            }, 3000);
        }
        
        function animateButton(buttonEl) {
            buttonEl.classList.remove('pop-animation');
            // This is a trick to restart the animation
            void buttonEl.offsetWidth; 
            buttonEl.classList.add('pop-animation');
        }

        function showConfirmation(message, onConfirm) {
            onConfirmCallback = onConfirm;
            confirmationMessageEl.textContent = message;
            confirmationModal.classList.remove('hidden');
            confirmationModal.classList.add('flex');
        }

        function hideConfirmation() {
            onConfirmCallback = null;
            confirmationModal.classList.add('hidden');
            confirmationModal.classList.remove('flex');
        }

        confirmActionBtn.addEventListener('click', () => {
            if (onConfirmCallback) {
                onConfirmCallback();
            }
            hideConfirmation();
        });

        cancelConfirmationBtn.addEventListener('click', hideConfirmation);

        // --- HISTORY API INTEGRATION ---
        
        // Initialize history state on load
        window.history.replaceState({ screen: 'setup' }, '', '#setup');

        function switchScreen(screenName, pushToHistory = true) {
            Object.values(screens).forEach(screen => {
                if(screen) screen.classList.remove('active');
            });
            if(screens[screenName]) {
                screens[screenName].classList.add('active');
                if (pushToHistory) {
                    window.history.pushState({ screen: screenName }, '', '#' + screenName);
                }
            }
        }

        window.addEventListener('popstate', (event) => {
            const activeScreen = document.querySelector('.screen.active');
            const activeId = activeScreen ? activeScreen.id : 'setup-screen';

            // GUARD: Prevent exiting Exam Mode accidentally
            if (activeId === 'exam-screen') {
                // Push state back immediately to maintain URL/State stability while showing modal
                window.history.pushState({ screen: 'exam' }, '', '#exam');
                showConfirmation("Are you sure you want to exit the exam? Your progress will be saved.", () => {
                    // If confirmed, proceed to finish exam (which goes to results)
                    handleNextSection(); 
                });
                return;
            }

            // GUARD: Prevent exiting Practice Mode accidentally
            if (activeId === 'practice-screen') {
                 window.history.pushState({ screen: 'practice' }, '', '#practice');
                 showConfirmation("Are you sure you want to exit practice mode?", () => {
                    if (practiceTimerInterval) clearInterval(practiceTimerInterval);
                    if (perQuestionTimerInterval) clearInterval(perQuestionTimerInterval);
                    recordTime(currentMcqs[currentPracticeIndex].id, practiceStates);
                    showPracticeResults();
                 });
                 return;
            }

            // Normal Navigation handling
            if (event.state && event.state.screen) {
                switchScreen(event.state.screen, false); // false = don't push again
            } else {
                switchScreen('setup', false);
            }
        });

        
        function shuffleArray(array) {
            for (let i = array.length - 1; i > 0; i--) {
                const j = Math.floor(Math.random() * (i + 1));
                [array[i], array[j]] = [array[j], array[i]];
            }
        }

        function formatTime(seconds) {
            const mins = String(Math.floor(seconds / 60)).padStart(2, '0');
            const secs = String(seconds % 60).padStart(2, '0');
            return mins + ':' + secs;
        }
        
        function formatTimeDetailed(seconds) {
            if (seconds < 60) return Math.round(seconds) + 's';
            const mins = Math.floor(seconds / 60);
            const secs = Math.round(seconds % 60);
            return mins + 'm ' + secs + 's';
        }

        function processQuestionContent(text, imageContainerId) {
            const imageContainer = document.getElementById(imageContainerId);
            imageContainer.innerHTML = ''; // Clear previous image

            const imageRegex = /{image\s+(\d+)}/g;
            let processedText = text;
            
            let match;
            const displayedImageIndices = new Set();
            while ((match = imageRegex.exec(text)) !== null) {
                const imageIndex = parseInt(match[1], 10) - 1;
                if (images[imageIndex] && !displayedImageIndices.has(imageIndex)) {
                    const img = document.createElement('img');
                    img.src = images[imageIndex];
                    img.alt = 'Illustration for question';
                    img.className = 'max-w-full max-h-96 object-contain rounded-md shadow-sm border mx-auto themed-border-primary';
                    imageContainer.appendChild(img);
                    displayedImageIndices.add(imageIndex);
                }
                processedText = processedText.replace(match[0], '');
            }
            
            return processedText.trim();
        }

        // --- TIME TRACKING LOGIC ---
        function recordTime(mcqId, stateCollection) {
            if (!mcqId || !questionStartTime) return;
            const state = stateCollection.find(s => s.mcqId === mcqId);
            if (state) {
                const elapsed = (Date.now() - questionStartTime) / 1000; // in seconds
                state.timeTaken = (state.timeTaken || 0) + elapsed;
            }
        }

        // --- DRAFT LOGIC ---
        function saveExamDraft() {
            try {
                recordTime(currentMCQ.id, answerStates);
                const draft = {
                    mcqs: currentMcqs, // Save potentially shuffled list
                    sections,
                    answerStates,
                    currentSectionIndex,
                    currentQuestionIndexInSection,
                    subjectName,
                    candidateName,
                    shortNote,
                    isShuffled,
                };
                localStorage.setItem(EXAM_DRAFT_KEY, JSON.stringify(draft));
                questionStartTime = Date.now(); // Reset timer after saving
            } catch (e) {
                console.error("Failed to save exam draft:", e);
            }
        }
        
        function savePracticeDraft() {
            try {
                recordTime(currentMcqs[currentPracticeIndex].id, practiceStates);
                const draft = {
                    mcqs: currentMcqs, // Save the subset of MCQs
                    practiceStates,
                    currentPracticeIndex,
                    subjectName,
                    candidateName,
                    isShuffled,
                    timePerMcq,
                    timeOverall,
                    currentStreak, // Save streak
                };
                localStorage.setItem(PRACTICE_DRAFT_KEY, JSON.stringify(draft));
                questionStartTime = Date.now(); // Reset timer after saving
            } catch (e) {
                console.error("Failed to save practice draft:", e);
            }
        }

        function clearExamDraft() { localStorage.removeItem(EXAM_DRAFT_KEY); }
        function clearPracticeDraft() { localStorage.removeItem(PRACTICE_DRAFT_KEY); }
        
        // --- SAVED QUESTIONS LOGIC ---
        function updateSavedQuestionsUI() {
            if (savedMcqIds.length > 0) {
                savedQuestionsCountEl.textContent = savedMcqIds.length;
                savedQuestionsContainer.classList.remove('hidden');
            } else {
                savedQuestionsContainer.classList.add('hidden');
            }
        }

        function toggleSaveMcq() {
            const mcq = currentMcqs[reviewQuestionIndex];
            if (!mcq) return;

            const mcqId = mcq.id;
            const index = savedMcqIds.indexOf(mcqId);
            let message = '';

            if (index > -1) {
                savedMcqIds.splice(index, 1);
                message = 'Question Unsaved!';
            } else {
                savedMcqIds.push(mcqId);
                message = 'Question Saved!';
                animateButton(saveMcqBtn);
            }

            showToast(message);
            localStorage.setItem(SAVED_MCQS_KEY, JSON.stringify(savedMcqIds));
            updateSaveButtonState();
            updateSavedQuestionsUI();

            if (isReviewingSaved && savedMcqIds.length === 0) {
                alert("You have no saved questions.");
                switchScreen('setup');
            } else if (isReviewingSaved) {
                // Refresh the view if an item is removed
                currentMcqs = initialMcqsState.filter(mcq => savedMcqIds.includes(mcq.id));
                if (reviewQuestionIndex >= currentMcqs.length) {
                    reviewQuestionIndex = Math.max(0, currentMcqs.length - 1);
                }
                renderReviewPalette();
                renderReviewQuestion();
            }
        }
        
        function toggleSavePracticeMcq() {
            const mcq = currentMcqs[currentPracticeIndex];
            if (!mcq) return;

            const mcqId = mcq.id;
            const index = savedMcqIds.indexOf(mcqId);
            let message = '';

            if (index > -1) {
                savedMcqIds.splice(index, 1);
                message = 'Question Unsaved!';
            } else {
                savedMcqIds.push(mcqId);
                message = 'Question Saved!';
                animateButton(saveMcqPracticeBtn);
            }
            
            showToast(message);
            localStorage.setItem(SAVED_MCQS_KEY, JSON.stringify(savedMcqIds));
            updatePracticeSaveButtonState();
            updateSavedQuestionsUI();
        }

        function updateSaveButtonState() {
            const mcq = currentMcqs[reviewQuestionIndex];
            if (!mcq) return;

            if (savedMcqIds.includes(mcq.id)) {
                saveMcqBtn.innerHTML = svgBookmarkSolid;
                saveMcqBtn.setAttribute('aria-label', 'Unsave Question');
            } else {
                saveMcqBtn.innerHTML = svgBookmarkOutline;
                saveMcqBtn.setAttribute('aria-label', 'Save Question');
            }
        }
        
        function updatePracticeSaveButtonState() {
            const mcq = currentMcqs[currentPracticeIndex];
            if (!mcq) return;

            if (savedMcqIds.includes(mcq.id)) {
                saveMcqPracticeBtn.innerHTML = svgBookmarkSolid;
                saveMcqPracticeBtn.setAttribute('aria-label', 'Unsave Question');
            } else {
                saveMcqPracticeBtn.innerHTML = svgBookmarkOutline;
                saveMcqPracticeBtn.setAttribute('aria-label', 'Save Question');
            }
        }

        // --- PALETTE VISIBILITY LOGIC ---
        if(hidePaletteBtn && showPaletteBtn && questionPalette && paletteContentWrapper) {
            hidePaletteBtn.addEventListener('click', () => {
                questionPalette.classList.remove('w-64');
                questionPalette.classList.add('w-0');
                paletteContentWrapper.classList.add('opacity-0');
                hidePaletteBtn.classList.add('hidden');
                showPaletteBtn.classList.remove('hidden');
            });

            showPaletteBtn.addEventListener('click', () => {
                questionPalette.classList.remove('w-0');
                questionPalette.classList.add('w-64');
                paletteContentWrapper.classList.remove('opacity-0');
                showPaletteBtn.classList.add('hidden');
                hidePaletteBtn.classList.remove('hidden');
            });
        }

        // --- CALCULATOR LOGIC ---
        const calculatorHeader = document.getElementById('calculator-header');
        const calculatorCloseBtn = document.getElementById('calculator-close-btn');
        const calculatorDisplay = document.getElementById('calculator-display');
        const calculatorButtons = document.getElementById('calculator-buttons');
        let isDragging = false;
        let dragOffset = { x: 0, y: 0 };

        function toggleCalculator(buttonEl) {
            const wasHidden = calculatorModal.classList.contains('hidden');
            
            if (wasHidden) {
                const rect = buttonEl.getBoundingClientRect();
                const calculatorWidth = 256; // Corresponds to Tailwind's w-64 class
                
                // Position it below the button, accounting for page scroll
                calculatorModal.style.top = (rect.bottom + window.scrollY + 10) + 'px';
                
                // Center it horizontally under the button
                let leftPos = rect.left + window.scrollX + (rect.width / 2) - (calculatorWidth / 2);
                
                // Constrain to viewport horizontal edges
                const minLeft = window.scrollX + 8;
                const maxLeft = window.scrollX + window.innerWidth - calculatorWidth - 8;
                leftPos = Math.max(minLeft, Math.min(leftPos, maxLeft));

                calculatorModal.style.left = leftPos + 'px';
            }
             
            calculatorModal.classList.toggle('hidden');
        }
        document.getElementById('calculator-toggle-btn').addEventListener('click', (e) => toggleCalculator(e.currentTarget));
        document.getElementById('practice-calculator-toggle-btn').addEventListener('click', (e) => toggleCalculator(e.currentTarget));
        
        calculatorCloseBtn.addEventListener('click', () => {
            calculatorModal.classList.add('hidden');
        });

        function dragStart(clientX, clientY) {
            isDragging = true;
            dragOffset.x = clientX - calculatorModal.offsetLeft;
            dragOffset.y = clientY - calculatorModal.offsetTop;
            calculatorModal.classList.add('dragging');
            document.body.style.userSelect = 'none'; // Prevent text selection
        }

        function dragMove(clientX, clientY) {
            if (!isDragging) return;
            const newX = clientX - dragOffset.x;
            const newY = clientY - dragOffset.y;
            const maxX = window.innerWidth - calculatorModal.offsetWidth;
            const maxY = window.innerHeight - calculatorModal.offsetHeight;
            calculatorModal.style.left = Math.max(0, Math.min(newX, maxX)) + 'px';
            calculatorModal.style.top = Math.max(0, Math.min(newY, maxY)) + 'px';
        }

        function dragEnd() {
            if (!isDragging) return;
            isDragging = false;
            calculatorModal.classList.remove('dragging');
            document.body.style.userSelect = '';
        }

        // Mouse Events
        calculatorHeader.addEventListener('mousedown', (e) => {
            e.preventDefault();
            dragStart(e.clientX, e.clientY);
        });

        document.addEventListener('mousemove', (e) => {
            if (isDragging) {
                dragMove(e.clientX, e.clientY);
            }
        });
        
        document.addEventListener('mouseup', dragEnd);

        // Touch Events
        calculatorHeader.addEventListener('touchstart', (e) => {
            if (e.touches.length === 1) {
                dragStart(e.touches[0].clientX, e.touches[0].clientY);
            }
        }, { passive: true });

        document.addEventListener('touchmove', (e) => {
            if (isDragging && e.touches.length === 1) {
                e.preventDefault(); // Prevent scrolling while dragging
                dragMove(e.touches[0].clientX, e.touches[0].clientY);
            }
        }, { passive: false });

        document.addEventListener('touchend', dragEnd);
        document.addEventListener('touchcancel', dragEnd);


        const calculatorState = {
            displayValue: '0',
            fullExpression: '', // Holds the full visual string e.g. "6+5"
            firstOperand: null,
            waitingForSecondOperand: false,
            operator: null,
            isResultDisplayed: false
        };

        function updateCalculatorDisplay() {
            calculatorDisplay.textContent = calculatorState.fullExpression || '0';
            calculatorDisplay.scrollLeft = calculatorDisplay.scrollWidth;
        }

        function inputDigit(digit) {
            if (calculatorState.isResultDisplayed) {
                calculatorState.fullExpression = digit;
                calculatorState.displayValue = digit;
                calculatorState.firstOperand = null;
                calculatorState.waitingForSecondOperand = false;
                calculatorState.operator = null;
                calculatorState.isResultDisplayed = false;
                return;
            }

            // Append to full expression, replacing single '0' unless digit is '.'
            if (calculatorState.fullExpression === '0') {
                calculatorState.fullExpression = digit;
            } else {
                calculatorState.fullExpression += digit;
            }

            const { displayValue, waitingForSecondOperand } = calculatorState;
            if (waitingForSecondOperand) {
                calculatorState.displayValue = digit;
                calculatorState.waitingForSecondOperand = false;
            } else {
                calculatorState.displayValue = displayValue === '0' ? digit : displayValue + digit;
            }
        }

        function inputDecimal(dot) {
            if (calculatorState.isResultDisplayed) {
                calculatorState.displayValue = '0.';
                calculatorState.fullExpression = '0.';
                calculatorState.firstOperand = null;
                calculatorState.waitingForSecondOperand = false;
                calculatorState.operator = null;
                calculatorState.isResultDisplayed = false;
                return;
            }

            if (calculatorState.waitingForSecondOperand) {
                calculatorState.displayValue = '0.';
                calculatorState.waitingForSecondOperand = false;
                calculatorState.fullExpression += '0.';
                return;
            }
            if (!calculatorState.displayValue.includes(dot)) {
                calculatorState.displayValue += dot;
                calculatorState.fullExpression += dot;
            }
        }
        
        const performCalculation = {
            '/': (first, second) => second === 0 ? 'Error' : first / second,
            '*': (first, second) => first * second,
            '+': (first, second) => first + second,
            '-': (first, second) => first - second,
        };

        function handleOperator(nextOperator) {
            if (calculatorState.isResultDisplayed) {
                // If starting new operation on result, keep result in display
                calculatorState.fullExpression = calculatorState.displayValue + nextOperator;
                calculatorState.isResultDisplayed = false;
            } else {
                calculatorState.fullExpression += nextOperator;
            }

            const { firstOperand, displayValue, operator } = calculatorState;
            const inputValue = parseFloat(displayValue);

            if (operator && calculatorState.waitingForSecondOperand) {
                calculatorState.operator = nextOperator;
                return;
            }

            if (firstOperand === null) {
                calculatorState.firstOperand = inputValue;
            } else if (operator) {
                const result = performCalculation[operator](firstOperand, inputValue);
                if (result === 'Error') {
                    calculatorState.displayValue = 'Error';
                    calculatorState.fullExpression = 'Error';
                } else {
                    // Truncate long decimals to avoid display issues
                    const resStr = String(parseFloat(result.toFixed(7)));
                    calculatorState.displayValue = resStr;
                }
                calculatorState.firstOperand = result === 'Error' ? null : result;
            }
            
            calculatorState.waitingForSecondOperand = true;
            calculatorState.operator = nextOperator;
        }

        function resetCalculator() {
            calculatorState.displayValue = '0';
            calculatorState.fullExpression = '';
            calculatorState.firstOperand = null;
            calculatorState.waitingForSecondOperand = false;
            calculatorState.operator = null;
            calculatorState.isResultDisplayed = false;
        }

        calculatorButtons.addEventListener('click', (event) => {
            const { target } = event;
            if (!target.matches('button')) return;

            if (calculatorState.displayValue === 'Error' && target.textContent !== 'C') return;

            if (target.classList.contains('digit')) { inputDigit(target.textContent); }
            else if (target.classList.contains('decimal')) { inputDecimal(target.textContent); }
            else if (target.classList.contains('operator')) { handleOperator(target.textContent); }
            else if (target.textContent === 'C') { resetCalculator(); }
            else if (target.classList.contains('equals')) {
                 if (calculatorState.operator && calculatorState.firstOperand !== null) {
                    const inputValue = parseFloat(calculatorState.displayValue);
                    const result = performCalculation[calculatorState.operator](calculatorState.firstOperand, inputValue);
                    
                    let resultStr = 'Error';
                    if (result !== 'Error') {
                         resultStr = String(parseFloat(result.toFixed(7)));
                    }
                    
                    calculatorState.displayValue = resultStr;
                    calculatorState.fullExpression += '=' + resultStr; // Append =Result
                    
                    calculatorState.firstOperand = null;
                    calculatorState.operator = null;
                    calculatorState.waitingForSecondOperand = false;
                    calculatorState.isResultDisplayed = true;
                }
            }
            updateCalculatorDisplay();
        });

        function handleCalculatorKeyPress(event) {
            if (calculatorModal.classList.contains('hidden')) return;

            const { key } = event;
            let buttonToAnimate;
            
            const buttons = Array.from(calculatorButtons.querySelectorAll('button'));

            if (key >= '0' && key <= '9') {
                inputDigit(key);
                buttonToAnimate = buttons.find(b => b.textContent === key && b.classList.contains('digit'));
            } else if (key === '.') {
                inputDecimal(key);
                buttonToAnimate = buttons.find(b => b.textContent === key && b.classList.contains('decimal'));
            } else if (['+', '-', '*', '/'].includes(key)) {
                handleOperator(key);
                buttonToAnimate = buttons.find(b => b.textContent === key && b.classList.contains('operator'));
            } else if (key === 'Enter' || key === '=') {
                event.preventDefault();
                if (calculatorState.operator && calculatorState.firstOperand !== null) {
                     const inputValue = parseFloat(calculatorState.displayValue);
                     const result = performCalculation[calculatorState.operator](calculatorState.firstOperand, inputValue);
                     let resultStr = 'Error';
                     if (result !== 'Error') { resultStr = String(parseFloat(result.toFixed(7))); }
                     calculatorState.displayValue = resultStr;
                     calculatorState.fullExpression += '=' + resultStr;
                     
                     calculatorState.firstOperand = null;
                     calculatorState.operator = null;
                     calculatorState.waitingForSecondOperand = false;
                     calculatorState.isResultDisplayed = true;
                }
                buttonToAnimate = buttons.find(b => b.classList.contains('equals'));
            } else if (key === 'Escape') {
                calculatorModal.classList.add('hidden');
                buttonToAnimate = calculatorCloseBtn;
            } else if (key === 'Backspace' || key.toLowerCase() === 'c') {
                resetCalculator();
                buttonToAnimate = buttons.find(b => b.textContent === 'C');
            }

            if (buttonToAnimate) {
                buttonToAnimate.classList.add('key-press-feedback');
                setTimeout(() => {
                    buttonToAnimate.classList.remove('key-press-feedback');
                }, 100);
            }
            
            if (['0','1','2','3','4','5','6','7','8','9','.','+','-','*','/','Enter','=','Backspace','c','C'].includes(key)) {
                updateCalculatorDisplay();
            }
        }
        document.addEventListener('keydown', handleCalculatorKeyPress);


        // --- SETUP SCREEN LOGIC ---
        const sectionsContainer = document.getElementById('sections-container');
        const setupErrorEl = document.getElementById('setup-error');
        
        function renderSections() {
            sectionsContainer.innerHTML = '';
            sections.forEach((section, index) => {
                const sectionEl = document.createElement('div');
                sectionEl.className = 'p-4 rounded-md flex items-center space-x-3 themed-bg-tertiary';
                const removeButtonHtml = sections.length > 1
                    ? '<button data-index="' + index + '" class="remove-section-btn themed-text-danger text-2xl">\u00d7</button>'
                    : '';
                
                sectionEl.innerHTML =
                    '<input type="text" value="' + section.name + '" data-index="' + index + '" data-field="name" class="section-input p-2 rounded w-1/4 border" placeholder="Section Name"/>' +
                    '<input type="number" value="' + section.startQuestion + '" data-index="' + index + '" data-field="startQuestion" class="section-input p-2 rounded w-1/5 border" placeholder="Start"/>' +
                    '<span class="themed-text-tertiary">to</span>' +
                    '<input type="number" value="' + section.endQuestion + '" data-index="' + index + '" data-field="endQuestion" class="section-input p-2 rounded w-1/5 border" placeholder="End"/>' +
                    '<input type="number" value="' + section.duration + '" data-index="' + index + '" data-field="duration" class="section-input p-2 rounded w-1/5 border" placeholder="Duration (min)"/>' +
                    removeButtonHtml;
                sectionsContainer.appendChild(sectionEl);
            });
        }

        document.getElementById('add-section-btn').addEventListener('click', () => {
            const lastSection = sections[sections.length - 1];
            const nextStart = lastSection.endQuestion + 1;
            if (nextStart > mcqs.length) return;
            sections.push({ name: 'Section ' + (sections.length + 1), startQuestion: nextStart, endQuestion: mcqs.length, duration: mcqs.length - nextStart + 1 });
            renderSections();
        });

        document.getElementById('auto-set-sections-btn').addEventListener('click', () => {
            if (!mcqs || mcqs.length === 0) return;
            
            sections = [];
            const chunkSize = 50;
            let currentStart = 1;
            let idx = 1;
            
            while (currentStart <= mcqs.length) {
                let currentEnd = Math.min(currentStart + chunkSize - 1, mcqs.length);
                sections.push({
                    name: 'Section ' + idx,
                    startQuestion: currentStart,
                    endQuestion: currentEnd,
                    duration: (currentEnd - currentStart + 1) // 1 minute per question
                });
                currentStart = currentEnd + 1;
                idx++;
            }
            renderSections();
            showToast("Sections auto-configured");
        });

        sectionsContainer.addEventListener('change', (e) => {
            const target = e.target;
            if (target.classList.contains('section-input')) {
                const { index, field } = target.dataset;
                const value = field === 'name' ? target.value : parseInt(target.value, 10);
                sections[index][field] = value;
            }
        });
        
        sectionsContainer.addEventListener('click', (e) => {
            const target = e.target;
            if(target.classList.contains('remove-section-btn')) {
                const { index } = target.dataset;
                sections.splice(parseInt(index, 10), 1);
                renderSections();
            }
        });

        document.getElementById('revise-btn').addEventListener('click', () => {
            setupErrorEl.textContent = '';
            subjectName = document.getElementById('subject-name').value;
            candidateName = document.getElementById('candidate-name').value;
            
            // Use full, unshuffled set for revision
            currentMcqs = [...initialMcqsState]; 
            answerStates = currentMcqs.map(mcq => ({ mcqId: mcq.id, status: QuestionStatus.NotVisited, selectedOption: undefined, timeTaken: 0 }));
            reviewQuestionIndex = 0;
            switchScreen('review');
            setupReviewScreen(true, false); // isReviseMode = true
        });

        document.getElementById('start-exam-btn').addEventListener('click', () => {
            setupErrorEl.textContent = '';
            subjectName = document.getElementById('subject-name').value;
            candidateName = document.getElementById('candidate-name').value;
            shortNote = document.getElementById('short-note').value;
            
            let questionSet = new Set();
            for(const section of sections) {
                if(section.startQuestion > section.endQuestion || section.startQuestion < 1 || section.endQuestion > mcqs.length) {
                    setupErrorEl.textContent = 'Invalid range in ' + section.name + '.'; return;
                }
                if(section.duration <= 0) {
                    setupErrorEl.textContent = 'Duration must be positive in ' + section.name + '.'; return;
                }
                for(let i = section.startQuestion; i <= section.endQuestion; i++) {
                    if(questionSet.has(i)) {
                        setupErrorEl.textContent = 'Question ' + i + ' is in multiple sections.'; return;
                    }
                    questionSet.add(i);
                }
            }
            if (questionSet.size !== mcqs.length && mcqs.length > 0) {
                 const allCoveredQuestions = Array.from(questionSet).sort((a,b) => a-b);
                 if (allCoveredQuestions.length !== mcqs.length || allCoveredQuestions[allCoveredQuestions.length - 1] !== mcqs.length) {
                    setupErrorEl.textContent = 'All questions must be covered exactly once across all sections.'; return;
                 }
            }
            
            startExam();
        });
        
        function initializeSetup() {
            sections = [{ name: 'Section 1', startQuestion: 1, endQuestion: mcqs.length, duration: mcqs.length }];
            renderSections();
            const qCountSlider = document.getElementById('practice-q-count-slider');
            const qCountLabel = document.getElementById('practice-q-count-label');
            if(qCountSlider) {
                qCountSlider.addEventListener('input', () => {
                    qCountLabel.textContent = qCountSlider.value;
                });
            }
        }

        function confirmAndProceedToNextSection() {
            const isLastSection = currentSectionIndex === sections.length - 1;
            const message = isLastSection
                ? "Are you sure you want to submit the exam? This will end the test."
                : "Are you sure you want to submit this section? You will not be able to return to it.";
            showConfirmation(message, handleNextSection);
        }


        // --- EXAM LOGIC ---
        let currentSectionMCQs = [];
        let currentMCQ;

        function startExam() {
            isShuffled = document.getElementById('shuffle-mcqs-checkbox').checked;
            let baseMcqs = JSON.parse(JSON.stringify(initialMcqsState));

            if (isShuffled) {
                // Shuffle questions *within* each section's defined range
                sections.forEach(section => {
                    const startIndex = section.startQuestion - 1;
                    const endIndex = section.endQuestion;
                    const sectionSlice = baseMcqs.slice(startIndex, endIndex);
                    shuffleArray(sectionSlice);
                    // Replace the original slice with the shuffled one
                    baseMcqs.splice(startIndex, sectionSlice.length, ...sectionSlice);
                });
            }
            
            currentMcqs.length = 0;
            Array.prototype.push.apply(currentMcqs, baseMcqs);


            answerStates = currentMcqs.map(mcq => ({ mcqId: mcq.id, status: QuestionStatus.NotVisited, selectedOption: undefined, timeTaken: 0 }));
            currentSectionIndex = 0;
            currentQuestionIndexInSection = 0;
            loadSection();
            switchScreen('exam');
        }

        function loadSection() {
            if (timerInterval) clearInterval(timerInterval);

            const section = sections[currentSectionIndex];
            document.getElementById('section-name').textContent = section.name;
            
            // Get questions for the current section from the (potentially shuffled) main list
            currentSectionMCQs = currentMcqs.slice(section.startQuestion - 1, section.endQuestion);
            
            loadQuestion();
            renderPalette();

            let timeLeft = section.duration * 60;
            const timerEl = document.getElementById('timer');
            timerEl.textContent = formatTime(timeLeft);
            timerInterval = setInterval(() => {
                timeLeft--;
                timerEl.textContent = formatTime(timeLeft);
                if (timeLeft <= 0) {
                    handleNextSection();
                }
            }, 1000);
        }
        
        function loadQuestion() {
            currentMCQ = currentSectionMCQs[currentQuestionIndexInSection];
            const answerState = answerStates.find(a => a.mcqId === currentMCQ.id);

            if (answerState.status === QuestionStatus.NotVisited) {
                answerState.status = QuestionStatus.NotAnswered;
            }
            
            document.getElementById('question-counter').textContent = 'Question ' + (currentQuestionIndexInSection + 1) + ' of ' + currentSectionMCQs.length;
            document.getElementById('question-text').innerHTML = processQuestionContent(currentMCQ.question, 'question-image-container');
            
            const optionsContainer = document.getElementById('options-container');
            optionsContainer.innerHTML = '';
            Object.keys(currentMCQ.options).forEach(key => {
                const isSelected = answerState.selectedOption === key;
                const optionEl = document.createElement('label');
                const selectedClass = isSelected ? 'selected' : '';
                optionEl.className = 'option-label flex items-center p-4 rounded-lg cursor-pointer border-2 ' + selectedClass;
                optionEl.innerHTML =
                    '<input type="radio" name="option" value="' + key + '" ' + (isSelected ? 'checked' : '') + ' class="hidden"/>' +
                    '<span class="radio-circle w-6 h-6 rounded-full border-2 themed-border-secondary mr-4 flex-shrink-0 relative"></span>' +
                    '<span class="flex-1">' + key.toUpperCase() + '. ' + currentMCQ.options[key] + '</span>';
                optionsContainer.appendChild(optionEl);
            });

            const saveNextBtn = document.getElementById('save-next-btn');
            if (currentQuestionIndexInSection === currentSectionMCQs.length - 1) {
                saveNextBtn.textContent = 'Submit Section';
            } else {
                saveNextBtn.textContent = 'Save & Next';
            }
            
            document.getElementById('prev-btn').disabled = currentQuestionIndexInSection === 0;
            updatePaletteItem(currentMCQ.id);
            updatePaletteLegendCounts();
            saveExamDraft(); // Auto-save on every question load
            questionStartTime = Date.now();
        }

        document.getElementById('options-container').addEventListener('change', e => {
            const target = e.target;
            if (target.name === 'option') {
                const answerState = answerStates.find(a => a.mcqId === currentMCQ.id);
                const newStatus = answerState.status === QuestionStatus.MarkedForReview ? QuestionStatus.MarkedForReview : QuestionStatus.Answered;
                answerState.selectedOption = target.value;
                answerState.status = newStatus;
                loadQuestion(); // Re-render to show selection and auto-save
            }
        });

        function navigateQuestion(offset) {
            recordTime(currentMCQ.id, answerStates);
            const newIndex = currentQuestionIndexInSection + offset;
            if (newIndex >= 0 && newIndex < currentSectionMCQs.length) {
                currentQuestionIndexInSection = newIndex;
                loadQuestion();
            } else if (newIndex >= currentSectionMCQs.length) {
                confirmAndProceedToNextSection();
            }
        }

        document.getElementById('save-next-btn').addEventListener('click', () => navigateQuestion(1));
        document.getElementById('prev-btn').addEventListener('click', () => navigateQuestion(-1));

        document.getElementById('mark-review-btn').addEventListener('click', () => {
            const answerState = answerStates.find(a => a.mcqId === currentMCQ.id);
            answerState.status = answerState.status === QuestionStatus.MarkedForReview 
                ? (answerState.selectedOption ? QuestionStatus.Answered : QuestionStatus.NotAnswered)
                : QuestionStatus.MarkedForReview;
            updatePaletteItem(currentMCQ.id);
            updatePaletteLegendCounts();
            navigateQuestion(1);
        });

        document.getElementById('clear-response-btn').addEventListener('click', () => {
            const answerState = answerStates.find(a => a.mcqId === currentMCQ.id);
            answerState.selectedOption = undefined;
            answerState.status = QuestionStatus.NotAnswered;
            loadQuestion();
        });

        function handleNextSection() {
            recordTime(currentMCQ.id, answerStates);
            if (currentSectionIndex < sections.length - 1) {
                currentSectionIndex++;
                currentQuestionIndexInSection = 0;
                loadSection();
            } else {
                clearInterval(timerInterval);
                showResults();
            }
        }

        // --- PALETTE LOGIC ---
        function updatePaletteLegendCounts() {
            const sectionMCQIds = new Set(currentSectionMCQs.map(mcq => mcq.id));

            const counts = {
                [QuestionStatus.Answered]: 0,
                [QuestionStatus.NotAnswered]: 0,
                [QuestionStatus.NotVisited]: 0,
                [QuestionStatus.MarkedForReview]: 0,
            };

            answerStates.forEach(state => {
                if (sectionMCQIds.has(state.mcqId)) {
                    counts[state.status]++;
                }
            });

            document.getElementById('answered-count').textContent = String(counts[QuestionStatus.Answered]);
            document.getElementById('not-answered-count').textContent = String(counts[QuestionStatus.NotAnswered]);
            document.getElementById('not-visited-count').textContent = String(counts[QuestionStatus.NotVisited]);
            document.getElementById('marked-for-review-count').textContent = String(counts[QuestionStatus.MarkedForReview]);
        }

        function renderPalette() {
            const paletteContainer = document.getElementById('palette-container');
            paletteContainer.innerHTML = '';
            currentSectionMCQs.forEach((mcq, index) => {
                const answerState = answerStates.find(a => a.mcqId === mcq.id);
                const btn = document.createElement('button');
                btn.id = 'palette-item-' + mcq.id;
                btn.dataset.index = String(index);
                btn.className = 'h-10 w-10 flex items-center justify-center rounded text-white font-bold relative ' + statusColors[answerState.status];
                btn.innerHTML = (index + 1);
                // Accessibility: Add dynamic aria-label
                btn.setAttribute('aria-label', 'Go to question ' + (index + 1));
                if (answerState.status === QuestionStatus.MarkedForReview) {
                    btn.innerHTML += '<svg xmlns="http://www.w3.org/2000/svg" class="absolute bottom-1 right-1 h-3 w-3 text-white" viewBox="0 0 24 24" fill="currentColor"><path d="M14.4 6L14 4H5v17h2v-7h5.6l.4 2h7V6z" /></svg>';
                }
                btn.addEventListener('click', () => {
                    recordTime(currentMCQ.id, answerStates);
                    currentQuestionIndexInSection = parseInt(btn.dataset.index, 10);
                    loadQuestion();
                });
                paletteContainer.appendChild(btn);
            });
        }

        function updatePaletteItem(mcqId) {
            const btn = document.getElementById('palette-item-' + mcqId);
            if (!btn) return;
            const answerState = answerStates.find(a => a.mcqId === mcqId);
            btn.className = 'h-10 w-10 flex items-center justify-center rounded text-white font-bold relative ' + statusColors[answerState.status];
            btn.innerHTML = String(parseInt(btn.dataset.index, 10) + 1);
            if (answerState.status === QuestionStatus.MarkedForReview) {
                btn.innerHTML += '<svg xmlns="http://www.w3.org/2000/svg" class="absolute bottom-1 right-1 h-3 w-3 text-white" viewBox="0 0 24 24" fill="currentColor"><path d="M14.4 6L14 4H5v17h2v-7h5.6l.4 2h7V6z" /></svg>';
            }
        }

        // --- RESULTS LOGIC ---
        function showResults() {
            clearExamDraft();
            const shortNoteHtml = shortNote ? '<p><span class="font-bold">Notes:</span> ' + shortNote + '</p>' : '';
            const detailsHtml =
                '<p><span class="font-bold">Subject:</span> ' + (subjectName || 'N/A') + '</p>' +
                '<p><span class="font-bold">Candidate:</span> ' + (candidateName || 'N/A') + '</p>' +
                shortNoteHtml;
            document.getElementById('exam-details').innerHTML = detailsHtml;

            const results = sections.map(section => {
                let correct = 0, incorrect = 0, unanswered = 0;
                // Use the section's original question indices to find the right questions in the shuffled list
                const sectionQs = currentMcqs.slice(section.startQuestion - 1, section.endQuestion);
                sectionQs.forEach(mcq => {
                    const answerState = answerStates.find(a => a.mcqId === mcq.id);
                    if(answerState) {
                        if(!answerState.selectedOption) unanswered++;
                        else if(answerState.selectedOption === mcq.correctAnswer) correct++;
                        else incorrect++;
                    }
                });

                const total = correct + incorrect + unanswered;
                return { name: section.name, correct, incorrect, unanswered, total, score: total > 0 ? (correct / total * 100) : 0 };
            });
            
            const totalCorrect = results.reduce((sum, r) => sum + r.correct, 0);
            const totalIncorrect = results.reduce((sum, r) => sum + r.incorrect, 0);
            const totalUnanswered = results.reduce((sum, r) => sum + r.unanswered, 0);
            const overallTotal = totalCorrect + totalIncorrect + totalUnanswered;
            const overallScore = overallTotal > 0 ? (totalCorrect / overallTotal * 100) : 0;
            const scoreColorClass = overallScore >= 50 ? 'themed-text-success' : 'themed-text-danger';
            
            const attemptedStates = answerStates.filter(s => s.timeTaken > 0);
            const totalTimeSpent = attemptedStates.reduce((acc, s) => acc + s.timeTaken, 0);
            const avgTime = attemptedStates.length > 0 ? totalTimeSpent / attemptedStates.length : 0;
            const avgTimeHtml = '<div class="mt-4 themed-text-secondary">Average time per question: <span class="font-semibold">' + formatTimeDetailed(avgTime) + '</span></div>';

            const performanceHtml =
                '<h2 class="text-2xl font-semibold">Overall Performance</h2>' +
                '<p class="text-5xl font-bold my-4 ' + scoreColorClass + '">' + overallScore.toFixed(2) + '%</p>' +
                '<div class="flex justify-center space-x-8 text-lg">' +
                    '<span><span class="font-bold themed-text-success">' + totalCorrect + '</span> Correct</span>' +
                    '<span><span class="font-bold themed-text-danger">' + totalIncorrect + '</span> Incorrect</span>' +
                    '<span><span class="font-bold themed-text-secondary">' + totalUnanswered + '</span> Unanswered</span>' +
                '</div>' + avgTimeHtml;
            document.getElementById('overall-performance').innerHTML = performanceHtml;
            
            const sectionAnalysisContainer = document.getElementById('section-analysis');
            sectionAnalysisContainer.innerHTML = '';
            results.forEach(r => {
                sectionAnalysisContainer.innerHTML +=
                    '<div class="p-4 rounded-lg themed-bg-primary">' +
                        '<div class="flex justify-between items-center mb-2">' +
                            '<h3 class="text-xl font-bold">' + r.name + '</h3>' +
                            '<p class="text-xl font-semibold themed-text-accent">' + r.score.toFixed(2) + '%</p>' +
                        '</div>' +
                        '<div class="flex justify-around text-sm">' +
                            '<span>Correct: <span class="font-bold themed-text-success">' + r.correct + '</span></span>' +
                            '<span>Incorrect: <span class="font-bold themed-text-danger">' + r.incorrect + '</span></span>' +
                            '<span>Unanswered: <span class="font-bold themed-text-secondary">' + r.unanswered + '</span></span>' +
                        '</div>' +
                    '</div>';
            });
            const analysisHtml = sectionAnalysisContainer.innerHTML;

            // Save result to localStorage history
            const historyJSON = localStorage.getItem(EXAM_RESULTS_HISTORY_KEY);
            let history = historyJSON ? JSON.parse(historyJSON) : [];
            const resultData = {
                timestamp: new Date().toISOString(),
                overallScore: overallScore.toFixed(2),
                detailsHtml,
                performanceHtml,
                analysisHtml,
                answerStates,
                currentMcqs,
                subjectName,
                candidateName,
                shortNote,
                isShuffled
            };
            history.unshift(resultData); // Add to the beginning
            localStorage.setItem(EXAM_RESULTS_HISTORY_KEY, JSON.stringify(history));
            
            const pastResultsContainer = document.getElementById('past-results-container');
            const pastResultsCount = document.getElementById('past-results-count');
            pastResultsContainer.classList.remove('hidden');
            pastResultsCount.textContent = history.length;


            switchScreen('results');
        }

        document.getElementById('restart-btn').addEventListener('click', () => {
            clearExamDraft();
            clearPracticeDraft();
            document.getElementById('subject-name').value = '';
            document.getElementById('candidate-name').value = '';
            document.getElementById('short-note').value = '';
            document.getElementById('shuffle-mcqs-checkbox').checked = false;
            
            currentMcqs.length = 0;
            Array.prototype.push.apply(currentMcqs, JSON.parse(JSON.stringify(initialMcqsState)));
            
            initializeSetup();
            switchScreen('setup');
        });
        
        document.getElementById('download-report-btn').addEventListener('click', () => {
            reportOptionsModal.classList.remove('hidden');
            reportOptionsModal.classList.add('flex');
        });
        
        document.getElementById('cancel-report-download-btn').addEventListener('click', () => {
            reportOptionsModal.classList.add('hidden');
            reportOptionsModal.classList.remove('flex');
        });

        document.getElementById('download-with-explanations-btn').addEventListener('click', () => {
            reportOptionsModal.classList.add('hidden');
            reportOptionsModal.classList.remove('flex');
            downloadReport(true);
        });

        document.getElementById('download-without-explanations-btn').addEventListener('click', () => {
            reportOptionsModal.classList.add('hidden');
            reportOptionsModal.classList.remove('flex');
            downloadReport(false);
        });

        function renderMarkdownToPdf(doc, markdown, options) {
            let { x, y, maxWidth, pageHeight, margin, lineHeight, bulletIndent } = options;
            if (!markdown) return y;

            const checkPageBreak = (neededHeight) => {
                if (y + neededHeight > pageHeight - margin) {
                    doc.addPage();
                    y = margin;
                }
                return y;
            };

            const renderTextBlock = (textBlock) => {
                if (!textBlock.trim()) return;
                
                const blocks = textBlock.split(/\n\s*\n/);
                blocks.forEach(block => {
                    const trimmedBlock = block.trim();
                    if (!trimmedBlock) return;
                    
                    const lines = trimmedBlock.split('\n');
                
                    let isUnordered = lines.every(l => l.trim().startsWith('- ') || l.trim().startsWith('* '));
                    let isOrdered = lines.every(l => l.trim().match(/^\d+\.\s/));
                    
                    if(isUnordered) {
                        lines.forEach(line => {
                            const itemText = line.trim().substring(2);
                            const splitText = doc.splitTextToSize(itemText, maxWidth - bulletIndent);
                            y = checkPageBreak(splitText.length * lineHeight);
                            doc.text('â€¢', x, y, { baseline: 'top' });
                            doc.text(splitText, x + bulletIndent, y, { baseline: 'top' });
                            y += splitText.length * lineHeight;
                        });
                        y += lineHeight / 2;
                    } else if (isOrdered) {
                        lines.forEach(line => {
                            const number = line.trim().match(/^\d+\./)[0];
                            const itemText = line.trim().substring(number.length).trim();
                            const splitText = doc.splitTextToSize(itemText, maxWidth - doc.getTextWidth(number) - bulletIndent);
                            y = checkPageBreak(splitText.length * lineHeight);
                            doc.text(number, x, y, { baseline: 'top' });
                            doc.text(splitText, x + doc.getTextWidth(number) + bulletIndent - 2, y, { baseline: 'top' });
                            y += splitText.length * lineHeight;
                        });
                        y += lineHeight / 2;
                    } else { // Paragraph
                        lines.forEach(line => {
                            let isBold = line.startsWith('**') && line.endsWith('**') && line.length > 4;
                            let isItalic = line.startsWith('*') && line.endsWith('*') && line.length > 2;
                            
                            let processedLine = line;
                            if (isBold) {
                                processedLine = line.substring(2, line.length - 2);
                                doc.setFont('helvetica', 'bold');
                            } else if (isItalic) {
                                processedLine = line.substring(1, line.length - 1);
                                doc.setFont('helvetica', 'italic');
                            }

                            const splitText = doc.splitTextToSize(processedLine, maxWidth);
                            y = checkPageBreak(splitText.length * lineHeight);
                            doc.text(splitText, x, y, { baseline: 'top' });
                            y += splitText.length * lineHeight;

                            doc.setFont('helvetica', 'normal'); // Reset font
                        });
                        y += lineHeight / 2;
                    }
                });
            };

            const imageRegex = /({image\s+\d+})/g;
            const parts = markdown.split(imageRegex).filter(part => part);

            parts.forEach(part => {
                if (part.match(imageRegex)) {
                    const imageIndex = parseInt(part.match(/\d+/)[0], 10) - 1;
                    if (images[imageIndex]) {
                        try {
                            const imgData = images[imageIndex];
                            const fileType = imgData.substring(imgData.indexOf('/') + 1, imgData.indexOf(';'));
                            const imgProps = doc.getImageProperties(imgData);
                            const imgWidth = Math.min(maxWidth, imgProps.width);
                            const imgHeight = (imgProps.height * imgWidth) / imgProps.width;

                            y = checkPageBreak(imgHeight + 5); 
                            doc.addImage(imgData, fileType.toUpperCase(), x, y, imgWidth, imgHeight);
                            y += imgHeight + 5;
                        } catch (e) {
                            console.error("Error adding image to PDF:", e);
                            const errorText = '[Error loading image]';
                            y = checkPageBreak(lineHeight);
                            doc.text(errorText, x, y, { baseline: 'top' });
                            y += lineHeight;
                        }
                    }
                } else {
                    renderTextBlock(part);
                }
            });

            return y;
        }

        async function downloadReport(includeExplanations) {
            const btn = document.getElementById('download-report-btn');
            btn.disabled = true;
            btn.textContent = 'Generating...';

            try {
                const { jsPDF } = window.jspdf;
                const doc = new jsPDF('p', 'mm', 'a4');
                const analyticsContainer = document.querySelector('#results-screen > div');

                // --- Page 1: Analytics ---
                doc.setFontSize(22);
                doc.text('Exam Report', 105, 20, { align: 'center' });
                
                doc.setFontSize(11);
                doc.text('Subject: ' + (subjectName || 'N/A'), 15, 35);
                doc.text('Candidate: ' + (candidateName || 'N/A'), 15, 42);
                if (shortNote) {
                    const noteLines = doc.splitTextToSize('Notes: ' + shortNote, 180);
                    doc.text(noteLines, 15, 49);
                }
                doc.setFontSize(9);
                doc.setTextColor(150);
                doc.text('Generated on: ' + new Date().toLocaleString(), 105, 58, { align: 'center' });

                const canvas = await window.html2canvas(analyticsContainer, { scale: 2, windowWidth: analyticsContainer.scrollWidth, windowHeight: analyticsContainer.scrollHeight });
                const imgData = canvas.toDataURL('image/png');
                const imgProps = doc.getImageProperties(imgData);
                const pdfWidth = doc.internal.pageSize.getWidth();
                const pdfHeight = (imgProps.height * pdfWidth) / imgProps.width;
                
                doc.addImage(imgData, 'PNG', 10, 65, pdfWidth - 20, pdfHeight);

                // --- Subsequent Pages: Detailed Review ---
                doc.addPage();
                doc.setFontSize(18);
                doc.text('Detailed Answer Review', 105, 15, { align: 'center' });

                let y = 30;
                const margin = 15;
                const pageHeight = doc.internal.pageSize.getHeight();
                const maxWidth = pdfWidth - margin * 2;

                currentMcqs.forEach((mcq, index) => {
                    const answerState = answerStates.find(a => a.mcqId === mcq.id);
                    if (y > pageHeight - 40) { 
                        doc.addPage();
                        y = 20;
                    }

                    doc.setFont('helvetica', 'bold');
                    doc.setFontSize(12);
                    
                    const questionContent = (index + 1) + '. ' + mcq.question;
                    const imageRegex = /({image\s+\d+})/g;
                    const questionParts = questionContent.split(imageRegex).filter(part => part);

                    const checkPageBreakForQuestion = (neededHeight) => {
                        if (y + neededHeight > pageHeight - margin) {
                            doc.addPage();
                            y = 20;
                        }
                    };

                    questionParts.forEach(part => {
                        if (part.match(imageRegex)) {
                            const imageIndex = parseInt(part.match(/\d+/)[0], 10) - 1;
                            if (images[imageIndex]) {
                                try {
                                    const imgData = images[imageIndex];
                                    const fileType = imgData.substring(imgData.indexOf('/') + 1, imgData.indexOf(';'));
                                    const imgProps = doc.getImageProperties(imgData);
                                    const imgWidth = Math.min(maxWidth, imgProps.width);
                                    const imgHeight = (imgProps.height * imgWidth) / imgProps.width;

                                    checkPageBreakForQuestion(imgHeight + 5);
                                    doc.addImage(imgData, fileType.toUpperCase(), margin, y, imgWidth, imgHeight);
                                    y += imgHeight + 5;
                                } catch (e) {
                                    console.error("Error adding image to PDF:", e);
                                    const errorText = '[Error loading image]';
                                    checkPageBreakForQuestion(7);
                                    doc.text(errorText, margin, y, { baseline: 'top' });
                                    y += 7;
                                }
                            }
                        } else {
                            const questionText = doc.splitTextToSize(part, maxWidth);
                            checkPageBreakForQuestion(questionText.length * 7);
                            doc.text(questionText, margin, y, { baseline: 'top' });
                            y += questionText.length * 7;
                        }
                    });
                    y += 3;


                    doc.setFont('helvetica', 'normal');
                    doc.setFontSize(10);
                    Object.keys(mcq.options).forEach(key => {
                        const isCorrect = mcq.correctAnswer === key;
                        const isSelected = answerState.selectedOption === key;

                        if (isCorrect) doc.setTextColor(34, 139, 34);
                        else if (isSelected && !isCorrect) doc.setTextColor(220, 20, 60);
                        else doc.setTextColor(0, 0, 0);
                        
                        const optionString = '(' + key.toUpperCase() + ') ' + mcq.options[key];
                        const optionText = doc.splitTextToSize(optionString, maxWidth - 5);
                        doc.text(optionText, margin + 5, y, { baseline: 'top' });
                        y += optionText.length * 5;
                    });
                    y += 3;
                    
                    doc.setTextColor(100, 100, 100);
                    doc.setFontSize(9);
                    const summaryText = 'Your Answer: ' + (answerState.selectedOption ? answerState.selectedOption.toUpperCase() : 'Not Answered') + ' | Correct Answer: ' + mcq.correctAnswer.toUpperCase();
                    doc.text(summaryText, margin, y, { baseline: 'top' });
                    y += 7;

                    if (includeExplanations && mcq.explanation) {
                        doc.setTextColor(55, 65, 81);
                        doc.setFont('helvetica', 'bold');
                        doc.setFontSize(10);
                        doc.text('Explanation:', margin, y, { baseline: 'top' });
                        y += 6;

                        doc.setFont('helvetica', 'normal');
                        doc.setFontSize(9);

                        const renderOptions = { x: margin, y: y, maxWidth: maxWidth, pageHeight: pageHeight, margin: margin, lineHeight: 4.5, bulletIndent: 4 };
                        y = renderMarkdownToPdf(doc, mcq.explanation, renderOptions);
                    }
                    
                    y += 4;

                    if (index < currentMcqs.length - 1) {
                        doc.setDrawColor(200, 200, 200);
                        doc.line(margin, y, pdfWidth - margin, y);
                        y += 7;
                    }
                });

                doc.save('exam_report.pdf');
            } catch (error) {
                console.error("Failed to generate report:", error);
                alert("Sorry, there was an error generating the report.");
            } finally {
                btn.disabled = false;
                btn.textContent = 'Download Report';
            }
        }
        
        function markdownToHtml(markdown) {
            if (!markdown) return '';

            let text = markdown
                .replace(/\*\*(.*?)\*\*/g, '<strong>$1</strong>')
                .replace(/\*(.*?)\*/g, '<em>$1</em>');

            const blocks = text.split(/\n\s*\n/);
            
            return blocks.map(block => {
                const trimmedBlock = block.trim();
                if (!trimmedBlock) return '';

                const lines = trimmedBlock.split('\n');

                if (lines.every(line => line.trim().startsWith('- ') || line.trim().startsWith('* '))) {
                    const listItems = lines.map(line => '<li>' + line.trim().substring(2) + '</li>').join('');
                    return '<ul>' + listItems + '</ul>';
                }

                if (lines.every(line => line.trim().match(/^\d+\.\s/))) {
                    const listItems = lines.map(line => '<li>' + line.trim().replace(/^\d+\.\s/, '') + '</li>').join('');
                    return '<ol>' + listItems + '</ol>';
                }

                return '<p>' + lines.join('<br />') + '</p>';
            }).join('');
        }
        
        // --- PRACTICE MODE LOGIC ---
        document.getElementById('start-practice-btn').addEventListener('click', () => {
            setupErrorEl.textContent = '';
            subjectName = document.getElementById('subject-name').value;
            candidateName = document.getElementById('candidate-name').value;

            const savedPracticeDraft = localStorage.getItem(PRACTICE_DRAFT_KEY);

            if (savedPracticeDraft) {
                practiceResumeModal.classList.remove('hidden');
                practiceResumeModal.classList.add('flex');
            } else {
                startPractice(false); // false means don't load from draft
            }
        });

        document.getElementById('practice-resume-btn').addEventListener('click', () => {
            practiceResumeModal.classList.add('hidden');
            practiceResumeModal.classList.remove('flex');
            startPractice(true); // true means load from draft
        });

        document.getElementById('practice-start-new-btn').addEventListener('click', () => {
            practiceResumeModal.classList.add('hidden');
            practiceResumeModal.classList.remove('flex');
            clearPracticeDraft();
            startPractice(false);
        });

        function handleQuestionTimeout() {
            if (perQuestionTimerInterval) clearInterval(perQuestionTimerInterval);
            const mcq = currentMcqs[currentPracticeIndex];
            const practiceState = practiceStates.find(p => p.mcqId === mcq.id);

            if (practiceState.attempted) return;

            practiceState.attempted = true;
            practiceState.selectedOption = null; // Timed out, considered incorrect
            practiceState.timeTaken = timePerMcq;
            
            revealPracticeAnswer(null);
            savePracticeDraft();
        }

        // Streak UI Helper
        function updateStreakUI() {
            const streakBadge = document.getElementById('streak-badge');
            const streakCountEl = document.getElementById('streak-count');
            
            if (currentStreak > 0) {
                streakBadge.classList.remove('hidden');
                streakCountEl.textContent = currentStreak;
                
                // Animate
                streakBadge.classList.remove('active');
                void streakBadge.offsetWidth; // Trigger reflow
                streakBadge.classList.add('active');
                setTimeout(() => streakBadge.classList.remove('active'), 200);
            } else {
                streakBadge.classList.add('hidden');
            }
        }

        function startPractice(loadFromDraft = false) {
            if (practiceTimerInterval) clearInterval(practiceTimerInterval);
            if (perQuestionTimerInterval) clearInterval(perQuestionTimerInterval);
            
            if (loadFromDraft) {
                try {
                    const draft = JSON.parse(localStorage.getItem(PRACTICE_DRAFT_KEY));
                    currentMcqs.length = 0;
                    Array.prototype.push.apply(currentMcqs, draft.mcqs);
                    practiceStates = draft.practiceStates;
                    currentPracticeIndex = draft.currentPracticeIndex;
                    subjectName = draft.subjectName;
                    candidateName = draft.candidateName;
                    isShuffled = draft.isShuffled;
                    timePerMcq = draft.timePerMcq || 0;
                    timeOverall = draft.timeOverall || 0;
                    currentStreak = draft.currentStreak || 0;
                    
                    document.getElementById('subject-name').value = subjectName || '';
                    document.getElementById('candidate-name').value = candidateName || '';
                    document.getElementById('shuffle-mcqs-checkbox').checked = isShuffled;

                } catch (e) {
                    console.error("Failed to load practice draft:", e);
                    alert("The saved practice draft is corrupted. Starting a new session.");
                    clearPracticeDraft();
                    loadFromDraft = false; // Fallback to new session
                }
            }
            
            if (!loadFromDraft) {
                currentStreak = 0; // Reset streak
                isShuffled = document.getElementById('shuffle-mcqs-checkbox').checked;
                let baseMcqs = [...initialMcqsState];
                if (isShuffled) {
                    shuffleArray(baseMcqs);
                }

                const qCountSlider = document.getElementById('practice-q-count-slider');
                let qCount = parseInt(qCountSlider.value, 10);
                if (isNaN(qCount) || qCount <= 0 || qCount > baseMcqs.length) {
                    qCount = baseMcqs.length;
                }
                currentMcqs = baseMcqs.slice(0, qCount);
                
                practiceStates = currentMcqs.map(mcq => ({ mcqId: mcq.id, selectedOption: null, attempted: false, timeTaken: 0 }));
                currentPracticeIndex = 0;
                timePerMcq = parseInt(document.getElementById('practice-time-per-mcq').value, 10) || 0;
                timeOverall = parseInt(document.getElementById('practice-time-overall').value, 10) || 0;
            }

            document.getElementById('practice-subject-name').textContent = subjectName || 'Practice Mode';
            updateStreakUI();
            switchScreen('practice');
            renderPracticePalette(); // Added call to render palette
            renderPracticeQuestion();
            
            const practiceTimerEl = document.getElementById('practice-timer');
            if (timeOverall > 0) {
                practiceTimerEl.classList.remove('hidden');
                let timeLeft = timeOverall * 60;
                practiceTimerEl.textContent = formatTime(timeLeft);
                practiceTimerInterval = setInterval(() => {
                    timeLeft--;
                    practiceTimerEl.textContent = formatTime(timeLeft);
                    if (timeLeft <= 0) {
                        if(practiceTimerInterval) clearInterval(practiceTimerInterval);
                        if(perQuestionTimerInterval) clearInterval(perQuestionTimerInterval);
                        alert("Practice time is up!");
                        showPracticeResults();
                    }
                }, 1000);
            } else {
                practiceTimerEl.classList.add('hidden');
            }
        }

        function renderPracticeQuestion() {
            if (perQuestionTimerInterval) clearInterval(perQuestionTimerInterval);

            const mcq = currentMcqs[currentPracticeIndex];
            const practiceState = practiceStates.find(p => p.mcqId === mcq.id);
            
            document.getElementById('practice-question-counter').textContent = 'Question ' + (currentPracticeIndex + 1) + ' of ' + currentMcqs.length;
            document.getElementById('practice-question-text').innerHTML = (currentPracticeIndex + 1) + '. ' + processQuestionContent(mcq.question, 'practice-question-image-container');

            // Update Palette Active State
            const allPaletteBtns = document.querySelectorAll('#practice-palette-grid button');
            allPaletteBtns.forEach(btn => btn.classList.remove('ring-2', 'ring-offset-2', 'ring-blue-500'));
            const currentBtn = document.getElementById('practice-palette-item-' + currentPracticeIndex);
            if (currentBtn) {
                currentBtn.classList.add('ring-2', 'ring-offset-2', 'ring-blue-500');
                // Ensure the active button is visible in the scrollable container
                currentBtn.scrollIntoView({ behavior: 'smooth', block: 'nearest', inline: 'center' });
            }

            const optionsContainer = document.getElementById('practice-options-container');
            optionsContainer.innerHTML = '';
            
            Object.keys(mcq.options).forEach(key => {
                const optionEl = document.createElement('div');
                optionEl.dataset.optionKey = key;
                optionEl.className = 'flex items-center p-4 rounded-lg border-2 transition-all themed-bg-tertiary themed-border-primary';
                optionEl.innerHTML = '<span class="flex-1">' + key.toUpperCase() + '. ' + mcq.options[key] + '</span>';
                optionsContainer.appendChild(optionEl);
            });
            
            // Hide previous results elements
            document.getElementById('practice-explanation-section').classList.add('hidden');
            document.getElementById('header-feedback-badge').classList.remove('visible');
            document.getElementById('header-feedback-badge').className = 'feedback-badge'; // Reset class

            if (practiceState.attempted) {
                revealPracticeAnswer(practiceState.selectedOption);
            } else {
                optionsContainer.classList.add('cursor-pointer');
                optionsContainer.querySelectorAll('[data-option-key]').forEach(el => el.classList.add('themed-bg-accent-hover'));
            }

            // Per-question timer logic
            const timerContainer = document.getElementById('per-question-timer-container');
            const timerBar = document.getElementById('per-question-timer-bar');
            if (timePerMcq > 0 && !practiceState.attempted) {
                timerContainer.classList.remove('hidden');
                timerBar.style.width = '100%';
                timerBar.classList.remove('bg-green-500');
                timerBar.classList.add('bg-green-500');

                const timerStart = Date.now();
                perQuestionTimerInterval = setInterval(() => {
                    const elapsed = (Date.now() - timerStart) / 1000;
                    if (elapsed >= timePerMcq) {
                        handleQuestionTimeout();
                        return;
                    }
                    const remainingPercent = ((timePerMcq - elapsed) / timePerMcq) * 100;
                    timerBar.style.width = remainingPercent + '%';

                    if (remainingPercent < 40) {
                        timerBar.classList.remove('bg-green-500');
                        timerBar.classList.add('bg-red-500');
                    }
                }, 100);
            } else {
                timerContainer.classList.add('hidden');
            }

            document.getElementById('practice-prev-btn').disabled = currentPracticeIndex === 0;
            document.getElementById('practice-next-btn').disabled = currentPracticeIndex === currentMcqs.length - 1;
            
            updatePracticeSaveButtonState();
            questionStartTime = Date.now();
        }

        function revealPracticeAnswer(selectedKey) {
            const mcq = currentMcqs[currentPracticeIndex];
            const optionsContainer = document.getElementById('practice-options-container');
            optionsContainer.classList.remove('cursor-pointer');
            
            // Check correctness
            const isCorrect = mcq.correctAnswer === selectedKey;
            
            // Update Palette Button Color for the answered question
            const paletteBtn = document.getElementById('practice-palette-item-' + currentPracticeIndex);
            if (paletteBtn) {
                // If selectedKey is null (timeout), it's incorrect (red)
                const paletteIsCorrect = selectedKey && (mcq.correctAnswer === selectedKey);
                paletteBtn.className = 'w-10 h-10 flex-shrink-0 flex items-center justify-center rounded-full text-white font-bold transition-all transform hover:scale-110 focus:outline-none ' + (paletteIsCorrect ? 'bg-green-600' : 'bg-red-600');
            }

            optionsContainer.querySelectorAll('[data-option-key]').forEach(el => {
                el.classList.remove('themed-bg-accent-hover');
                const key = el.dataset.optionKey;
                const isOptionCorrect = mcq.correctAnswer === key;
                const isSelected = selectedKey === key;

                el.classList.remove('themed-bg-tertiary', 'themed-border-primary');
                
                // SVG Icons
                const checkIcon = '<svg xmlns="http://www.w3.org/2000/svg" class="h-6 w-6 ml-2 text-green-700" fill="none" viewBox="0 0 24 24" stroke="currentColor" stroke-width="3"><path stroke-linecap="round" stroke-linejoin="round" d="M5 13l4 4L19 7" /></svg>';
                const crossIcon = '<svg xmlns="http://www.w3.org/2000/svg" class="h-6 w-6 ml-2 text-red-700" fill="none" viewBox="0 0 24 24" stroke="currentColor" stroke-width="3"><path stroke-linecap="round" stroke-linejoin="round" d="M6 18L18 6M6 6l12 12" /></svg>';

                if (isOptionCorrect) {
                    el.style.backgroundColor = 'var(--bg-success)';
                    el.style.borderColor = 'var(--bg-success-border)';
                    if (!el.innerHTML.includes('<svg')) el.innerHTML += checkIcon;
                    
                    if (isCorrect && isSelected) {
                        triggerConfetti(el.getBoundingClientRect());
                    }
                } else if (isSelected && !isOptionCorrect) {
                    el.style.backgroundColor = 'var(--bg-danger)';
                    el.style.borderColor = 'var(--bg-danger-border)';
                     if (!el.innerHTML.includes('<svg')) el.innerHTML += crossIcon;
                } else {
                    el.classList.add('opacity-60');
                }
            });
            
            // --- HEADER FEEDBACK ---
            const badge = document.getElementById('header-feedback-badge');
            const badgeText = document.getElementById('header-feedback-text');
            
            if (isCorrect) {
                badge.className = 'feedback-badge visible correct';
                badgeText.innerHTML = 'Excellent! ðŸŽ‰';
            } else {
                badge.className = 'feedback-badge visible incorrect';
                badgeText.innerHTML = 'Incorrect âŒ';
            }

            // --- EXPLANATION SECTION ---
            const explanationSection = document.getElementById('practice-explanation-section');
            const explanationContainer = document.getElementById('practice-explanation-container');
            
            if (mcq.explanation) {
                const cleanedExplanationText = processQuestionContent(mcq.explanation, 'practice-explanation-image-container');
                explanationContainer.innerHTML = markdownToHtml(cleanedExplanationText);
            } else {
                document.getElementById('practice-explanation-image-container').innerHTML = '';
                explanationContainer.innerHTML = '<p class="themed-text-tertiary">No explanation was provided for this question.</p>';
            }
            explanationSection.classList.remove('hidden');
        }

        document.getElementById('practice-options-container').addEventListener('click', (e) => {
            const optionEl = e.target.closest('[data-option-key]');
            if (!optionEl) return;

            const mcq = currentMcqs[currentPracticeIndex];
            const practiceState = practiceStates.find(p => p.mcqId === mcq.id);
            
            if (practiceState.attempted) return;
            if (perQuestionTimerInterval) clearInterval(perQuestionTimerInterval);

            recordTime(mcq.id, practiceStates);
            
            const selectedKey = optionEl.dataset.optionKey;
            practiceState.attempted = true;
            practiceState.selectedOption = selectedKey;

            // STREAK LOGIC UPDATE
            if (selectedKey === mcq.correctAnswer) {
                currentStreak++;
            } else {
                currentStreak = 0;
            }
            updateStreakUI();

            revealPracticeAnswer(selectedKey);
            savePracticeDraft();
        });
        
        // ADDED: Function to render the practice palette
        function renderPracticePalette() {
            const paletteGrid = document.getElementById('practice-palette-grid');
            if (!paletteGrid) return;
            paletteGrid.innerHTML = '';

            currentMcqs.forEach((mcq, index) => {
                const btn = document.createElement('button');
                btn.id = 'practice-palette-item-' + index;
                btn.dataset.index = String(index);
                
                // Determine color based on state
                const pState = practiceStates.find(p => p.mcqId === mcq.id);
                let bgClass = 'bg-gray-400'; // Default gray
                if (pState && pState.attempted) {
                     const isCorrect = pState.selectedOption === mcq.correctAnswer;
                     bgClass = isCorrect ? 'bg-green-600' : 'bg-red-600';
                }

                btn.className = 'w-10 h-10 flex-shrink-0 flex items-center justify-center rounded-full text-white font-bold transition-all transform hover:scale-110 focus:outline-none ' + bgClass; 
                btn.textContent = String(index + 1);
                btn.setAttribute('aria-label', 'Go to question ' + (index + 1));
                
                btn.addEventListener('click', () => {
                    if (perQuestionTimerInterval) clearInterval(perQuestionTimerInterval);
                    // Record time for current before switching if not answered
                    const currentMcq = currentMcqs[currentPracticeIndex];
                    if(currentMcq) {
                         const currentState = practiceStates.find(p => p.mcqId === currentMcq.id);
                         if (!currentState.attempted) recordTime(currentMcq.id, practiceStates);
                    }
                    
                    currentPracticeIndex = parseInt(btn.dataset.index, 10);
                    renderPracticeQuestion();
                    savePracticeDraft();
                });
                paletteGrid.appendChild(btn);
            });
        }
        
        function navigatePractice(offset) {
            if (perQuestionTimerInterval) clearInterval(perQuestionTimerInterval);
            const mcq = currentMcqs[currentPracticeIndex];
            const practiceState = practiceStates.find(p => p.mcqId === mcq.id);
            if (!practiceState.attempted) {
                recordTime(mcq.id, practiceStates); // Record time even if unanswered
            }

            const newIndex = currentPracticeIndex + offset;
            if (newIndex >= 0 && newIndex < currentMcqs.length) {
                currentPracticeIndex = newIndex;
                renderPracticeQuestion();
                savePracticeDraft();
            }
        }

        document.getElementById('practice-prev-btn').addEventListener('click', () => navigatePractice(-1));
        document.getElementById('practice-next-btn').addEventListener('click', () => navigatePractice(1));

        document.getElementById('exit-practice-btn').addEventListener('click', () => {
            if (practiceTimerInterval) clearInterval(practiceTimerInterval);
            if (perQuestionTimerInterval) clearInterval(perQuestionTimerInterval);
            recordTime(currentMcqs[currentPracticeIndex].id, practiceStates);
            showPracticeResults();
        });

        // --- REVIEW LOGIC ---
        let reviewQuestionIndex = 0;
        
        function setupReviewScreen(isReviseMode = false, isSavedMode = false) {
            const backBtn = document.getElementById('back-to-results-btn');
            const exitBtn = document.getElementById('exit-revise-btn');
            isReviewingSaved = isSavedMode;

            if (isSavedMode) {
                reviewTitleEl.textContent = 'Saved Questions';
                backBtn.style.display = 'none';
                exitBtn.style.display = 'inline-block';
                document.getElementById('review-time-taken').style.display = 'none';
            } else if (isReviseMode) {
                reviewTitleEl.textContent = 'Revise Mode';
                backBtn.style.display = 'none';
                exitBtn.style.display = 'inline-block';
                document.getElementById('review-time-taken').style.display = 'none';
            } else {
                reviewTitleEl.textContent = 'Review Answers';
                backBtn.style.display = 'inline-block';
                exitBtn.style.display = 'none';
                document.getElementById('review-time-taken').style.display = 'flex';
                if (reviewReturnScreen === 'practiceResults') {
                    backBtn.textContent = 'Back to Practice Results';
                } else {
                    backBtn.textContent = 'Back to Exam Results';
                }
            }
            renderReviewPalette();
            renderReviewQuestion();
        }
        
        document.getElementById('review-answers-btn').addEventListener('click', () => {
            reviewQuestionIndex = 0;
            reviewReturnScreen = 'results';
            switchScreen('review');
            setupReviewScreen(false, false);
        });
        
        document.getElementById('exit-revise-btn').addEventListener('click', () => {
            switchScreen('setup');
        });

        document.getElementById('review-practice-answers-btn').addEventListener('click', () => {
            answerStates = currentMcqs.map(mcq => {
                const pState = practiceStates.find(p => p.mcqId === mcq.id);
                return { mcqId: mcq.id, selectedOption: pState ? pState.selectedOption : null, timeTaken: pState ? pState.timeTaken : 0 };
            });
            reviewQuestionIndex = 0;
            reviewReturnScreen = 'practiceResults';
            switchScreen('review');
            setupReviewScreen(false, false);
        });

        document.getElementById('back-to-results-btn').addEventListener('click', () => switchScreen(reviewReturnScreen));
        
        function renderReviewPalette() {
            const paletteGrid = document.getElementById('review-palette-grid');
            if (!paletteGrid) return;
            paletteGrid.innerHTML = '';

            currentMcqs.forEach((mcq, index) => {
                const answerState = answerStates.find(a => a.mcqId === mcq.id);
                const isCorrect = answerState && answerState.selectedOption === mcq.correctAnswer;
                const hasAnswered = answerState && answerState.selectedOption !== undefined && answerState.selectedOption !== null;
                
                let bgClass = 'bg-gray-400';
                if (hasAnswered) {
                    bgClass = isCorrect ? 'bg-green-600' : 'bg-red-600';
                }

                const btn = document.createElement('button');
                btn.id = 'review-palette-item-' + index;
                btn.dataset.index = String(index);
                btn.className = 'w-10 h-10 flex-shrink-0 flex items-center justify-center rounded-full text-white font-bold transition-all transform hover:scale-110 focus:outline-none ' + bgClass;
                btn.textContent = String(index + 1);
                // Accessibility: Dynamic aria label
                btn.setAttribute('aria-label', 'Review question ' + (index + 1));
                btn.addEventListener('click', () => {
                    reviewQuestionIndex = parseInt(btn.dataset.index, 10);
                    renderReviewQuestion();
                });
                paletteGrid.appendChild(btn);
            });
        }

        function renderReviewQuestion() {
            updateSaveButtonState();
            const allPaletteBtns = document.querySelectorAll('#review-palette-grid button');
            allPaletteBtns.forEach(btn => btn.classList.remove('ring-2', 'ring-offset-2', 'ring-blue-500'));
            const currentBtn = document.getElementById('review-palette-item-' + reviewQuestionIndex);
            if (currentBtn) {
                currentBtn.classList.add('ring-2', 'ring-offset-2', 'ring-blue-500');
                currentBtn.scrollIntoView({ behavior: 'smooth', block: 'nearest', inline: 'center' });
            }

            const mcq = currentMcqs[reviewQuestionIndex];
            const answerState = answerStates.find(a => a.mcqId === mcq.id);
            
            document.getElementById('review-question-text').innerHTML = (reviewQuestionIndex + 1) + '. ' + processQuestionContent(mcq.question, 'review-question-image-container');
            document.getElementById('review-question-counter').textContent = 'Question ' + (reviewQuestionIndex + 1) + ' of ' + currentMcqs.length;
            
            const timeTakenEl = document.getElementById('review-time-taken');
            if (answerState && answerState.timeTaken) {
                timeTakenEl.innerHTML = '<svg xmlns="http://www.w3.org/2000/svg" class="h-4 w-4 mr-1.5" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.414-1.415L11 9.586V6z" clip-rule="evenodd" /></svg> Time Taken: <span class="font-semibold ml-1">' + formatTimeDetailed(answerState.timeTaken) + '</span>';
            } else {
                timeTakenEl.innerHTML = '';
            }

            const explanationContainer = document.getElementById('explanation-container');
            if (mcq.explanation) {
                const cleanedExplanationText = processQuestionContent(mcq.explanation, 'explanation-image-container');
                explanationContainer.innerHTML = markdownToHtml(cleanedExplanationText);
            } else {
                document.getElementById('explanation-image-container').innerHTML = '';
                explanationContainer.innerHTML = '<p class="themed-text-tertiary">No explanation was provided for this question.</p>';
            }
            
            const reviewOptionsContainer = document.getElementById('review-options-container');
            reviewOptionsContainer.innerHTML = '';
            Object.keys(mcq.options).forEach(key => {
                const isSelected = answerState && answerState.selectedOption === key;
                const isCorrect = mcq.correctAnswer === key;
                let style = 'background-color: var(--bg-tertiary); border-color: transparent;';
                let indicatorText = '';

                if (isCorrect) {
                    style = 'background-color: var(--bg-success); border-color: var(--bg-success-border);';
                    indicatorText = '<span class="ml-auto text-sm font-semibold themed-text-success">Correct Answer</span>';
                }
                
                if (isSelected && !isCorrect) {
                    style = 'background-color: var(--bg-danger); border-color: var(--bg-danger-border);';
                    indicatorText = '<span class="ml-auto text-sm font-semibold themed-text-danger">Your Answer</span>';
                } else if (isSelected && isCorrect) {
                     indicatorText = '<span class="ml-auto text-sm font-semibold themed-text-success">Your Answer (Correct)</span>';
                }
                
                reviewOptionsContainer.innerHTML +=
                    '<div class="flex items-center p-4 rounded-lg border-2" style="' + style + '">' +
                        '<span class="flex-1">' + key.toUpperCase() + '. ' + mcq.options[key] + '</span>' +
                        indicatorText +
                    '</div>';
            });
            
            document.getElementById('review-prev-btn').disabled = reviewQuestionIndex === 0;
            document.getElementById('review-next-btn').disabled = reviewQuestionIndex === currentMcqs.length - 1;
        }

        document.getElementById('review-prev-btn').addEventListener('click', () => {
            if(reviewQuestionIndex > 0) {
                reviewQuestionIndex--;
                renderReviewQuestion();
            }
        });

        document.getElementById('review-next-btn').addEventListener('click', () => {
            if(reviewQuestionIndex < currentMcqs.length - 1) {
                reviewQuestionIndex++;
                renderReviewQuestion();
            }
        });
        
        // --- SWIPE NAVIGATION LOGIC ---
        function setupSwipeNavigation(container) {
            let touchStartX = 0;
            let touchStartY = 0;
            const mainContent = container.querySelector('main');
            let isAnimating = false;

            container.addEventListener('touchstart', e => {
                if (isAnimating) return;
                
                // FIX: Prevent page swipe if user is trying to scroll the palette
                if (e.target.closest('.overflow-x-auto')) return;

                touchStartX = e.changedTouches[0].screenX;
                touchStartY = e.changedTouches[0].screenY;
            }, { passive: true });

            container.addEventListener('touchend', e => {
                if (isAnimating) return;
                const touchEndX = e.changedTouches[0].screenX;
                const touchEndY = e.changedTouches[0].screenY;
                const diffX = touchEndX - touchStartX;
                const diffY = touchEndY - touchStartY;

                if (Math.abs(diffX) > 50 && Math.abs(diffX) > Math.abs(diffY)) {
                    
                    const isNext = diffX < 0; // Swipe Left
                    
                    // FIX: Re-enabled swipe backward (swipe right)
                    // The line that prevented it was removed here.

                    isAnimating = true;
                    const outClass = isNext ? 'slide-out-left' : 'slide-out-right';
                    const inClass = isNext ? 'slide-in-from-right' : 'slide-in-from-left';
                    
                    const onAnimationOutEnd = () => {
                        mainContent.removeEventListener('animationend', onAnimationOutEnd);
                        mainContent.classList.remove(outClass);

                        // Perform navigation action
                        if (container.id === 'practice-screen') {
                            if (isNext) navigatePractice(1);
                            else navigatePractice(-1);
                        } else if (container.id === 'review-screen') {
                            if (isNext) document.getElementById('review-next-btn').click();
                            else document.getElementById('review-prev-btn').click();
                        }

                        mainContent.classList.add(inClass);
                        
                        const onAnimationInEnd = () => {
                            mainContent.removeEventListener('animationend', onAnimationInEnd);
                            mainContent.classList.remove(inClass);
                            isAnimating = false;
                        };
                        mainContent.addEventListener('animationend', onAnimationInEnd);
                    };

                    mainContent.addEventListener('animationend', onAnimationOutEnd);
                    mainContent.classList.add(outClass);
                }
            }, { passive: true });
        }

        setupSwipeNavigation(screens.practice);
        setupSwipeNavigation(screens.review);

        // --- PAST RESULTS LOGIC ---
        function showPastResultsList() {
            const historyJSON = localStorage.getItem(EXAM_RESULTS_HISTORY_KEY);
            const history = historyJSON ? JSON.parse(historyJSON) : [];
            const listEl = document.getElementById('past-results-list');
            listEl.innerHTML = '';

            if (history.length === 0) {
                listEl.innerHTML = '<p class="text-center themed-text-tertiary">No past results found.</p>';
            } else {
                history.forEach((result, index) => {
                    const date = new Date(result.timestamp).toLocaleString();
                    const scoreColor = result.overallScore >= 50 ? 'themed-text-success' : 'themed-text-danger';
                    const item = document.createElement('button');
                    item.className = 'w-full text-left p-4 rounded-lg border flex justify-between items-center transition-colors themed-bg-primary themed-border-primary hover:bg-[var(--bg-tertiary)]';
                    item.dataset.resultIndex = index;
                    item.innerHTML = 
                        '<div>' +
                            '<p class="font-bold themed-text-primary">' + (result.subjectName || 'Untitled Exam') + '</p>' +
                            '<p class="text-sm themed-text-secondary">' + date + '</p>' +
                        '</div>' +
                        '<div class="text-right">' +
                            '<p class="text-xl font-bold ' + scoreColor + '">' + result.overallScore + '%</p>' +
                            '<p class="text-xs themed-text-tertiary">Click to view details</p>' +
                        '</div>';
                    listEl.appendChild(item);
                });
            }
            switchScreen('pastResults');
        }
        
        document.getElementById('past-results-list').addEventListener('click', (e) => {
            const target = e.target.closest('[data-result-index]');
            if (target) {
                const index = parseInt(target.dataset.resultIndex, 10);
                const historyJSON = localStorage.getItem(EXAM_RESULTS_HISTORY_KEY);
                const history = historyJSON ? JSON.parse(historyJSON) : [];
                const resultData = history[index];
                if (resultData) {
                    loadResultIntoView(resultData);
                }
            }
        });

        function loadResultIntoView(resultData) {
            document.getElementById('exam-details').innerHTML = resultData.detailsHtml;
            document.getElementById('overall-performance').innerHTML = resultData.performanceHtml;
            document.getElementById('section-analysis').innerHTML = resultData.analysisHtml;
            
            // Set state for the "Review Answers" button for this specific result
            answerStates = resultData.answerStates;
            currentMcqs = resultData.currentMcqs;
            subjectName = resultData.subjectName;
            candidateName = resultData.candidateName;
            shortNote = resultData.shortNote;
            isShuffled = resultData.isShuffled;
            
            switchScreen('results');
        }
        
        document.getElementById('back-to-setup-from-history-btn').addEventListener('click', () => switchScreen('setup'));

        // --- PROGRESS CHARTS RENDERING ---
        function renderProgressCharts() {
            const examHistoryJSON = localStorage.getItem(EXAM_RESULTS_HISTORY_KEY);
            const examHistory = examHistoryJSON ? JSON.parse(examHistoryJSON) : [];
            
            const practiceHistoryJSON = localStorage.getItem(PRACTICE_RESULTS_HISTORY_KEY);
            const practiceHistory = practiceHistoryJSON ? JSON.parse(practiceHistoryJSON) : [];

            // --- KPI DASHBOARD STATS ---
            // Combine scores for calculation? No, separate is better. Let's show Exam stats primarily.
            const examScores = examHistory.map(h => parseFloat(h.overallScore || 0));
            const totalExams = examHistory.length;
            const avgScore = totalExams > 0 ? (examScores.reduce((a,b)=>a+b, 0) / totalExams).toFixed(1) : '0';
            const maxScore = totalExams > 0 ? Math.max(...examScores).toFixed(1) : '0';
            
            // Total Practice Questions Solved
            const totalPracticeQs = practiceHistory.reduce((acc, curr) => acc + (curr.attempted || 0), 0);

            const kpiDashboard = document.getElementById('kpi-dashboard');
            kpiDashboard.innerHTML = ''; // Clear previous

            const kpis = [
                { label: 'Avg Exam Score', value: avgScore + '%', color: 'text-blue-500' },
                { label: 'Highest Score', value: maxScore + '%', color: 'text-green-500' },
                { label: 'Total Attempts', value: totalExams, color: 'text-purple-500' },
                { label: 'Practice Qs', value: totalPracticeQs, color: 'text-orange-500' }
            ];

            kpis.forEach(kpi => {
                const card = document.createElement('div');
                card.className = 'stat-card themed-bg-primary themed-border-primary';
                card.innerHTML = `
                    <span class="stat-value ${kpi.color}">${kpi.value}</span>
                    <span class="stat-label">${kpi.label}</span>
                `;
                kpiDashboard.appendChild(card);
            });


            // Helper to create bars
            const createBar = (score, labelText, tooltipTitle, subtitle, index, prevScore) => {
                const scoreNum = parseFloat(score);
                const isSuccess = scoreNum >= 50;
                const barClass = isSuccess ? 'bar-success' : 'bar-danger';
                
                const barContainer = document.createElement('div');
                barContainer.className = 'chart-bar-container';
                
                const bar = document.createElement('div');
                bar.className = 'chart-bar ' + barClass;
                bar.style.height = Math.max(scoreNum, 5) + '%'; 
                // Staggered Animation Delay
                bar.style.animationDelay = (index * 0.1) + 's';
                
                // Text inside bar
                const barText = document.createElement('span');
                barText.className = 'chart-bar-text';
                barText.textContent = scoreNum.toFixed(1) + '%';
                if (scoreNum < 15) barText.style.display = 'none';
                bar.appendChild(barText);
                
                const label = document.createElement('div');
                label.className = 'chart-bar-label';
                label.textContent = labelText;
                
                // Trend Indicator
                let trendHtml = '';
                if (prevScore !== null) {
                    const diff = scoreNum - prevScore;
                    if (diff > 0) trendHtml = '<span class="text-green-400 ml-2 text-xs">â–² +' + diff.toFixed(1) + '%</span>';
                    else if (diff < 0) trendHtml = '<span class="text-red-400 ml-2 text-xs">â–¼ ' + diff.toFixed(1) + '%</span>';
                    else trendHtml = '<span class="text-gray-400 ml-2 text-xs">- 0%</span>';
                }

                const tooltip = document.createElement('div');
                tooltip.className = 'chart-bar-tooltip';
                tooltip.innerHTML = '<strong>' + tooltipTitle + '</strong>' + trendHtml + '<br/>' + subtitle;
                
                barContainer.appendChild(tooltip);
                barContainer.appendChild(bar);
                barContainer.appendChild(label);
                
                return barContainer;
            };

            // 1. Render Exam Chart
            const examContainer = document.getElementById('exam-chart-container');
            const examEmpty = document.getElementById('exam-chart-empty');
            
            examContainer.innerHTML = '';
            if (examHistory.length === 0) {
                examEmpty.classList.remove('hidden');
            } else {
                examEmpty.classList.add('hidden');
                // Process in chronological order for trends, but show recent last? 
                // Actually history is stored newest first. Let's reverse to show chronological left-to-right.
                const reversedHistory = [...examHistory].reverse();
                
                reversedHistory.forEach((result, i) => {
                    let correct = 0, total = 0;
                    if (result.answerStates && result.currentMcqs) {
                        result.answerStates.forEach(state => {
                            const mcq = result.currentMcqs.find(m => m.id === state.mcqId);
                            if(mcq) {
                                total++;
                                if (state.selectedOption === mcq.correctAnswer) correct++;
                            }
                        });
                    }
                    
                    const date = new Date(result.timestamp).toLocaleDateString(undefined, {month: 'short', day: 'numeric'});
                    const subject = (result.subjectName || 'Exam').substring(0, 15);
                    
                    // Previous score for trend
                    const prevScore = i > 0 ? parseFloat(reversedHistory[i-1].overallScore) : null;

                    const bar = createBar(
                        result.overallScore, 
                        date, 
                        subject, 
                        'Score: ' + result.overallScore + '%<br>Marks: ' + correct + ' / ' + total,
                        i,
                        prevScore
                    );
                    examContainer.appendChild(bar);
                });
            }

            // 2. Render Practice Chart
            const practiceContainer = document.getElementById('practice-chart-container');
            const practiceEmpty = document.getElementById('practice-chart-empty');
            
            practiceContainer.innerHTML = '';
            if (practiceHistory.length === 0) {
                practiceEmpty.classList.remove('hidden');
            } else {
                practiceEmpty.classList.add('hidden');
                const reversedHistory = [...practiceHistory].reverse();
                
                reversedHistory.forEach((result, i) => {
                    const date = new Date(result.timestamp).toLocaleDateString(undefined, {month: 'short', day: 'numeric'});
                    const subject = (result.subjectName || 'Practice').substring(0, 15);
                    const prevScore = i > 0 ? parseFloat(reversedHistory[i-1].score) : null;

                    const bar = createBar(
                        result.score, 
                        date, 
                        subject, 
                        'Score: ' + result.score + '%<br>Marks: ' + result.correct + ' / ' + result.attempted,
                        i,
                        prevScore
                    );
                    practiceContainer.appendChild(bar);
                });
            }
        }

        document.getElementById('reset-practice-history-btn').addEventListener('click', () => {
            showConfirmation("Are you sure you want to clear all practice history? This cannot be undone.", () => {
                localStorage.removeItem(PRACTICE_RESULTS_HISTORY_KEY);
                renderProgressCharts();
            });
        });
        
        function showPracticeResults() {
            if (practiceTimerInterval) clearInterval(practiceTimerInterval);
            if (perQuestionTimerInterval) clearInterval(perQuestionTimerInterval);
            clearPracticeDraft();
            
            const detailsHtml =
                '<p><span class="font-bold">Subject:</span> ' + (subjectName || 'N/A') + '</p>' +
                '<p><span class="font-bold">Candidate:</span> ' + (candidateName || 'N/A') + '</p>';
            document.getElementById('practice-exam-details').innerHTML = detailsHtml;

            let correct = 0, incorrect = 0, attempted = 0;
            practiceStates.forEach(state => {
                if (state.attempted) {
                    attempted++;
                    const mcq = currentMcqs.find(m => m.id === state.mcqId);
                    if (mcq && state.selectedOption === mcq.correctAnswer) {
                        correct++;
                    } else {
                        incorrect++;
                    }
                }
            });
            
            const score = attempted > 0 ? (correct / attempted * 100) : 0;
            const scoreColorClass = score >= 50 ? 'themed-text-success' : 'themed-text-danger';
            
            document.getElementById('practice-score').className = 'text-5xl font-bold my-4 ' + scoreColorClass;
            document.getElementById('practice-score').textContent = score.toFixed(2) + '%';
            
            document.getElementById('practice-correct').innerHTML = '<span class="font-bold themed-text-success">' + correct + '</span> Correct';
            document.getElementById('practice-incorrect').innerHTML = '<span class="font-bold themed-text-danger">' + incorrect + '</span> Incorrect';
            document.getElementById('practice-attempted').innerHTML = '<span class="font-bold themed-text-secondary">' + attempted + '</span> Attempted';
            
            const attemptedStates = practiceStates.filter(s => s.timeTaken > 0);
            const totalTimeSpent = attemptedStates.reduce((acc, s) => acc + s.timeTaken, 0);
            const avgTime = attemptedStates.length > 0 ? totalTimeSpent / attemptedStates.length : 0;
            document.getElementById('practice-avg-time').innerHTML = 'Average time per question: <span class="font-semibold">' + formatTimeDetailed(avgTime) + '</span>';

            // SAVE PRACTICE RESULT
            const historyJSON = localStorage.getItem(PRACTICE_RESULTS_HISTORY_KEY);
            let history = historyJSON ? JSON.parse(historyJSON) : [];
            const resultData = {
                timestamp: new Date().toISOString(),
                score: score.toFixed(2),
                correct,
                incorrect,
                attempted,
                subjectName
            };
            history.unshift(resultData);
            localStorage.setItem(PRACTICE_RESULTS_HISTORY_KEY, JSON.stringify(history));

            switchScreen('practiceResults');
        }

        document.getElementById('restart-practice-btn').addEventListener('click', () => {
            clearPracticeDraft();
            startPractice(false);
        });
        
        document.getElementById('back-to-setup-btn').addEventListener('click', () => switchScreen('setup'));
        document.getElementById('back-to-setup-from-progress-btn').addEventListener('click', () => switchScreen('setup'));

        // --- INITIALIZE APP ---
        const savedExamDraft = localStorage.getItem(EXAM_DRAFT_KEY);
        if (savedExamDraft) {
            const resumeBanner = document.getElementById('resume-banner');
            resumeBanner.classList.remove('hidden');

            document.getElementById('resume-session-btn').addEventListener('click', () => {
                try {
                    const draft = JSON.parse(savedExamDraft);
                    
                    currentMcqs.length = 0;
                    Array.prototype.push.apply(currentMcqs, draft.mcqs);
                    sections = draft.sections;
                    answerStates = draft.answerStates;
                    currentSectionIndex = draft.currentSectionIndex;
                    currentQuestionIndexInSection = draft.currentQuestionIndexInSection;
                    subjectName = draft.subjectName;
                    candidateName = draft.candidateName;
                    shortNote = draft.shortNote;
                    isShuffled = draft.isShuffled;

                    document.getElementById('subject-name').value = subjectName || '';
                    document.getElementById('candidate-name').value = candidateName || '';
                    document.getElementById('short-note').value = shortNote || '';
                    document.getElementById('shuffle-mcqs-checkbox').checked = isShuffled;
                    
                    renderSections();
                    loadSection();
                    switchScreen('exam');

                } catch (e) {
                    console.error("Failed to load exam draft:", e);
                    alert("The saved exam draft appears to be corrupted and could not be loaded.");
                    clearExamDraft();
                    resumeBanner.classList.add('hidden');
                }
            });

            document.getElementById('discard-draft-btn').addEventListener('click', () => {
                clearExamDraft();
                resumeBanner.classList.add('hidden');
            });
        }
        
        const savedMcqsData = localStorage.getItem(SAVED_MCQS_KEY);
        if (savedMcqsData) {
            try {
                savedMcqIds = JSON.parse(savedMcqsData);
            } catch (e) {
                console.error("Could not parse saved MCQs", e);
                savedMcqIds = [];
            }
        }
        updateSavedQuestionsUI();
        
        const savedResultsData = localStorage.getItem(EXAM_RESULTS_HISTORY_KEY);
        if (savedResultsData) {
            const history = JSON.parse(savedResultsData);
            if(history.length > 0) {
                const pastResultsContainer = document.getElementById('past-results-container');
                const pastResultsCount = document.getElementById('past-results-count');
                pastResultsContainer.classList.remove('hidden');
                pastResultsCount.textContent = history.length;
            }
        }

        document.getElementById('view-past-results-btn').addEventListener('click', showPastResultsList);

        saveMcqBtn.addEventListener('click', toggleSaveMcq);
        saveMcqPracticeBtn.addEventListener('click', toggleSavePracticeMcq);
        
        if (toggleSparklesBtn) {
            toggleSparklesBtn.addEventListener('click', () => {
                isSparklesEnabled = !isSparklesEnabled;
                const svg = toggleSparklesBtn.querySelector('svg');
                if (isSparklesEnabled) {
                    svg.classList.remove('themed-text-secondary');
                    svg.classList.add('text-yellow-500');
                    svg.setAttribute('fill', 'currentColor');
                    showToast("Sparkles On âœ¨");
                } else {
                    svg.classList.add('themed-text-secondary');
                    svg.classList.remove('text-yellow-500');
                    svg.setAttribute('fill', 'none');
                    showToast("Sparkles Off");
                }
            });
        }

        viewSavedBtn.addEventListener('click', () => {
            if (savedMcqIds.length === 0) {
                alert("You have no saved questions.");
                return;
            }
            currentMcqs = initialMcqsState.filter(mcq => savedMcqIds.includes(mcq.id));
            answerStates = currentMcqs.map(mcq => ({
                mcqId: mcq.id,
                status: QuestionStatus.NotVisited,
                selectedOption: undefined,
                timeTaken: 0
            }));
            reviewQuestionIndex = 0;
            switchScreen('review');
            setupReviewScreen(true, true);
        });

        if (mcqs.length > 0) {
            currentMcqs = [...mcqs];
            initializeSetup();
        } else {
            switchScreen('setup');
            document.getElementById('setup-error').textContent = "No questions were loaded. Please generate a new file.";
            document.getElementById('start-exam-btn').disabled = true;
            document.getElementById('add-section-btn').disabled = true;
        }
      } catch (error) {
          console.error("Fatal error during exam initialization:", error);
          document.body.innerHTML =
              '<div style="padding: 2rem; text-align: center; font-family: sans-serif; color: #333;">' +
                  '<h1 style="color: #d9534f; font-size: 2rem;">An Unexpected Error Occurred</h1>' +
                  '<p style="margin-top: 1rem;">The exam file could not be loaded. This is likely due to an internal script error.</p>' +
                  '<p style="margin-top: 0.5rem;">Please try generating the exam file again from the main application.</p>' +
                  '<div style="margin-top: 2rem; padding: 1rem; background-color: #f7f7f7; border: 1px solid #ddd; text-align: left; white-space: pre-wrap; word-wrap: break-word; font-family: monospace; font-size: 0.8rem; max-width: 800px; margin-left: auto; margin-right: auto;">' +
                      '<h3 style="margin-bottom: 0.5rem; font-weight: bold;">Error Details:</h3>' +
                      error.message +
                  '</div>' +
              '</div>';
      }
    });

</script>
<script>
    // --- DISABLE BROWSER BACK/FORWARD ---
    // This script prevents the user from using the browser back button or swipe gestures
    // to leave the page or navigate history, keeping them in the exam app.
    history.pushState(null, document.title, location.href);
    window.addEventListener('popstate', function (event) {
        history.pushState(null, document.title, location.href);
    });
</script>
</body>
</html>
    
